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Abstract
Aberrant choline metabolism is a characteristic shared by many human cancers. It is
predominantly caused by elevated expression of choline kinase alpha, which catalyses the
phosphorylation of choline to phosphocholine, an essential precursor of membrane lipids.
In this thesis, a novel choline kinase inhibitor has been developed and its therapeutic
potential evaluated. Furthermore the probe was used to elaborate choline kinase biology.
A lead compound, ICL-CCIC-0019 (IC50 of 0.27±0.06 µM), was identified through a
focused library screen. ICL-CCIC-0019 was competitive with choline and non-competitive
with ATP. In a selectivity screen of 131 human kinases, ICL-CCIC-0019 inhibited only
5 kinases more than 20% at a concentration of 10 µM (< 35% in all 131 kinases). ICL-
CCIC-0019 potently inhibited cell growth in a panel of 60 cancer cell lines (NCI-60 screen)
with a median GI50 of 1.12 µM (range: 0.00389–16.2 µM). Importantly, proliferation of
normal cells was only minimally a↵ected (MCF-10A, ST-T1b and CCD-18Co; GI50 30–120
µM). In HCT116 cells, ICL-CCIC-0019 potently inhibited the formation of phosphocholine
(EC50 0.67± 0.28 µM), which consequently decreased the formation of phosphatidylcholine.
The compound arrested cells in the G1 phase of the cell cycle, and induced endoplasmic
reticulum stress and apoptosis. A single injection of ICL-CCIC-0019 at 10 mg/kg decreased
tumour uptake of the choline kinase specific PET tracer [18F]fluoromethyl-[1,2-2H4]-choline
at 24 hours (AUC0–60 –23%). Treatment of HCT116 colon cancer cell xenograft bearing
mice with 5 mg/kg ICL-CCIC-0019 i.p. resulted in strong tumour growth inhibition.
Human breast cancer cell lines oncogenically transformed by HER2 exhibit increased
levels of phosphocholine and are therefore more likely respond to CHKA inhibition. To
identify such patients more readily, a novel, non-invasive, PET-imaging-based HER2-
targeting diagnostic tool, [18F]GE-226, was developed. [18F]GE-226 (KD=76 pM) uptake
was 11 to 67-fold higher in 10 HER2 positive versus negative cell lines in vitro. Tumour
uptake correlated with HER2 expression in 5 di↵erent tumour models (r2=0.78), and a
3
4fluorophore-labelled tracer analogue co-localised with HER2 expression. Tracer uptake
was not influenced by short-term or continuous treatment with trastuzumab, but reflected
HER2 degradation by short-term HSP90 inhibition.
Taken together, these data further validate CHKA as a drug target and warrant the
further development of ICL-CCIC-0019, potentially in the setting of HER2 positive can-
cers.
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Chapter 1
Introduction
Although cancer is a conglomerate of immensely complex and heterogeneous diseases, the
majority of neoplasms share the characteristic of a deregulated cellular metabolism [5].
Otto Warburg first observed almost a century ago, that cancer cells very distinctly utilise
glucose [6–8]. Most normal cells metabolise glucose in the presence of oxygen to pyruvate
by glycolysis and subsequently to carbon dioxide through oxidative phosphorylation in
the mitochondria. Under anaerobic conditions, pyruvate emerging from glycolysis is redi-
rected away from the mitochondria to be reduced to lactate. Cancer cells, however, tend
to metabolise the majority of glucose to lactate, even under aerobic conditions [6–8]. This
seemingly paradox phenomenon called Warburg e↵ect evokes tumours to take up more
glucose than normal tissues, which can be clinically exploited by positron emission tomog-
raphy (PET) imaging and radiolabelled glucose ([18F]fluorodeoxyglucose, [18F]FDG) as a
marker [9]. While oxidative phosphorylation is highly e cient to generate energy equiv-
alents in form of ATP — 36 mol ATP can be gained from 1 mol of glucose — anaerobic
glycolysis to lactate only yields in 2–4 mol of ATP from 1 mol of glucose. Importantly,
however, resting and proliferating cells, have diverging demands to satisfy metabolic needs.
Normal cells mainly require ATP to maintain cellular functions. In contrast, proliferating
cells additionally need to accumulate large amounts of biomass for DNA, protein and lipid
synthesis while maintaining their redox environment under cellular stress. It was recently
proposed that anaerobic glycolysis better satisfies the sum of these needs [10].
With increasing understanding of tumour heterogeneity, it has become apparent that
glycolysis is not the only deregulated metabolic trait and that other nutrients than glucose
are essential for proliferation. Many cancer cells rely, for example, on su cient supply of
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glutamine. While normal cells only use this amino acid as a nitrogen source, highly pro-
liferating cells shunt it into energy metabolism, where it is converted to a-ketoglutarate to
replenish the tricarboxylic acid (TCA) cycle [11]. In addition, lipid metabolism typically
also undergoes rearrangements under malignant transformation [12]. This is not unex-
pected, as lipids are required for the synthesis of cell membranes and therefore in demand
in highly proliferating tissues. Membrane lipids usually comprise of two hydrophobic fatty
acid chains and a polar, hydrophilic head group, connected by glycerol. This amphiphilic
character is required for the typical bilayer structure of membranes. The most abun-
dant membrane lipid is phosphatidylcholine (PtdCho), which contains choline as the polar
head group. Both fatty acid and choline metabolic pathways are deregulated in cancer,
but choline biochemistry and its implications on energy homeostasis and proliferation are
less well understood. This thesis focuses on the investigation of choline metabolism with
the aim to identify therapeutic strategies.
1.1 Deregulated choline metabolism in cancer
Aberrant choline metabolic profiles have been described by proton magnetic resonance
spectroscopy (1H MRS) in most of human cancers, including brain, breast, bone colon,
colorectal, endometrial, lung, oesophageal, ovarian, and prostate carcinomas [13–26]. Hy-
peractivated choline metabolism is characterised by elevated intracellular concentrations of
phosphocholine (PCho) and total choline-containing metabolites [27]. The overexpression
of choline kinase alpha (CHKA), has been identified to be mainly responsible for this phe-
notype [28]. Importantly, CHKA expression is of prognostic significance in clinical breast
and lung cancer, where overexpression correlates with disease progression, poor progno-
sis and reduced survival [29, 30]. Additionally, CHKA has been linked drug resistance
by activating multidrug resistance transporters and to invasiveness through an unknown
mechanism, but potentially involving interleukin 6 and 8 [31, 32].
While it can be anticipated that precursors of membrane lipid synthesis, such as PCho,
need to be elevated in cancer to satisfy the demand for lipid building blocks in highly pro-
liferating tissues, choline handling has additional implications in oncogenic development
and disease progression. A tight relationship between PCho and malignant transformation
has been described in breast cancer [33]. Cell lines at di↵erent stages of malignancy —
ranging from normal human mammary epithelial cells (HMEC) to spontaneously immor-
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talised, chemically immortalised, oncogene-transformed HMECs and breast cancer-derived
cells with low and high metastaticity — show with increasing malignant progression cor-
relative elevated PCho accumulation [33].
The notion that these metabolic rearrangements are specifically related to cancer is
further substantiated by the observation that the tumour microenvironment profoundly
influences the cholinic phenotype. Acetic extracellular pH significantly reduces PCho
accumulation [34], while hypoxia induces CHKA expression and PCho accumulation by
direct interaction of hypoxia inducible factor 1 alpha (HIF1A) with CHKA’s putative
promoter region [35]. These results, however, are conflicting with other reports, which
described opposite e↵ects in hypoxic conditions and microarray data indicating an inverse
regulation of HIF on CHKA expression [36–38].
Consequently, the active involvement of CHKA in cancer progression, its interaction
with the tumour microenvironment and— as later described — the regulation by oncogenic
signalling pathways make it a putative drug target.
1.2 Choline biochemistry
Apart from its involvement in oncogenic transformation, choline is an essential nutrient
that is required for normal cellular physiology of all cells [39]. The adequate dietary intake
of around 500 mg/day is usually met or exceeded by healthy adults [40]. Short term
dietary choline deprivation, as for example during pregnancy, embryonic development,
lactation and in liver cirrhosis patients, can be overcome through a salvage mechanism
in the liver, where choline is synthesised through the second most abundant phospholipid
phosphatidylethanolamine (PE) [41, 42]. Prolonged deficiency, however, leads to apoptosis,
liver and muscle damage [43], as well as increases homocysteine levels [44], which contribute
to the risk for cardiovascular conditions and Alzheimer’s disease [45, 46]. The physiological
choline concentration in the plasma ranges between 10–50 µM [47]. Choline is an essential
component of four types of biomolecules: it (i) forms the polar head of the membrane lipids
PtdCho and sphingomyelin, (ii) is required for the biosynthesis of the neurotransmitter
acetylcholine, (iii) is a component of the potent lipid mediators platelet-activating factor
(PAF) and sphingosylphosphorylcholine, and (iv) can be oxidised to betaine, which serves
as an osmolyte and methyl group donor in various reactions (Figure 1.1).
The predominant metabolite of choline is the membrane lipid PtdCho, which consti-
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Figure 1.1: Fate of choline. Choline can be used for 4 classes of biomolecules: the membrane
lipids phosphatidylcholine and sphingomyelin, the neurotransmitter acetylcholine, the osmolyte
and methyl group donor betaine or for the lipid mediators platelet-activating factor and sphingo-
sylphosphorylcholine. Figure from: Blusztajn, J. K. Science. 1998;281,794–795; Ref. [39].
tutes half of the total membrane lipid content [48]. Besides acting as a natural barrier to
the surrounding environment, the cell membrane functions as an important energy stor-
age and serves as precursor of lipid second messengers [42]. PtdCho biosynthesis occurs
through the Kennedy (or CDP-choline) or phosphatidylethanolamine N -methyltransferase
(PEMT) pathways.
Perhaps the best-characterised choline metabolite is the neurotransmitter acetylcholine.
Among other functions, acetylcholine transmits signals in the central and peripheral ner-
vous system, where it is required at all pre- and postganglionic parasympathetic and all
preganglionic sympathetic neurons. Acetylcholine is also required at the neuromuscu-
lar junction, where it translates neuronal impulses into muscle movement. Furthermore,
acetylcholine is important for synaptic plasticity, learning and memory and loss of cholin-
ergic neurons is one of the hallmarks of Alzheimer’s disease [49, 50].
Choline is also a component of the lipid mediators PAF and sphingosylphosphoryl-
choline. PAF is a very potent proinflammatory phospholipid contributing to immune
response, inflammation and the cancer microenvironment. PAF is usually produced from
membrane glycerophosphocholines and signals through its G-protein coupled PAF receptor
[51]. This results in platelet aggregation, adhesion of neutrophils to endothelial cells, pro-
liferation of fibroblasts and endothelial cells, migration of granulocytes to sites of inflam-
mation and production of angiogenic factors [52]. PAF-mediated signals activate mitogen-
activated protein kinase (MAPK), phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K),
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phospholipase A2 (PLA2) and protein kinase C (PKC) pathways [52] and inhibition of
PAF reduces cell proliferation in vitro and metastasis in mouse xenografts [53]. Similar to
PAF, sphingosylphosphorylcholine exerts a wide spectrum of biological actions, including
promotion of cell growth, migration, adhesion and cytoskeleton rearrangement [54–56].
Finally, choline’s oxidation product betaine, is an important osmolyte and a vital carbon
source for methylation processes [57]. Betaine replenishes methionine levels through the
transfer of a methyl group to homocysteine. Subsequently synthesised S-adenosyl methio-
nine (SAM) serves as a major dietary source for methyl groups [57]. Epigenetic regulation
through methylation signatures, which are commonly found to be deregulated in cancers,
rely on su cient one-carbon sources, which potentially could explain elevated choline oxi-
dase (the enzyme that governs the conversion from choline to betaine) expression in some
cancers. The reaction to betaine cannot be reversed and therefore also poses a way for
tissues to excrete choline [41].
1.3 Kennedy (CDP-choline) pathway for PtdCho synthesis
Upon choline uptake into cells, the synthesis of PtdCho from choline is catalysed by three
enzymes, which together form the Kennedy or CDP-choline pathway (Figure 1.2). In the
first step, choline kinase alpha (CHKA) or beta (CHKB) phosphorylate choline in the
presence of ATP and Mg2+ to PCho. The activating nucleotide cytidine triphosphate
(CTP) is then added through CTP:phosphocholine cytidylyltransferase (CCT) to form
CDP-choline. In the final step, CDP-choline:1,2-diacylglycerol cholinephosphotransferase
(CPT) catalyses the formation of PtdCho from CDP-choline and diacylglycerol (DAG)
[42]. These biochemical processes and their implications on carcinogenesis are discussed
below in greater detail.
1.3.1 Choline transport
Choline is a quaternary amine and due to its charge requires transport proteins to cross
the lipophilic cell membrane. Three distinct systems are responsible for choline uptake
(Table 1.1): organic cation transporters (OCT), choline transporter family (CHT) and
choline transporter-like protein family (CTL).
OCTs or solute carrier 22 family of proteins (SLC22) are polyspecific for various organic
cationic compounds. The sodium-independent transport is based on passive di↵usion, is
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Figure 1.2: Kennedy pathway describing PtdCho synthesis. Choline kinase alpha or beta (CHKA,
CHKB) catalyses the reaction from choline to phosphocholine. The activating nucleotide cytidine
triphosphate (CTP) is added by CTP : phosphocholine cytidylyltransferase (CCT). The final reac-
tion between diacylglycerol (DAG) and CDP-choline is catalysed by CDP-choline:1,2-diacylglycerol
cholinephosphotransferase (CPT) and leads to the formation of the membrane lipid PtdCho. CTP,
cytidine triphosphate; PPi, diphosphate, CMP, cytidine monophosphate.
therefore reversible, and the a nity for its substrates is usually low (OCT1–3 KM
1 for
choline ca. 300 µM to 16 mM) [58]. They are mainly located in the liver and kidneys to
provide organic cationic compounds, such as choline, carnitine, creatinine and guanidine
for metabolic pathways in these organs [59].
CHTs are predominately located in brain regions rich in cholinergic neurons. They are
responsible for the provision of choline for acetylcholine synthesis [59] and characterised
by very high a nity for choline (KM for choline 0.5–3 µM) [59].
In the context of tumour choline metabolism, the intermediate-a nity, choline-specific
CTL family of transporters forms the mainstay of cross-membrane choline tra cking [25,
60]. CTLs are expressed in a variety of tissues, including brain, heart, small intestine,
kidney, liver, lung, skeletal muscle, pancreas, spleen, ovary, and testis [59, 61]. They
are characterised by a KM of 20–70 µM for choline and their main purpose is choline
transport for PtdCho synthesis. The di↵erent classes of choline transporters are linked
to their specific biochemical function and many organs rely on a combination of choline
transporters to secure su cient supply. For example, neurons derive choline through high-
a nity transporters for acetylcholine synthesis and CTL-mediated transport for PtdCho
production [59, 62, 63]. Additionally, the KM for transfer of choline to acetylcholine and
PCho are di↵erent in brain cells [64].
1Michaelis-Menten constant KM is the substrate concentration at which the reaction velocity is at
half-maximum.
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Table 1.1: Tissue distribution of choline transporters. Data from: Michel et al. Exp Biol Med.
2006;231:490–504. Ref. [59].
 
  Name Chromosome Organism Tissue distribution 
Choline-specific       
I. CHT1s hCHT1b 2q12 Human Brain, spinal cord 
  mCHT1 17D Mouse Brain, spinal cord 
  rCHT1b 9q11 Rat Brain, spinal cord 
  CHO-1 IV C. elegans Brain, synaptic vesicles 
          
II. CTL1s hCTL1b 9q31.2 Human Multiple tissues 
  mCTL1 4B2 Mouse Muscle 
  rCTL1 5q24 Rat Brain, spinal cord, colon 
  tCTL1   Torpedo Central nervous system, myelin 
          
Choline-nonspecific       
OCTs hOCT1 6q26 Human Liver 
  hOCT2 6q26 Human Kidney, brain 
  mOCT1 17A1 Mouse Intestine, liver, kidney 
  mOCT2 17A1 Mouse Kidney 
  rOCT1b 1q11–q12 Rat Liver, kidney, intesine 
  rOCT2b 1q11 Rat Kidney 
 
1.3.2 Choline kinase alpha and beta
CHK 2 exists in at least three isoforms, CHKA1, CHKA2 and CHKB, of which the A,
but not the B isoforms, have been implicated in cancer [65]. CHKA1 (50 kDa) and 2
(52 kDa) originate from the CHKA gene on chromosome 11, while the CHKB gene on
chromosome 22 encodes for CHKB (43 kDa) [66–68]. The two genes have a sequence
homology of ca. 60% [69]. CHK is a cytoplasmic protein, although presence in the nucleus
has been reported in some studies [65, 70]. The significance nuclear localisation awaits
to be understood, but potentially it translocates with other enzymes to contribute to
endonuclear PtdCho synthesis and lipid signalling [65]. All isoforms are inactive in their
monomeric form and homo- or heterodimerisation is required for full activity. Di↵erences
in dimer composition augment enzyme activity. In normal mouse tissues, 60% of the
kinase activity can be attributed to CHKA/B dimers, while alpha and beta homodimers
contribute in equal parts to the remaining enzymatic activity. Importantly, in a model
of carcinogen-induced liver cancer in mice, the A/A homodimer becomes with ca. 75%
the prevailing contributor to total CHK activity, with the A/B heterodimer (15%) and
B/B homodimer (10%) only having subordinate roles [69]. CHKA1 and 2 are di↵erent
splice variants, whereby the CHKA2 isoform has an insertion of 18 amino acids. X-ray
crystallography revealed that that this sequence segment is adjacent to an a-helix, which
2CHKA and CHKB refer to the respective isoforms, while CHK is used when both isoforms are implied
or isoform selectivity is unknown.
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is responsible for enzyme dimerisation. When inserted, the KM for choline is reduced to
0.098 mM compared to 1.69 mM for CHKA1 [71]. These data suggest that this sequence
facilitates dimerisation and thereby enhances enzymatic activity.
CHKA and CHKB have di↵erential roles in embryonic development and tissue phys-
iology. Heterozygote CHKA knockout mice are viable, fertile and without any obvious
phenotype. Homozygote deletion of CHKA causes embryonic death within the first 7.5
days [72]. In heterozygote CHKA knockout mice CHK activity is significantly reduced in
liver and testes, but remains una↵ected in muscle. PtdCho membrane content remains
stable and the ethanolamine pathway, a salvage pathway under choline deprivation (dis-
cussed below), does not seem to compensate for the loss of CHKA activity [72]. CHKB
is implicated in muscle development, as mice with a truncated, dysfunctional CHKB pro-
tein exhibit hindlimb muscular dystrophy, forelimb bone deformity and megamitochondria
[73, 74]. This can be partly reversed when these mice are supplemented with CDP-choline
to circumvent impaired CHK activity [75]. As knockout of CHKA but not CHKB is lethal,
it can be anticipated that CHKB cannot compensate for loss of CHKA.
In normal cells, the rate-limiting step of the Kennedy pathway is considered to be
CCT [42, 76, 77], while in malignant cells with altered choline biochemistry, the regula-
tory role appears to be taken over by CHKA. Only a minor increase in PtdCho content is
found in breast cancer cells compared to healthy controls and the increase of total choline-
containing metabolites is predominantly due to elevated PCho synthesis [78]. In epithelial
ovarian cancer cells, 3.5-fold increased CHKA mRNA expression is accompanied by a 50%
reduction of CCT1 expression while the CCT2 expression is almost completely abolished
compared to healthy control cells [25]. Furthermore, glioblastoma cells that are resistant
to radiotherapy have ca. 7-fold higher PCho concentrations compared to corresponding
radiosensitive cell lines, however, their CDP-choline levels are only 1.6-fold higher in ra-
dioresistant cells [28].
1.3.3 Cytidltransferase and phosphocholine transferase
CTP:phosphocholine cytidylyltransferase catalyses the reaction from PCho to CDP-choline.
The two isoforms, CCTa and CCTb, are encoded by PCYT1A and PCYT1B, respectively
[42]. CCT exists in homodimers and their subcellular localisation regulates their activity.
Decrease in PtdCho, increase in DAG or changes in CCT phosphorylation prompts it to
become membrane-bound and active. Conversely, in its soluble, cytosolic form, it is inac-
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tive [79]. On transcriptional level, CCT expression is regulated by the transcription factors
specific protein 1 (Sp1), retinoblastoma protein (pRb), transcriptional enhancer factor 4
(TEF4), v-ets avian erythroblastosis virus E26 oncogene homolog 1 (Ets-1) and E2F, but
not by transcription factors involved in de novo fatty acid or cholesterol biosynthesis, such
as sterol regulatory element-binding protein (SREBP), liver X receptor (LXR) or perox-
isome proliferator-activated receptors (PPAR), suggesting that its regulation is linked to
cell cycle, growth and di↵erentiation, but not lipid or energy metabolism [80]. CCTa-/-
deletion in mice is embryonically lethal, whereas CCTb-/- knockout mice are viable but
with reduced fertility [81, 82]. CCTa, but not CCTb, has a nuclear localisation signal,
which is cleaved during caspase-mediated apoptosis, to impede lipid synthesis during cell
death [83].
In the final step of the Kennedy pathway, CPT condenses CDP-choline with DAG to
form PtdCho. This enzyme is sparsely characterised, at least in part because attempts to
purify it failed due to its membrane-bound nature [84]. It is su ciently expressed in most
tissues, and therefore does not limit PtdCho synthesis. Its activity is mainly regulated by
the supply of CDP-choline and DAG [85, 86].
1.3.4 Alternative ways to generate PtdCho
In parallel to the Kennedy pathway, PtdCho can be synthesised through the ethanolamine
kinase pathway. With similarities to its choline counterpart, three enzymes, namely
ethanolamine kinase 1 and 2, CTP:phosphoethanolamine cytidyltransferase and CDP-
ethanolamine:1,2-diacylglycerol ethanolamine phosphotransferase, catalyse the generation
of PE. PEMT is then responsible for the sequential methylation of the nitrogen to obtain
PtdCho [84]. The methylation requires three molecules of S-adenosyl methionine, which is
in turn is converted to homocysteine [87]. PEMT is only expressed in liver and localises in
the endoplasmic reticulum and mitochondria-associated membranes [88]. In normal phys-
iology, the Kennedy pathway is predominantly responsible for PtdCho synthesis, while
the ethanolamine kinase pathway contributes only at high demand or starvation [89, 90].
While choline can be synthesised through this pathway and subsequent cleavage by li-
pases, the capacity for de novo synthesis is limited and comes at the cost of generating
homocysteine, a risk factor for heart disease, and therefore only occurs under conditions
of extreme demand [42].
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Figure 1.3: The major enzymes involved in choline phospholipid metabolism in the cell. Enzymes
shown in grey indicate active choline cycle enzymes, which are shown in the organelle in which they
are active. Enzymes shown in dark blue indicate the location of choline cycle enzymes that are de-
activated by translocation to a di↵erent organelle. Black arrows represent the choline metabolism
pathway, proteins in grey catalyse the reaction that is depicted by the corresponding black ar-
row and choline cycle metabolites are shown in bold. Dashed grey arrows show translocation to
di↵erent subcellular locations, which can deactivate (dark blue) or activate (grey) the enzyme.
CCT, CTP: phosphocholine cytidylyltransferase; CDP-Cho, cytidine diphosphate-choline; CHK,
choline kinase; Choe, extracellular free choline; Choi, intracellular free choline; CHPT1, diacyl-
glycerol cholinephosphotransferase 1; CMP, cytidine monophosphate; CTP, cytidine triphosphate;
FA, fatty acid; GPC, glycerophosphocholine; GPC-PDE, glycerophosphocholine phosphodiesterase;
Gro-3-P, glycerol-3-phosphate; Lyso-PLA1, lyso-phospholipase A1; PCho, phosphocholine; PC-
PLC, phosphatidylcholine-specific phospholipase C; PC-PLD, phosphatidylcholine-specific phos-
pholipase D; PLA2, cytoplasmic phosphatidylcholine-specific phospholipase A2; PPi, diphosphate.
Figure and legend from: Glunde et al. Nat Rev Cancer. 2011;11,835–848. Ref. [28].
1.3.5 PtdCho catabolic pathways
1.3.5.1 Phospholipase D
PtdCho-specific phospholipase D (PC-PLD) exists in two isoforms, PC-PLD1 and 2 [91].
It has been reported to localise at Golgi membranes, the cell membrane or in the cytosol
and its subcellular distribution may depend on the cell type or physiological context [28].
PC-PLD catalyses the reaction that breaks down PtdCho into phosphatidic acid and free
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choline (Figure 1.3) [91]. It represents the only mechanism that can directly generate free
choline. Apart from having structural importance to the membrane, phosphatidic acid
acts as a precursor for many lipids and signalling molecules that can recruit proteins to
the cell membrane to activate them [27].
PC-PLD activity or protein expression is upregulated in melanoma, gastric, ovarian,
breast, renal and colorectal cancers or cell lines [19, 28]. High PC-PLD activity correlates
with invasiveness of breast cancer cell lines, which could be linked to upregulation of matrix
metalloproteinase 9 (MMP9) [92].
1.3.5.2 Phospholipase C
PtdCho-specific phospholipase C catalyses the breakdown from PtdCho to DAG and PCho
(Figure 1.3) [93]. Little is known about PC-PLC, as it exists in no less than 13 isoforms,
which have not been cloned to date [28]. DAG is not only a precursor for many lipids,
but together with phosphatidic acid one of the most important lipid second messenger
signalling molecules, that can be derived from PtdCho. Its activates PKC, which regulates
signalling pathways related to proliferation, apoptosis, cell survival and migration [94].
1.3.5.3 Catabolic pathways leading to glycerophosphocholine
Additionally, PtdCho can be cleaved to form glycerophosphocholine (GPC) and free
choline via specific phospholipase A2, lysophospholipase and GPC phosphodiesterase EDI3
(Figure 1.3) [42, 95]. GPC alterations have been well documented in cancer due to its res-
onance on 1H MRS and typically inversely correlate with PCho content. This lead to the
description of a glycerophosphocholine to phosphocholine switch that is associated with a
malignant phenotype [33]. The exact role of GPC or the enzymes in these pathways are
poorly understood, in part because of the plethora of isoforms for each enzyme [28].
1.4 Molecular imaging of choline metabolism
Hyperactivated CHKA and intracellular enrichment of PCho in cancer can consequently
be exploited for diagnosis, patient stratification and treatment surveillance. Due to their
non-invasive character, MRS and PET imaging are predominantly used in preclinical and
clinical settings to investigate choline metabolism.
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1.4.1 MRS
MRS is based on the principle that when nuclear magnetic resonance active atomic nuclei,
such as 1H or 31P, are placed in an electromagnetic field, they absorb energy and a res-
onating radiofrequency signal can be detected [27]. This signal depends on the chemical
environment of nuclei and therefore the number of chemical bonds, neighbouring nuclei,
and overall chemical structure. These steric e↵ects can alter the frequency, which is re-
ferred to as chemical shift [27]. Choline-containing metabolites resonate at a chemical
shift of 3.2 and 3.3 parts per million (ppm) and the peak arises from the nine 1H of the
quaternary ammonium moiety (Figure 1.4) [27]. In cell extracts, free choline, PCho and
GPC can be distinguished, as the di↵erent chemical structures slightly alter the chemical
shifts. In vivo imaging of lesions does not permit separation of the individual choline peaks
and gives rise to a single peak representing total choline-containing metabolites [27].
In 31P MRS the signal arises from the phosphate groups of extracted metabolites, and
therefore — with respect to choline-containing metabolites — PCho and GPC can be
detected. Due to its low sensitivity, 31P MRS has limited application in vivo [28].
Figure 1.4: Metabolite analysis by 1H and 31P MRS. A, Typical MRS spectra obtained from cancer
cell extracts, live cells or in vivo tumour models. B, Structures of the di↵erent choline containing
metabolites. Highlighted in blue are the nine equivalent protons resonating in 1H MRS and in
green the 31P containing phosphate giving rise to the 31P MRS signal. Figure from: Glunde et
al. Nat Rev Cancer. 2011;11,835–848. Ref. [28].
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As indicated above, deregulated choline biochemistry denoted by a marked increase in
PCho or total choline-containing metabolites has been detected by 1H MRS in a vast array
of human cancers. In addition, this technique can be — at least in a preclinical setting —
used to monitor drug response. PCho content decreases upon inhibition of PI3K by PI-103,
HER2 by trastuzumab, protein kinase A (PKA) by H-89, fatty acid synthetase (FASN) by
orlistat, and CHKA by MN58B and hemicholinium-3 (HC-3) [96–99]. Interestingly, pan
HDAC inhibition by LAQ824 and vorinostat increases CHKA expression and PCho peaks
through an unknown mechanism [100, 101].
1.4.2 PET imaging
PET imaging traces the behaviour of radiolabelled metabolites or ligands in the body. A
typical PET experiment comprises of synthesis and radiolabelling of the tracer, intravenous
administration, monitoring of tissue distribution by a PET scanner and interpretation of
the reconstructed images.
Commonly used tracers in oncology visualise glucose ([18F]FDG), thymidine ([18F]-
3’-fluoro-3’-deoxy-L-thymidine; [18F]FLT) and choline metabolism. The isotopes have
very short half-lives and the most commonly used include 11C (20.4 minutes), 18F (109.8
minutes), 64Cu (12.7 hours), 68Ga (67.7 minutes) and 89Zr (78.4 hours). Because of the
rapid decay, the radioactivity usually needs to be synthesised by a cyclotron and therefore
only has a limited radius where it can be delivered to. The nuclei are positrons, which are
positively charged electrons. The signal arises through annihilation of the positron with
an electron in the tissues. This process emits two gamma rays in form of 511 keV photons
travelling in 180° direction to each other. A detector ring measures the exact time and
location of the impact, allowing reconstruction of a three dimensional image (Figure 1.5).
PET imaging of choline metabolism has been successfully used for patient stratification
and treatment surveillance in breast, prostate, brain, oesophageal and lung cancer [70, 102–
109].
Several choline metabolic PET tracers are clinically used or currently investigated. All
of them mimic choline and are taken up into cells by choline transporters. Phosphorylation
by CHKA traps the tracer in the cell and accumulation in regions with hyperactivated
CHKA are characterised by high tissue tracer uptake.
[11C]choline is associated with the shortest half-life of choline tracers and is rapidly
metabolised to PCho and betaine [110]. It is particularly useful in prostate cancer, as
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Figure 1.5: Principle of PET imaging. A positron originating from a radioactive tracer annihilates
with an electron, resulting in two gamma-rays that can be detected. Signals are then converted
into a three-dimensional picture.
its renal excretion is almost negligible. It gives therefore superior images in compari-
son with [18F]FDG, for which the accumulation of radioactivity in the bladder obstructs
vision of the pelvic region. The conversion to betaine over time (75% parent tracer is
converted to betaine in liver and kidney within the first 15 minutes [110]) bears the dis-
advantage that the measured radioactivity is not entirely related to the Kennedy pathway
(specific signal), but its oxidation product (non-specific signal). Furthermore, betaine
could be excreted from cells into the blood stream, which would skew results. Several
attempts were taken to increase the half-life of choline tracers by use of fluorinated la-
bels. [18F]fluoromethylcholine and [18F]fluoroethylcholine are specific for CHKA, but are
metabolically unstable, which makes longer scans di cult to interpret [111]. This lead to
the development of a deuterated tracer, [18F]fluoromethyl-[1,2-2H4]-choline ([
18F]D4-FCH)
[112]. [18F]D4-FCH is characterised by superior metabolic stability (only 10% of parent
tracer are converted to betaine in liver and 30% in kidneys within the first 15 minutes
[110]), which increases the specific signal related to PCho, while retaining equal a nity to
CHKA [110]. [18F]D4-FCH is currently under clinical evaluation [113].
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Figure 1.6: Scheme of the two-compartment, single input 3k model used to model choline PET
data. The parent input function (pIF) represents the tracer concentration in plasma. The constants
K 1 and k2 describe the rate at which tracer is transferred from plasma to tissue and back. The
irreversible intracellular trapping is described by k3. Figure from: Witney et al. Clin Cancer
Res. 2012;18,1063–1072. Ref. [110]
Choline PET imaging provides distinctly di↵erent information to MRS. While the
latter represents a “snap shot” of intracellular metabolite concentrations, the use of PET
tracers monitors the enzymatic activity over time. Therefore it derives kinetic information,
which can be modelled to further understand biological processes.
Kinetic modelling relates the signals in a tissue, e.g. tumour, to plasma radioactivity.
Therefore it considers the haemodynamic parameters in addition to tissue distribution.
The obtained signal in a region of interest from a choline PET scan is the sum of membrane
transport and phosphorylation by CHKA. For an accurate model, the tracer metabolism
over the time of imaging needs to be taken into consideration to distinguish the specific
signal from metabolic by-products.
Choline PET has typically been described by two-tissue, single input irreversible com-
partment (3k) pharmacokinetic model [110] (Figure 1.6). The parent input function (pIF;
parent relates to the administered, non-metabolised tracer) represents the radioactivity
measured in plasma. In clinical scans, this parameter is derived by obtaining blood sam-
ples over a time course and measurement of the containing radioactivity. As such an
approach is not feasible in small-animal studies due to the limited blood volume, pIF
is estimated by drawing three dimensional regions of interest (ROI) over the heart and
measuring its radioactivity over time [114]. K 1 (mL/cm
3/min) and k2 (1/min) describe
the rate of tracer transfer from plasma to tissue and back. The choline kinase reaction
is represented by k3, which denotes the irreversible trapping of the tracer. Although the
CHKA reaction is in principle reversible, it can be assumed that at least in tumour no
significant amounts of PCho are dephosphorylated.
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1.5 Regulation of choline biochemistry in cancer
CHK activity is stimulated by hormones such as oestrogens and insulin, growth factors
like epidermal growth factor (EGF) and platelet-derived growth factor (PDGF), as well
as oncogenes including Ras, Raf and Mos [69, 115–121]. Although many mitogenic and
growth promoting factors result in CHK activation, the exact mechanisms remain unclear.
In particular, interaction with other proteins or kinases and possible phosphorylation sites
on human CHK isoforms remain to be further characterised.
Incubation of serum-starved HeLa cells with either EGF or insulin enhances uptake of
radiolabelled choline and its incorporation in phospholipids. Cells need to be stimulated
for at least 24 hours to obtain increased PCho production, whereas no changes occur in the
first 4 hours of incubation [119]. This delay in response suggests that no direct interaction
between the corresponding growth factor receptors and CHK exist and that serum starved
cells require synthesis of downstream proteins to activate CHK. CCT activity was not
altered in these experiments, which further supports notion that CHK is the predominant
rate-limiting step of the Kennedy pathway in cancer.
More recently, a mechanistic link between EGFR and CHK through c-Src was pro-
posed [122]. EGFR forms a complex with the cytosolic kinase c-Scr, which recruits CHKA
to the cell membrane. This interaction is dependent on c-Src activity, which was shown
to phosphorylate and activate CHKA at Tyr197 and Tyr333. Loss of the c-Src kinase
domain or mutations at the CHKA phosphorylation sites decreases CHKA recruitment
and activity. While c-Src is required for CHKA phosphorylation, EGFR co-expression is
not necessary, but potentiates the e↵ect [122]. It is likely that similar receptor tyrosine
kinases — especially of the v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Ho-
molog (ErbB) family, such as HER2 — could also interact with CHKA through c-Src.
These results reveal for the first time an activating phosphorylation in human CHKA and
demonstrate a link to growth factor signalling. However, confirmation of these results in
vivo and the e↵ects on cell proliferation when disrupting this EGFR-c-Src-CHKA complex
need to be further studied.
Activating phosphorylation sites of choline kinase were more intensively characterised
in yeast (CKI1; only one isoform exists in this organism). CKI1 is phosphorylated by
PKA and PKC. PKA activates CKI1 in a dose- and time-dependent manner through phos-
phorylation at Ser30 and Ser85 [123–125]. PKC predominantly activates CKI1 through
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phosphorylation at Ser25, although several other putative target sites have been identi-
fied [126]. CKI1 stimulation is greater through PKA than PKC [123, 126]. The role of
PKA and PKC-mediated CHKA regulation in humans is less well investigated. While
pharmacological inhibition of PKA with H-89 e↵ectively inhibits CHK activity, possible
phosphorylation sites remain to be discovered [127].
At transcriptional level, CHK is regulated by the transcription factor activator pro-
tein 1 (AP-1) and potentially HIF1A and c-Myc. Exposure of cells to UV irradiation
or carcinogens induces AP-1 mediated transcription through increased binding of c-Jun,
which results in increased PCho concentrations and CHK expression [128, 129]. As indi-
cated above, ambiguous results on CHK regulation were reported under hypoxic condi-
tions. Myc also has a potential role in CHK regulation, as c-Myc expressing fibroblasts
have 3-fold higher PCho levels than the corresponding knockout cell line [130].
High PCho levels reflecting augmented CHK activity are also associated with expres-
sion of the family of Ras oncogenes [131]. These small GTPases are encoded by three RAS
genes, Harvey-RAS (HRAS ), Kirsten-RAS (KRAS ), and neuroblastoma-RAS (NRAS ),
which are frequently mutated in human cancers. Transformation of NIH3T3 cells with
either of the RAS genes results in increased CHK activity makes cells 2–3 times more
sensitive to CHK inhibitors than untransformed cells [131]. The exact mechanism of Ras-
induced CHKA activation remains unclear. Ras does not directly interact with CHKA and
the regulation is independent of PLD activation [120]. Ramirez de Molina et al. proposed
that Ral guanine nucleotide dissociation stimulator (Ral-GDS) in conjunction with PI3K
plays a pivotal role in CHKA activation in the setting of Ras mutations. Cells overex-
pressing wild-type Ras show vast CHK activation, which is reduced when transfected with
mutant Ras isoforms that only interact with either Ral-GDS or PI3K. When a mutant Ras
isoform, engineered to simultaneously and selectively interact with these two downstream
targets only, is introduced, CHK activity is again comparable to Ras overexpressing cells
[120]. Although a Ras/Ral-GDS/PI3K interaction seems apparent, these data do not rule
out other Ras downstream targets, which could equally be responsible for CHK activa-
tion. Furthermore, a mechanistic link is missing, in particular as it was shown in a di↵erent
context that PI3K and CHK do not physically interact [132]. CHK regulation has also
been associated with Rho kinase signalling by activation of RhoA and ROCK, but similar
constraints in the study design apply [133].
Several downstream modulators of CHK have been proposed, which are known to pro-
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mote cell survival. These include DAG, phosphatidic acid, Akt, MAPK, cell cycle regulat-
ing proteins and PCho. Several reports suggest that choline-related e↵ects are mediated
through the pool of membrane lipids like PtdCho, which are cleaved by phospholipase C
and D to form the mitogenic metabolites DAG or PA [134–136]. As previously mentioned,
PtdCho content in cancer cells is often not vastly altered and CHK as opposed to CCT
seems to regulate the Kennedy pathway in cancer. This suggests, that lipid signalling
might only in part explain the growth promoting signalling of CHK. Recently, an RNAi
screen against the human kinome in triple negative breast cancer cell lines MDA-MD-468
identified CHKA as a key regulator for Akt phosphorylation [132]. CHKA was among
the strongest hits in the screen and its knockdown resulted in more than 50% reduction
of Akt phosphorylation [132]. Reduced Akt phosphorylation occurs downstream of PI3K
and silencing CHKA also results decreased Erk1/2 phosphorylation [132, 136]. Overex-
pression of human CHKA leads to di↵erential expression of proteins important for cell
cycle progression, in particular for the G1–S phase transition, while inhibiting apoptosis.
This e↵ect can be reversed with CHK inhibitors [137].
More defined studies of CHK up- and downstream targets will be vital to thoroughly
understand its regulation in cancer. Most of the publications cited above describe the
functional e↵ects upon CHK overexpression or inhibition, and — apart from c-Src — could
not identify interaction partners of CHK, which could explain how CHK deregulation feeds
into oncogenic signalling pathways.
1.6 Inhibition of CHKA as a treatment strategy in cancer
Due to its involvement in oncogenic transformation, upregulation in a variety of cancers
and interaction with key signal transduction pathways, CHKA has emerged as a potential
target for cancer therapeutics. Several RNA interference (RNAi) studies have supported
this and led to the discovery of small molecule inhibitors.
1.6.1 CHKA RNAi impedes proliferation
Transcriptional silencing of CHKA depletes the intracellular PCho pool [136, 138], which
translates into reduced proliferation of MDA-MB-231, MDA-MB-468 and HeLa cells [136,
139] and induction of apoptosis [140]. Furthermore, it promotes di↵erentiation, prevents
anchorage-independent growth in HeLa cells and abolishes their ability to form xenografts
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in athymic mice [136, 139]. This is associated with a reduction of Akt and Erk phospho-
rylation and di↵erential expression of genes involved in proliferation, cell cycle regulation
and DNA repair [136, 141]. These e↵ects are more pronounced in cancer cells than normal
cells [141], giving hope that CHK inhibitors would potentially be selectively cytotoxic to
tumours, while sparing other tissues. CHKA inhibition sensitises cells to chemotherapy,
as treatment with 5-fluorouracil (5-FU) potentiates the e↵ect of siRNA against CHKA in
MDA-MB-231 cells [141].
Krishnamachary and colleagues have established a gene therapy mouse model targeting
CHK [142]. Athymic mice bearing MDA-MB-231 xenografts were intravenously (i.v.)
injected short-hairpin RNA delivered through a lentiviral vector. CHK mRNA levels were
reduced by 35%, which diminished CHK activity and tumour volume. A gene therapy
approach targeting solid tumours would be challenging to translate into humans, because
of ethical and technical considerations, but this experiment substantiates the evidence for
CHK to be a potential drug target.
1.6.2 Pharmacological inhibitors of CHK
Several small molecule CHK inhibitors have been developed and typically comprise of two
cationic moieties in form of quaternary pyridinium salts connected by a lipophilic linker.
Table 1.2 summarises CHK inhibitors published to date.
HC-3 is amongst the first discovered small-molecule inhibitors of CHK and targets both
CHT transporters and CHKA [143, 151]. Di↵erent reports exist regarding its potency. It
has been shown to have an IC50
3 against purified human CHKA of 0.95 µM [143], an
EC50
3 > 500 µM in exracts containing yeast CKI [144], and a GI503 of > 500 µM against
SKBR-3 and NIH3T3 cells [143, 145]. The large discrepancy between the published data is
unclear, but could be due to incomplete description of the methodology and the caveat of
di↵erent assays used. More importantly, interference with high-a nity choline transporters
prevents uptake of choline for acetylcholine synthesis and causes neurotoxicity and apnoea
[63]. This led to the development of novel CHK inhibitors with increased antiproliferative
activity, but that do not interact with CHTs and therefore possess reduced neurological
toxicity.
Through systematic screening, MN58B was identified (Table 2; Ref. [144]). MN58B
3IC50 refers to the half-maximal inhibitory concentration in an enzyme-based assay, EC50 to the half-
maximal inhibitory concentration in biological assays, whereas GI50 describes the half-maximal growth
inhibitory concentration in cells.
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Table 1.2: Structures of choline kinase inhibitors and their pharmacological characteristics as
published in the literature. Data from Refs [132, 143–150].
Compound Inventor Structure Binding site IC50 (µM) GI50 (µM) 72h
Hemicholinium-3
Choline, additionally 
inhibits CHT 
transporters
0.95
SKBR-3: > 500
NIH3T3: 600
MN58B
Juan Carlos 
Lacal, University 
of Madrid
Expected to be 
choline competitive
22
MCF7: 0.6
HT29: 1.4
HeLa: 1.2
A431: 2.1
U937: 0.5
K562: 0.7
TCD-828 TCD Pharma
TCD-717 TCD Pharma
Expected to be 
choline competitive
Not disclosed Not disclosed
V-11-023907 Vertex ATP 0.47 Not disclosed
V-11-0711 Vertex ATP 0.02
HeLa: 26.5
HT29: 15
 H23: 50
 HCT116: 20
CK37 (distributed 
by Merck)
Jason Chesney, 
University of 
Louisville
Choline
5-10 µM in various 
cell lines after 48h 
treatment
Compound 10 
ChemMedChem. 
2002;7(4):663-9
University of 
Granada
Mixed; predominately 
choline
0.09
Only 2 conc. tested:
1 µM: 80% survival
10 µM: 15% survival in 
SKBR-3
Compound 14 
ChemMedChem. 
2002;7(4):663-9
University of 
Granada
Mixed; predominately 
choline
0.08
Only 2 conc. tested:
1 µM: 80% survival
10 µM: 20% survival in 
SKBR-3
Compound 14 
MedCHem 
2012;50:154-62
University of 
Granada
Mixed; predominately 
choline
Only 2 conc. tested:
10 µM: 67%
50 µM: 90%
CHKA inhibition
Only 2 conc. tested:
10 µM: 90% survival
50 µM: 55% survival in 
HepG2
No properties disclosed, but CHK inhibition demonstrated in Mol Cancer 2009;8:131
has an IC50 of 4.2 µM and a GI50 of 0.5–2.1 µM after 72-hour treatment in di↵erent cell
lines [146]. The lower GI50 than IC50 is indicative of o↵-target e↵ects. MN58B inhibits
tumour growth by 70% in HT-29 and A431 mouse xenografts [146]. PCho conversion
is only inhibited by 60% at 20 µM MN58b in MDA-MB-468 and 6 µM in MDA-MB-
231 cells [96, 132]. Therefore, it is not able to completely inhibit the CHK reaction
at pharmacologically relevant doses. Pharmacokinetic or target selectivity data have not
been reported for this compound. TCD-717, a further development of MN58B, is currently
under Phase I clinical investigation (clinical trials number NCT01215864) in solid tumours,
but preclinical data are undisclosed [152].
MN58B e↵ects cell death by induction of cytotoxic ceramides and endoplasmic reticu-
lum (ER) stress. Ceramides are a class of bioactive lipids, that stimulate growth inhibition,
apoptosis, di↵erentiation and senescence [153]. Jurkat cells are upon drug treatment in-
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sensitive to changes in pRb phosphorylation. pRb is governed by an inhibiting phosphory-
lation, and therefore is inactive when phospohorylated, but acts as a tumour suppressor in
its hypophosphorylated state. Lack of phospho-pRb dephosphorylation causes a metabolic
crisis and the release of cermides and subsequent induction of apoptosis [154]. Conversely,
in normal primary lymphocytes phospho-pRb is dephosphorylated by MN58B treatment,
which transiently induced G0/1 arrest. Once the drug is removed, these cells proliferate
again.
Additionally, MN58B enhances ER stress response. The ER is an organelle that ensures
correctness of protein folding and maturation as well as vesicular transport. Imbalance
in protein synthesis and degradation, calcium overload or PtdCho depletion cause ER
stress, a mechanism to resolve these perturbations [155, 156]. Transcription factors are
released, which activate gene expression of diverse sets of genes that counteract this stress.
If unsuccessful, cells enter the apoptotic pathway [156]. Several approved drugs use ER
stress-induced apoptosis as their main mechanism of action, including vorinostat, sorafenib
and bortezomib [157]. MN58B and TCD-717 induce ER stress response by increasing
the expression of inositol-requiring protein 1 (IRE1a) and glucose-regulated protein 78
(GRP78), a chaperone to counteract missfolded proteins. Additionally, the transcription
factors CHOP and C/EBPb are activated, which cause a pronounced apoptotic response
[157]. Importantly, these e↵ects were exclusive to cancer cells and not observed in normal
counterparts [157].
Structurally distinct from the pyridinium analogues is CK37 [149]. It was identified
by an in silico screen of more than 2.6 million compounds. Despite being uncharged, it is
competitive with choline, but only weakly inhibits recombinant CHKA: 25 µM decrease
PCho formation by 60%, which translates into a modest GI50 of 5-10 µM in di↵erent cell
lines. At high concentrations, it is capable of decreasing Akt and Erk phosphorylation
[149].
The only ATP competitive CHKA inhibitors developed to date are V-11-023907 and
V-11-0711, of which only the latter has been tested in cell systems [147]. It has the
highest reported inhibitory activity against CHKA — with the caveat that di↵erent and
not comparable assays were used across various studies. Interestingly and in contrast to
CHKA siRNA, it failed to induce apoptosis and cell death. Cell proliferation, as measured
by percentage confluency over time, was delayed but reversible when the compound was
withdrawn from the medium [148]. It cannot be excluded that cross-reactivity with other
50
targets prevents antiproliferative activity, but this divergence from data of choline com-
petitive inhibitors and CHKA siRNA suggests that either inhibition of the choline pocket
is required or that CHKA possesses sca↵olding properties, which are independent of its
catalytic activity [148].
1.7 Aims of thesis
Given the extensively characterised deregulated choline biochemistry in cancer and favour-
able preliminary results from genetic and pharmacologic interventions, the main aim of
this project is to develop novel choline kinase inhibitors to elucidate choline biochemistry
in cancer. The following milestones were set:
1. Development of novel, synthetically accessible sca↵olds and detailed characterisation
of their mode of inhibition.
2. Comprehensive in vitro and in vivo pharmacological evaluation, including data on se-
lectivity, antiproliferative activity, antitumour activity, pharmacokinetics, and phar-
macodynamics.
3. Elucidation of the mechanisms leading to cell death subsequent to CHKA inhibition.
4. Application of [18F]D4-FCH PET imaging to assess target inhibition in vivo.
5. Development of imaging tools that could facilitate the selection of patients that
might benefit from CHKA inhibitors.
Chapter 2
Materials and Methods
2.1 Synthetic procedures
2.1.1 Synthesis of choline kinase inhibitors
Choline kinase inhibitors were synthesised by Dr. Laurence Carroll and Dr. Andrew Kalusa,
Imperial College London, according to procedures described in [1]. In brief, for synthesis
of the symmetrical compounds (Scheme 2.1), each linker was dissolved in 2-butanone with
DMAP and subsequently heated to 110°C for three hours. Precipitation began to occur
within 10 minutes of the reaction starting, due to the insolubility of the desired doubly-
charged bis-DMAP products in 2-butanone, allowing for a straight forward purification
by filtration. Yields were good in each example (ca. 80% in all but one case) and the
reactions could be easily carried out routinely on a large scale.
For synthesis of the ATP-mimicking compunds (Scheme 2.2), initially, nonsymmetric
half-linker compounds 14–16 (where 14=C12 linker, 15=C8 linker, 16=PEG4 linker)
were synthesised using a modified procedure based upon our route for the symmetrical
compounds. When a 1:1 ratio of DMAP to linker was used, in 2-butanone at 110°C for
three hours, yields of the desired compound containing only one DMAP end group were
ca. 70%. However, under these reaction conditions, up to 15% of the analogous symmetrical
compound was also formed, and due to the similar nature of these compounds, separation
proved di cult. A revised chemical procedure was developed, using only half an equivalent
of DMAP (four times less than the initial procedure for the symmetrical synthesis), which
gave lower yields of the desired compounds (ca. 50%), but importantly, a↵orded none
of the unwanted symmetrical analogue. With compounds 14–16 in hand, subsequent
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Scheme 2.1: Synthesis of symmetrical compounds 1, 3, 5–8 and 13
coupling of a number of ATP-mimicking groups was attempted. Benzimidazole was used
as an initial test compound, due to its symmetry preventing any possibly regioisomers, to
ascertain conditions required for coupling. After optimisation, it was found that by using
DMF as a solvent instead of 2-butanone, and adding 1.2 equivalents of K2CO3, coupling
occurred in moderate to good isolated yields (46–72%) to give compounds 2, 4, and 9–12.
One drawback, which became apparent upon using adenine or purine, was the formation
of an N-9 substituted product, as well as the N-3 substituted product, in approximately
a 2:1 ratio of N-3 to N-9, which has been noted in previous work. Separation of these
compounds could be carried out e ciently by column chromatorgraphy, giving the pure
nonsymmetrical N-3 substituted compounds for biological testing.
NMR spectra of relevant compounds can be found in Appendix A. Compounds were
dissolved in sterile H2O and aliquots stored at a concentration of 40 mM at –80°C.
2.1.2 Radiochemistry of [18F]D4-FCH
Radiosynthesis of [18F]D4-FCH was carried out by Dr. Diana Brickute, Dr. Robin Fortt,
Dr. Graham Smith and Frazer Twyman, Imperial College London. [18F]D4-FCH was ra-
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Scheme 2.2: Synthesis of nonsymmetrical compounds 2, 4, and 9-12
diolabelled using a FASTlab-compatible procedure via [18F]-fluoromethyl tosylate, shown
in Scheme 2.3 and described elsewhere [110, 158]. Typical non-decay corrected end of
synthesis yields were 5-15% with a radiochemical purity of 100% and a pseudo-specific
activity of 5–14 GBq/µmol.
2.1.3 Radiochemistry of [18F]GE-226
Radiosynthesis was carrid out by Peter Iveson, GE Healthcare. ZHER2:2891 (ABY-025),
synthesised as described elsewhere [159], was provided by A body AB. [18F]GE-226 was
labeled using a fluorobenzaldehyde (FBA) strategy optimised for automated manufacture
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Scheme 2.3: Radiolabelling of [18F]D4-FCH.
on FASTlab (Scheme 2.4), as previously described [160]. Typical non-decay corrected end
of synthesis yields were 30% and a radiochemical purity of 95%. The specific activity
across all preparations was 38–110 GBq/µmol with a median of 46.2 GBq/µmol.
2.2 Cell Culture
A431 (squamous carcinoma; Sigma-Aldrich), A549 (lung carcinoma; ATCC), Ishikawa
(endometrial adenocarcinoma; Sigma-Aldrich), HEK293T (embryonic kidney; ATCC),
MCF wild type (breast adenocarcinoma; ATCC), MCF7-vector (piRES), MCF7-p95HER2
and MCF7-HER2 (the latter three cell lines were a kind gift of Professor Jose´ Baselga’s
laboratory, Memorial Sloan-Kettering Cancer Center [161]), MDA-MB-231 (breast ade-
nocarcinoma; ATCC), MDA-MB-361 [breast (brain metastasis), Sigma-Aldrich], MDA-
MB-468 (breast adenocarcinoma; ATCC), U2OS (osteosarcoma; Sigma-Aldrich), SKBR-3
(breast adenocarcinoma; ATCC) and SKOV-3 ovarian adenocarcinoma (ovarian carci-
noma; Sigma-Aldrich) cells were maintained in DMEM (Sigma-Aldrich). A2780 (ovar-
ian carcinoma; Sigma-Aldrich), AGS (gastric adenocarcinoma; Sigma-Aldrich), HCT116
(colon carcinoma; ATCC), HGC-27 (gastric adenocarcinoma; Sigma-Aldrich), NCI-N87
(gastric adenocarcinoma; ATCC) and OE-33 (esophageal carcinoma; ATCC) cells were
maintained in RPMI (Sigma-Aldrich). St-T1b cells (immortalised endometrial stromal
cells), a kind gift of Professor Jan Brosen’s laboratory, Imperial College London [162], and
MCF-10A (mammary gland from human female with fibrocystic disease); ATCC) cells
were maintained in DMEM/F12 (Invitrogen). CCD-18Co (normal human colon; ATCC)
Scheme 2.4: FASTlab-compatible automated synthesis of [18F]GE-226.
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were cultured in Eagle’s Minimum Essential Medium (Sigma-Aldrich). Growth media
were supplemented with 10% FCS (Lonza), glutamine and antibiotics (both Invitrogen).
MCF-10A were additionally supplemented with 5% horse serum (used instead of FCS),
20 ng/ml EGF (both Invitrogen), 10 µg/ml insulin, 0.5 µg/ml hydrocortisone and 100
ng/ml cholera toxin (all Sigma-Aldrich). Caco-2 cells (ATCC) were maintained in DMEM
containing 4.5 g/L glucose (Invitrogen), 20% FCS and antibiotics. Cells were cultured at
37°C in humidified atmosphere containing 5% CO2.
2.3 [18F]D4-FCH-based CHK activity assay
2.3.1 Whole cell assay
CHK activity was evaluated by a cell-based assay using [18F]D4-FCH and a method previ-
ously described [112]. In brief, HCT116 cells were grown in 15 cm culture dishes (Corning)
and allowed to recover overnight. Cells were treated with 1 mM HC-3 (Sigma-Aldrich)
or 1 µM MEK inhibitor PD0325901 (obtained from the Division of Signal Transduction
Therapy, University of Dundee) for 24 hours. Cells were pulsed with 5.55 MBq [18F]D4-
FCH for 1 hour, washed 3 times in PBS, scraped into 2 mL microcentrifuge tubes and
homogenised in 2 mL methanol (Sigma-Aldrich). After centrifugation at 14 000× g at 4°C
for 5 minutes, the supernatant was dried on a rotary evaporator at a bath temperature
of 40°C. The residues were resuspended in 1.1 mL mobile phase A (see below), clarified
using a 0.2 µm filter and analysed by radio-HPLC on an Agilent 1100 series HPLC sys-
tem (Agilent Technologies) comprised of a g-RAM Model 3 gamma detector and Laura 3
software (Lablogic). A Waters µBondapak C18 reverse-phase column (300× 7.8 mm) was
used as stationary phase. Samples were separated at a flow rate of 3 mL/minute us-
ing a mobile phase comprised of solvent A (acetonitrile/water/ethanol/acetic acid/1.0 M
ammonium acetate/0.1 M sodium phosphate; 800/127/68/2/3/10) and solvent B (ace-
tonitrile/water/ethanol/acetic acid/1.0 M ammonium acetate/0.1 M sodium phosphate;
400/400/68/44/88/10; all Sigma-Aldrich) with a gradient of 0% B for 6 minutes, 0–100%
B in 10 minutes, 100% B for 0.5 minutes, 100%– 0% B in 1.5 minutes and 0% B for 2
minutes.
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2.3.2 Cell lysate-based assay using [18F]D4-FCH
Exponentially growing HCT116 cells were trypsinised, washed 3 times with PBS and
cytosolic extracts isolated using NE-PER Nuclear and Cytoplasmic Extraction reagent
(Thermo Scientific, Cat. Nr.: 78833) according to manufacturer’s instructions. In brief,
10× 106 cells were transferred into a 1.5 ml eppendorf tube, spun down at 500× g for 5
minutes. The pellet was subjected to 10 times its volume CERI bu↵er containing protease
and phosphatase inhibitors (e.g. for a cell pellet with 30 µL volume, 300 µL CERI bu↵er
was added). Samples were vortexed for 15 seconds and incubated for 10 minutes on ice.
For each 300 µL CERI bu↵er used, 16.5 µL CERII bu↵er was added. After briefly vor-
texing, samples were incubated for 1 minute on ice and again quickly vortexed. Samples
were centrifuged at 16 000× g for 5 minutes and protein concentration of collected super-
natants determined by bicinchoninic acid (BCA) assay (Pierce) and immediately used for
experiments. Indicated protein concentrations were incubated with 10 mM ATP, 100 mM
MgCl2, 100 mM Tris pH 7.5 (all Sigma-Aldrich) and 740 kBq [
18F]D4-FCH at a total vol-
ume of 150 µL. Reactions were carried out for 30 minutes at 37°C, terminated by addition
of 600 µL ice-cold methanol (Sigma-Aldrich) and processed and separated by radio-HPLC,
as described in section 2.3.1.
2.4 Enzyme-based CHKA activity assays
2.4.1 Kinase Glo assay
In white-walled 96-well plates (Costar) and a total volume of 50 µL, 80 ng D49N CHKA2
(a kind gift of Professor Arnon Lavie (University of Illinois) and Professor Manfred Konrad
(Max Planck Institute for Biophysical Chemistry) [71]) was incubated with reaction bu↵er
containing 600 µM choline chloride, 10 µM ATP, 100 mM Tris pH 7.5, 10 mM MgCl2. For
initial optimisation experiments, choline concentrations above KM were chosen to ensure
su cient substrate availability. Reactions were carried out at 37°C or as recommended by
the manufacturer at room temperature for uniform temperatures across the plate. The
reaction was stopped by addition of 50 µl Kinase Glo reagent (Promega) and luminescence
read after 15 minutes on a Tecan Infinite M200 microplate reader. Data were analysed by
fitting of sigmoidal curves with variable slope by least squares (ordinary) fitting method
in GraphPad Prim version 5.01.
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2.4.2 ADP Glo assay
In a total volume of 25 µL, 50 ng D49N CHKA2 was incubated with reaction bu↵er
containing 600 µM choline, 1 mM ATP, 100 mM Tris pH 7.5 and 10 mM MgCl2. Choline
and ATP concentrations were above their respective KM in order to ensure su cient
substrate availability. The reaction was carried out in white-walled 96-well plates (Costar)
by incubation at room temperature. The reaction was stopped by addition of 25 µl ADP
Glo Reagent (Promega) and incubation for 40 minutes. Then, 50 µl Kinase Detection
Reagent (Promega) was added and luminescence read after 30 minutes on a Tecan Infinite
M200 microplate reader. Reaction progress was determined by fitting of curves using
Michaelis-Menten kinetics in GraphPad Prism version 5.01.
2.4.3 PEP / LDH coupled CHKA acitivty assay (IC50)
Choline kinase activity was measured using a modified spectrophotometric pyruvate ki-
nase / lactate dehydrogenase-coupled assay [71]. In a total volume of 50 µL, 20 ng D49N
CHKA2 was subjected to reaction bu↵er containing 72 µM choline (KM), 450 µM ATP
(KM), 100 mM Tris pH 7.5, 100 mM KCl, 10 mM MgCl2, 500 µM phosphoenolpyruvate, 4
units pyruvate kinase, 5 units lactate dehydrogenase and 250 µM NADH (all from Sigma-
Aldrich) in presence of varying concentrations of inhibitor. The reaction was carried out
at 37°C in UV-star half-area 96-well microplates (Greiner Bio-one) and initiated by addi-
tion of reaction bu↵er. ADP formation was indirectly measured by detection of NADH
depletion at 340 nm on a Tecan Infinite M200 microplate reader. Half-maximal inhibitory
concentrations (IC50) were calculated by fitting of sigmoidal curves with variable slope by
least squares (ordinary) fitting method in GraphPad Prim version 5.01.
The mode of inhibition was determined by Lineweaver-Burk plots. To assess competi-
tiveness with choline, ATP was kept constant at 450 µM, while choline concentrations were
varied between 40 µM and 20 mM. Competitiveness with ATP was determined by keeping
choline constant at 72 µM while varying ATP concentrations between 10 µM and 5 mM.
Both experiments were carried out in absence or presence of 0.1, 1, 10 µM inhibitor. Dou-
ble reciprocal plots of substrate concentrations versus velocity were obtained as described
elsewhere [143] and linear regression (best fit by minimised sum of squares) performed in
GraphPad Prism version 5.01. Due to the endogenous ATPase activity of CHKA2, which
results in higher than anticipated velocity at low substrate concentrations, data are curved
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in some cases where the lowest substrate concentration had to be excluded once reciprocal
velocity changed in non-linear fashion.
2.5 Molecular modelling
All calculations were performed at Imperial College High Performance Computing cluster
by Dr. Ola A˚berg. Ligands were drawn in ChemDraw, imported into Maestro (version
9.2.112, Schrodinger) and prepared using LigPrep, Epik (pH 7± 2) and OPLS2005 force
fields. The protein was imported from the PDB-database (3G15.pdb). Chain A was used
throughout the study and the Protein Preparation Wizard was used to remove water
molecules, to add hydrogens, hydrogen bonding network optimisation and finally for a
restrained energy minimisation. For some dockings two water molecules close to the biding
site of HC-3 that connects Asp306, Asn345 and Glu349 and Arg444 were kept, as well as
one water molecule that is involved in bridging hydrogen bonding between the carboxylate
of Glu206 and N7 of ADP. Docking grids were constructed from the resulting proteins
using the grid generator in GLIDE. The box was placed around HC-3 and ADP (virtually
connected via a carbon chain bond into a single ligand for convenient positioning of the
box around the site). The size of the grid box was adjusted to dock ligands < 36 A˚.
Docking of the inhibitors 3–13 (compound 7 in multiple protonation states) was performed
with GLIDE in standard precision (SP) or extra precision (XP) mode, sample nitrogen
inversions, sample ring conformations (2.5 kcal/mol) and expanded sampling. 15 000 poses
per ligand were kept during the initial state and 800 were kept for energy minimisation
(dielectric constant 2.0 and maximum minimisation steps 1000). The van der Waals radii
of the ligands were scaled with 0.8 and with a partial cut-o↵ of 0.15. No constraints
were used. The ligand interaction diagram script (Schrodinger) was used to generate 2D-
representations of the binding modes. For subsequent scoring of the docked ligands with
the molecular mechanics generalised Born surface area (MM-GBSA) method the Prime
module within Schrodinger was used. The flexible residues including the water molecule
within 5 A˚ from the ligand were minimised with a harmonic constraint applied. All non-
flexible residues were frozen. The ligand interaction diagram tool was used to construct
Figures 3.15–3.17. Docking was evaluated both in the presence and in the absence of
ADP and crystal water molecules in close proximity to the binding site. The presence
or absence of the water molecules that connects Asp306, Asn345 and Glu349 and Arg444
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did not alter the binding poses significantly, however removal of the water molecule in the
ATP-site resulted in the loss of a hydrogen bond and lower scores, hence in subsequent
dockings the water molecule in the ATP site was kept.
2.6 Growth inhibition assay (GI50)
Half-maximal growth inhibitory concentrations (GI50) were determined in clear 96-well
plates (Costar) using sulforhodamine B (SRB) assay as described elsewhere [163]. Cell
numbers were optimised that the SRB-derived signal was in the linear range of the assay
and the following seeding densities were used: 2 000 cells per well, HCT116; 2 500, MCF7
and A2780; 3 000, HEC-1B; 4 000, A431 and A549; 7 000, Ishikawa and Caco-2; 10 000,
MDA-MB361; 20 000, St-T1b and CCD-18Co. Cells were seeded in a volume of 150 µL and
allowed to attach overnight. Cells were treated in sixtuplicates with medium or 9 di↵erent
concentrations of inhibitor in 50 µL medium and incubated for 72 hours at 37°C. Cells
were fixed by addition of 50 µL 10% trichloroacetic acid (Sigma-Aldrich) for 1 hour at 4°C,
washed with tap water and dried. Cells were stained with 50 µL 0.4% SRB in 1% acetic acid
(both Sigma-Aldrich) for 1 hour, rinsed with 1% acetic acid and dried. The stained protein
was solubilised by addition of 150 µL 10 mM Tris and optical densities measured at 540 nm
using a Multiskan EX spectrophotometer (Thermo Scientific). Growth inhibition curves
were plotted as percentage of control cells and GI50 determined by fitting of sigmoidal
curves with variable slope by least squares (ordinary) fitting method in GraphPad Prism
version 5.01.
2.7 [3H]choline whole cell CHK inhibition assay (EC50)
Inhibitor-dependent reduction of CHK activity in whole cells was determined in HCT116
cells by monitoring the decrease of PCho formation following a modified Bligh and Dyer
extraction [164]. In brief, HCT116 cells were seeded in 6-well plates and treated with 0.16,
0.8, 4, 20 and 100 µM inhibitor for 1 hour and pulsed in presence of inhibitor with 18.5
kBq/mL [3H]choline chloride (PerkinElmer) at a total volume of 2 mL for an additional
hour. Cells were washed 3 times in cold PBS and 750 µL of methanol/chloroform (2:1;
both from Sigma-Aldrich) added. The solubilised cytosolic content was transferred into
microcentrifuge tubes and 200 µL H2O added. Samples were centrifuged for 10 minutes
and 750 µL supernatant transferred to fresh microcentrifuge tubes. 250 µL chloroform
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and 250 µL H2O were added and samples vortexed and centrifuged. 650 µL of the upper
aqueous phase was transferred to a fresh microcentrifuge tube and 500 µL 12 mM sodium
phosphate (pH 7.0) and 750 µL 5 mg/mL tetraphenylborate (TPB) in heptan-4-one (all
from Sigma-Aldrich) added. Samples were vortexed and the phases separated by cen-
trifugation. The choline-containing upper phase was discarded and any residual choline
re-extracted with 500 µL TPB from the lower PCho phase. After vortexing and centrifu-
gation, 200 µL of the lower aqueous phase was added to 2 mL of Ultima Gold scintillation
cocktail (PerkinElmer) and radioactivity measured on a Beckman multipurpose LS6500
scintillation counter. [3H]PCho content was normalised to protein as determined by BCA
assay and compared to drug-na¨ıve control cells.
2.8 siRNA transfections
HCT116 cells were transfected with siRNAs targeting CHKA (12.5 nM; Dharmacon,
Cat. Nr.: L-006704-00-0005), CHKB (12.5 nM, Dharmacon, L-006705-00-0005), or non-
targeting scramble control (SCR; 12.5 nM; Dharmacon, D-001810-10-2). For CHKA and
CHKB double knockdown 25 nM siRNA each was used. Plated cells were transfected with
RNAiMAX (Invitrogen) according to manufacturer’s instructions.
2.9 Caspase 3/7 Glo assay
Apoptosis was determined using Caspase 3/7 Glo assay (Promega) according to the man-
ufacturer’s instructions. Briefly, cells were seeded into white opaque 96-well plates and
treated in at least quadruplicate. Caspase Glo reagent was added and luminescence mea-
sured after 60 minutes on a Tecan Infinite M200 microplate reader. Values were normalised
to protein content of cell treated in parallel as determined by SRB assay.
2.10 Western blotting
Cells were lysed in radioimmunoprecipitation assay (RIPA) bu↵er containing protease
and phosphatase inhibitors (all from Sigma-Aldrich). Snap-fozen tumour samples were
homogenised in RIPA bu↵er using CK14 bead-containing tubes with a PreCellys 24 ho-
mogeniser (2 cycles of 25 seconds at 6 500 revolutions per minute; Bertin Technologies).
Equal amounts of protein (20 µg) were resolved on 4–15% mini-protean TGX gels (Biorad)
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and transferred to PVDF membranes (Trans-Blot Turbo Transfer Packs, Biorad). Mem-
branes were blocked for 1 hour in 5% milk in Tris-bu↵ered saline or phosphate bu↵ered
saline containing 0.1% v/v tween-20 (TBST or PBST) and incubated with the following an-
tibodies overnight at 4°C: Actin (Abcam, Cat. Nr.: ab6276), pAkt (Cell Signaling, 4060),
Akt (Cell Signaling, 2920), ATF4 (Cell Signaling, 11815), Bax (Millipore, 06-499), Bcl2
(Millipore, 05-729), CHKA (Sigma-Aldrich, HPA024153), EGFR (Cell Signaling, 4267),
pErk (Cell Signaling, 4370), Erk (Cell Signaling, 4695), GAPDH (Cell Signaling, 5174S),
HER2 (Cell Signaling, 2165 for visualisation of p95HER2 and full-length HER2 bands and
Cat. Nr: 4290 for blots where only full-length HER2 is shown), HSP90 (Cell Signaling,
4876), HSP90 (Santa Cruz Biotechnology, sc-69703), IRE1a (Cell Signaling, 3294), and
Ubiquitin (Cell Signaling, 3936). Secondary HRP-conjugated mouse and rabbit antibod-
ies (Santa Cruz Biotechnology, sc-2004 and sc-2005, respectively) were applied for 1 hour
at room temperature. Signals were visualised using Amersham ECL Western Blotting
Detection Reagent (GE Healthcare) and Amersham Hyperfilm (GE Healthcare).
2.11 RNA extraction and qRT-PCR
RNA was extracted from cells using RNeasy Mini Kit (Qiagen) and 1 µg total RNA
reverse transcribed using QuantiTect Reverse Transcription Kit (Qiagen). Gene expres-
sion was analysed by quantitative real-time PCR (qRT-PCR) using SYBR green method.
Primers and Platinum SYBR Green qPCR SuperMixUDG (Invitrogen) were added ac-
cording to manufacturer’s instructions to 5 µL cDNA (1:10 dilution) for a total volume
of 20 µL. The following custom designed primers were supplied by Invitrogen: CHKA
(F: CGGAAGTATCCCACCAAGAA; R: TCCCCAGAGGAAATGAGATG), ETNK1 (F:
AGCCTCCTGCAACACCTG; R: TGTGATTCCATCTGTGAAGACC); ETNK2 (F: GC-
TATGAGTACATGCAGGGTGT; R: TGCCATTTCTAAGGCGATTAAC), PCYT1A (F:
GCAACCAGCTCCTTTTTCTG; R: GCAAACTCCCACAATGAGGT), PPIA (F: CT-
GCACTGCCAAGACTGA, R: CATTCCTGGACCCAAA). Primers were used at a fi-
nal concentration of 500 nM. The following primer assays from PrimerDesign were used:
CHPT1 (F: TCTGCTCTTTTATTGGGATGTTTG; R: CAACACAAAGACAATCAC-
TAAAGC), PLD1 (F: CTCTGCTGCTGATTGGTCTG; R: GATATAGATATAGTGC-
CTGCTGCTGTTC), PLD2 (F: GCCAGCACTTTCCTCTACATTG, R: CATCGCCCAC-
CTTGTTCAG), GPCPD1 (F: CCCTGGACTTCCTCTCTGTG; R: GAAGTTTCCA-
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CAAGGGCTCAG). Primers were used at a final concentration of 300 nM. Gene expression
assays were performed on an ABI 7900HT Fast Real-Time PCR machine (Applied Biosys-
tems) under the following conditions: 50°C for 2 minutes, 95°C for 2 minutes, 40 cycles
of 95°C for 3 seconds and 60°C for 30 seconds, followed by a dissociation step. Data were
analysed using comparative CT method as described elsewhere with PPIA as internal
control [165].
2.12 DNA cell cycle analysis using flow cytometry
HCT116 cells were incubated with drugs or siRNA for indicated times. Supernatant and
cells were harvested, washed and centrifuged. The cell pellet was resuspended it 1 mL
ice-cold PBS and the suspension added to 9 mL 70% ethanol, while mixing gently. Cells
were fixed for at least 2 hours at –20°C. Cells were centrifuged and rehydrated in 3 mL cold
PBS for 15 minutes. Samples were stained in 500 µL bu↵er containing 100 mM Tris pH
7.4, 150 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, 0.1% Triton X-100, 0.1 mg/ml RNase A,
50 µg/ml propidium iodide (all items from Sigma-Aldrich) at 37°C for 3 hours protected
from light. Data of 10 000 cells per treatment were acquired on a BD FACSCanto flow
cytometer (BD Bioscience) and analysed using FlowJo 7.6.4 software (Tree Star).
2.13 Transfection of U2OS cells with CHKA and CHKB
U2OS cells were transfected with GFP-tagged ORF clones of CHKA or CHKB (Insight Bio,
Cat. Nr: RG207209 and RG210253, respectively) using Lipofectamine 2000 (Invitrogen)
according to manufacturer’s instructions. In brief, 4 µg DNA was diluted with OptiMEM
(Invitrogen) to a volume of 100 µL and combined with a solution of 12.5 µL transfection
reagent and 87.5 µL OptiMEM. After incubation for 20 minutes at room temperature, the
transfection complexes were added to 2.5× 105 cells in 2 mL OptiMEM seeded in 6-well
plates. After 6 hours, the medium was replaced with fresh complete growth medium.
The following day, cells were transferred to 15 cm dishes and 48 hours post transfection,
cells were exposed to 0.5 mg/mL G418 (Invitrogen) for selection. Individual clones were
picked using cloning cylinders (Sigma-Aldrich). GFP expression of individual clones was
determined using flow cytometry. Cells were trypsinised, washed 3 times with PBS and
diluted to a concentration of 1× 106 cells per mL. Fluorescence was detected on a FACS
canto flow cytometer and analysed using FlowJo 7.6.4 software.
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2.14 Native gel western blots to detect protein dimerisation
Native gels were run using blue native polyacrylamide gel electrophoresis (BN-PAGE)
method [166]. Cell homogenates were obtained by addition of passive lysis bu↵er (Promega)
containing protease and phosphatase inhibitors to cell pellets and incubation for 30 min-
utes on a tube rotor at 4°C. After centrifugation for 20 minutes at 12 000× g at 4°C, the
protein concentration of the collected supernatants was determined by BCA assay. Sam-
ples were prepared by mixing 30 µg protein with an equal volume of 2× sample bu↵er
(62.5 mM Tris-HCl, pH 6.8, 25% (v/v) glycerol, 0.01% (w/v) bromophenol blue, 0.02%
(w/v) Coomassi Blue G250; all from Sigma-Aldrich). As control, D49N CHKA2 was ei-
ther applied under native conditions (100 ng diluted to 10 µL in 100 mM Tris bu↵er pH
7.4 added to 10 µL 2× sample bu↵er) or denatured using SDS [100 ng diluted in RIPA
bu↵er, 1× NuPAGE LDS sample bu↵er and 1× sample reducing agent (both Invitrogen)]
and incubated at 70°C for 10 minutes. Samples were resolved on 4–15% mini-protean
TGX gels using 1× native running bu↵er (25 mM Tris, 192 mM glycine, pH 8 .3). The
cathode bu↵er was additionally supplemented with 750 µL Coomassi Blue G250 [final
concentration ca. 0.04% (w/v)]. Membranes were transferred and probed as described in
section 2.10.
2.15 [3H]choline uptake
HCT116 cells were seeded at a density of 3× 105 cells/well into 12-well plates. In some
experiments, cells were treated as indicated. Cells were incubated with 18.5 kBq/mL
[3H]choline chloride in 500 µL for 1 hour, washed 3 times with PBS, trypsinised, neutralised
with complete medium and centrifuged. Pellets were washed 3 times with PBS and lysed
in 120 µL RIPA bu↵er. The radioactivity of 100 µL lysate was counted on a Packard Cobra
II gamma counter (Perkin Elmer) and normalised to protein content, as determined by
BCA assay.
2.16 Lactate dehydrogenase assay
Cell membrane integrity was assessed using a fluorescent kit measuring lactate dehydro-
genase (LDH) release (CytoTox-ONETM, Promega) according to the manufacturer’s in-
structions. In brief, HCT116 cells (5 000 cells/well) were incubated in 96-well plates for
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4 hours with test compounds at a total volume of 100 µL. Plates were allowed to adjust
to room temperature and 50 µL CytoTox-ONETM solution was added. The reaction was
terminated after 10 minutes by addition of 25 µL stop solution. The fluorescence was
measured at an excitation wavelength of 560 nm and an emission wavelength of 590 nm.
Background readings were subtracted and results expressed in per cent to maximal LDH
release, as measured after incubation with Triton X-100.
2.17 [3H]choline pulse-chase experiment
HCT116 cells were seeded at a density of 3× 105 cell per well into 12-well plates and
incubated overnight. Cells were treated with 1 or 10 µM ICL-CCIC-0019 for 1 hour and
pulsed in presence of inhibitor with 18.5 kBq/mL [3H]choline chloride in 500 µL for 1
additional hour. Then, cells were briefly rinsed with RPMI and incubated with fresh, non-
radioactive medium for 6 hours. Metabolites were extracted as described in section 2.7, but
additionally the radioactivity of the choline-containing and chloroform (lipid-containing)
fractions was measured.
2.18 Immunofluorescence
HCT116 cells (3× 104) were seeded into 4-well chamber slides (BD Biosciences), cultured
overnight and treated with 1 or 10 µM ICL-CCIC-0019 for 24 hours or 2 µg/mL tuni-
camycin (Sigma-Aldrich) for 4 hours. Cells were washed 2× 5 minutes with PBS and fixed
with 4% formaldehyde (Sigma-Aldrich) in PBS for 15 minutes at room temperature. Cells
were washed 3× 5 minutes with PBS and permeabilised with 100 µL 0.1% Triton-X100
(Sigma-Aldrich) in PBS for 10 minutes at room temperature. Cells were washed 3× 5
minutes with PBS at room temperature and blocked with 1% BSA / 0.1% Triton in PBS
(PBST-BSA) for 1 hour at room temperature. Cells were incubated with CHOP primary
antibody (Cell Siganling, Cat. Nr: 2895S) at a dilution of 1:3 000 in 100 µL/well PBST-
BSA overnight at 4°C. The next day, cells were washed 3× 10 min PBS and incubated with
secondary Alexa fluor 594 goat anti-mouse IgG antibody (Invitrogen, Cat. Nr: A-21125) at
a dilution of 1:400 in 100 µL PBST-BSA for 1 hour at room temperature in the dark. Cells
were washed 3× 10 minutes with PBS actin fibres stained with Phallloidin Alexa Fluor
488 (Invitrogen, Cat. Nr: A12379) for 15 min at room temperature. Cells were washed
3× 10 minutes with PBS and coverslips mounted using ProLong Gold Antifade Reagent
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containing DAPI (Invitrogen, Cat. Nr: P-36931). Images were acquired on an Olympus
BX51 microscope and DP controller software version 2.1.
2.19 High-performance liquid chromatography (HPLC)
The HPLC system comprised of a Waters 600E series connected to a Waters 717 autosam-
pler and a Waters 2487 dual UV detector. The stationary phase was a Gemini-NX 5
µm C18, 150× 4.6 mm column (Phenomenex) protected by a guard column. The mobile
phase solvent A was water with 0.1% trifluoroacetic acid and solvent B was methanol with
0.1% trifluoroacetic acid (all Sigma-Aldrich). Compounds were separated at a flow rate
of 1 mL/min using a gradient of 95% A for 1 minute, 95–5% A for 4 minutes, 5% A for
10 minutes, 5-95% A for 1 minute and 95% A for 4 minutes. ICL-CCIC-0019, propranolol
and verapamil were detected at a wavelength of 290 nm, hydrocortisone at 240 nm and
vinblastine at 254 nm. Between each injection the column was rinsed for 2 minutes. The
analysis was carried out at room temperature.
2.20 In vitro metabolism
Human and mouse liver microsomes (BD Bioscience, Cat. Nr.: 452117, 452702, 452116
and 452792) were used to predict phase I metabolism. These subcellular fractions of liver
homogenates contain a variety of metabolic enzymes. While mouse microsomes originated
from a pure-bred strain of female CD-1 mice, human microsomes represent a pool of
150 donor livers to reduce intra-subject variability. Furthermore, S9 fractions were used,
which additionally contain cytosol and therefore di↵erent metabolic enzymes. In a total
volume of 250 µL, compounds were incubated at a concentration of 10 µM with 1 mg/mL
microsomes, 100 mM Tris pH 7.0 and 1 mM freshly prepared NADPH (Sigma-Aldrich).
Control samples did not contain microsomes. After incubation for 60 minutes at 37°C, the
reaction was stopped by placing samples on ice and addition of 1 mL ice-cold methanol
containing 10 µM hydrocortisone (Sigma-Aldrich) as internal standard. Proteins were
allowed to precipitate for 30 minutes at –20°C. Samples were centrifuged at 14 000× g for
10 minutes and supernatants dried on a rotary evaporator. Residues were resuspended in
300 µL water containing 0.1% trifluoroacetic acid (Sigma-Aldrich), filtered and analysed
by HPLC, as described in section 2.19. Peak areas were normalised to internal standard
and data expressed as per cent parent compound detected compared to control.
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2.21 Cell permeability in Caco-2 cells
Caco-2 cells (8× 104) were seeded on the permeable support of transwell plates (Millipore,
Cat. Nr.: PSRP010R5) and allowed to form a tight monolayer for 21 days with medium
changes every other day. Cells were gently washed 3 times with warm Hank’s bu↵ered salt
solution (HBSS, Thermo Scientific) and monolayer integrity confirmed by measuring trans
epithelial electric resistance (TEER), where values of ca. 400 W*cm2 indicated tightness
[167, 168]. Compounds were added at a concentration of 10 µM in HBSS either to the
apical side to determine absorption (i.e. permeability from the apical side to the basal side;
Papp A-B) or to the basolateral side to measure secretion (i.e. permeability from the basal to
the apical; Papp B-A). After 2 hours on an orbital shaker at 37°C, drug concentrations were
quantified by HPLC as described in section 2.19. After the experiment, monolayer integrity
was re-assessed by applying lucifer yellow to the upper compartment and quantifying
transport to the lower compartment. The concentration in the receiver well was < 1%
confirming an intact cell layer throughout the experiment. Permeability was calculated
with the following equation:
Papp = Va × drug conc. acceptor
A × T × initial drug conc. donor (2.1)
where Va is the volume of the acceptor in cm
3, A the area of the cell monolayer in cm2
(0.7 cm2), and T time in seconds (7 200). The Papp is expressed in cm/sec.
The mass balance is the percentage of drug left at the end of the experiment. It was
determined to ensure that results are not biased by e.g. intracellular metabolism, com-
pounds bound to culture dish or intracellular retention. The mass balance was calculated
with the following equation:
MB = (Cat × Va) + (Cbt × Vb)
C0 × Vd (2.2)
where Ca and Cb are the drug concentrations and Va and Vb the volumes in chambers
A and B at the end of experiment (time t), respectively, C 0 is the drug concentration in
the donor chamber at time 0 and Vd is the volume of the donor solution added. A mass
balance greater than 80% is regarded as acceptable [169] and values > 90% were measured.
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2.22 Plasma protein binding
Plasma protein binding was determined using rapid equilibrium dialysis (RED) plates
(Thermo Scientific, Cat Nr.: 90006) according to manufacturer’s instructions. In brief,
10 µM compound was diluted in human or mouse plasma (Sera Laboratories, Cat. Nr.:
PLH-123-H and PLHCD-808-J) and 300 µL applied to the sample chamber, while 500 µL
PBS was pipetted into the receiver chamber. Plates were covered with sealing tape and
incubated at 37°C for 4 hours on an orbital shaker at 100 revolutions per minute. Samples
from both chambers were transferred to microcentrifuge tubes and 250 µL PBS added to
plasma samples and 250 µL plasma added to PBS samples. Proteins were precipitated
by addition of 1 mL methanol containing 10 µM hydrocortisone as internal standard and
incubation at –20°C for 30 minutes. Samples were centrifuged at 14 000× g for 10 minutes,
supernatants dried on a rotary evaporator, residues solubilised in 300 µL water containing
0.1% trifluoroacetic acid, filtered and analysed by HPLC, as described in section 2.19.
2.23 Tumour model for the evaluation of ICL-CCIC-0019
All animal experiments were conducted in accordance with the United Kingdom Home Of-
fice Guidance on the Operation of The Animals (Scientific Procedures) Act 1986 Amend-
ment Regulations 2012 and within the published guidelines for the welfare and use of
animals in cancer research [170].
Xenografts were established in female BALB/c nude mice aged 6–8 weeks (Harlan) by
subcutaneous (s.c.) injection of 100 µL HCT116 cells (5× 106 in PBS) on the back of mice.
Tumour dimensions were measured frequently using a calliper and volumes calculated by
the following equation: volume mm3 = (⇡￿6) × a × b × c, where a, b, and c represent 3
orthogonal axes of the tumour. When tumour volumes reached approximately 50–100 mm3
(ca. 10 days post injection), mice were used for subsequent studies.
2.24 Pharmacokinetic and plasma metabolite studies
Plasma pharmacokinetic parameters of ICL-CCIC-0019 were established in female BALB/c
mice aged 6-8 weeks (Harlan). Mice were intraperitoneally (i.p.) or perorally (p.o.) ad-
ministered a single dose of 10 mg/kg and blood collected by cardiac puncture after 5, 15, 30
minutes and 1, 2, 4, 6 and 24 hours. For tissue pharmacokinetic studies, HCT116 xenograft
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bearing mice were administered 10 mg/kg ICL-CCIC-0019 i.p. and blood collected after
5 minutes, 2, 6 and 24 hours. Plasma was obtained by centrifugation at 1 000× g for 10
minutes. Samples were snap-frozen and stored at –80°C prior to analysis. Analysed was
carried out by Cyprotex Inc. using liquid chromatography–mass spectrometry (LC–MS).
For analysis of plasma metabolites, 2 hour samples of tissue pharmacokinetic studies were
pooled and analysed by Cyprotex using LC–MS.
2.25 PET-CT imaging studies related to ICL-CCIC-0019
Mice were anesthetised through isoflurane inhalation and scanned on a Siemens Mul-
timodality Inveon small animal PET-CT scanner for [18F]D4-FCH PET studies using
HCT116 xenografts. Low dose CT scans were first acquired (80 kVp, 0.5 mA, 220 de-
gree rotation, 600 ms per degree exposure time, 80 µm reconstruction pixel size) for PET
attenuation correction and anatomical reference. PET images were acquired following a
bolus i.v. injection of approximately 3.7 MBq tracer in the tail vein. Dynamic emission
scans were acquired in list mode format over 60 minutes. Data were sorted into 0.5-mm
sinogram bins and 19 time frames for image reconstruction by filtered back projection
(4× 15 seconds, 4× 60 seconds and 11× 300 seconds).
For [18F]D4-FCH studies in HCT116-shRNA tumour bearing mice, cohorts were im-
aged on a GENISYS4 small animal PET scanner (Sofie Biosciences), following a bolus
i.v. injection of ca. 1.85 MBq of radiotracer. Dynamic PET images were acquired in
list mode format and data were sorted into 19 time frames for image reconstruction by
maximum-likelihood expectation maximisation (4× 15 seconds, 4× 60 seconds and 11× 300
seconds).
To image proliferation using [18F]FLT, ca. 1.85 MBq radiotracer was injected i.v. and
static scans were acquired on a GENISYS4 scanner for 10 minutes (50–60 minutes post
injection) and images were reconstructed using maximum-likelihood expectation maximi-
sation.
The Siemens Inveon Research Workplace software was used for visualisation of radio-
tracer uptake. To define 3-dimensional regions of interest (ROI), 30 to 60-minute cumula-
tive images of the dynamic data and the 10-minute frame of static scans were employed.
Arterial input function was estimated by drawing ROIs over the centre of the heart cavity
using cumulative images from 0.25 to 2 minutes of the dynamic series, a method, previ-
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ously validated for use in rodents [114]. The count densities were averaged for all ROIs at
each time point to obtain time versus radioactivity curves (TAC). Tumour TACs were nor-
malised to injected dose measured by a VDC-304 dose calibrator (Veenstra Instruments)
and normalised uptake was expressed as percentage injected dose per mL tissue (NUV;
%ID/mL).
2.26 Kinetic modelling of [18F]D4-FCH data
Kinetic analysis of PET data was performed by Dr. Giampaolo Tomasi applying a standard
two-tissue irreversible compartmental model described in detail elsewhere [110].
2.27 Antitumour Activity
For e cacy studies HCT116 tumour bearing mice were employed. Dosing commenced
when tumours reached ca. 50 mm3 using described schedules and changes in tumour volume
and body weight were monitored.
2.28 shRNA targeting CHKA
Doxycycline (DOX)-inducible lentiviral pTRIPZ vectors encoding for shRNAs targeting
CHKA2 (ThermoScientific, clones: V2THS 113013, V3THS 335370 and V3THS 335372)
or non-targeting control (ThermoScientific) were purified from bacterial stocks using Plas-
mid Midi Kit (Qiagen) and size verified on a 1% agarose gel. Recombinant lentiviruses
were generated using Trans-Lentiviral shRNA Packaging System (Open Biosystems). 6 µg
lentiviral transfer vector shRNA, 4.2 µL trans-lentiviral packaging mix and 15 µL CaCl2
were diluted with water to a total volume of 150 µL. While vortexing, 150 µL 2×HBSS was
added, precipitates allowed to form for 3 minutes. The suspension was added to 1.2× 106
HEK293T cells plated in 6-well plates. The following day, the medium was replaced with 2
mL reduced-serum medium (high glucose DMEM containing 5% FCS, 2 mM L-glutamine
and 1×penicillin-streptomycin). Cells were incubated for additional 48 hours. The viral
particles-containing supernatants were centrifuged at 2 000× g at 4°C for 10 minutes to
pellet cell debris and 200 µg/mL polybrene (Sigma-Aldrich) was added to supernatants.
The solution was added to 3× 104 HCT116 cells seeded in 24-well plates and incubated
overnight. The medium was replaced with complete RPMI and cells incubated for ad-
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ditional 48 hours. Transduced clones were selected by addition of 1 µg/mL puromycin
(Invitrogen). Clones were induced with 0.5 µg/mL DOX for 48 hours and the 90th per-
centile of cells with highest fluorescent intensity collected by fluorescence-activated cell
sorting (FACS). Knockdown of protein was determined by western blotting.
2.29 Drug combination experiments
HCT116 cells were seeded at a density of 2 000 cells per well into 96-well plates. For
each drug combination, 5 plates were used. The following day, cells were treated with 9
doses of ICL-CCIC-0019 alone or in combination with 0.1, 0.5, 1 and 5 µM C1A or 0.01,
0.05, 0.1, 0.5 µM vorinostat. Each plate therefore contained varying concentrations of ICL-
CCIC-0019 and a fixed concentration of HDAC inhibitor. After 72 hours, proliferation was
measured by SRB assay as described in section 2.6. Data was analysed using CalcuSyn
software, based on the Chou-Talalay method [171]. The derived combination index (CI)
indicates anatagonism if CI> 1, additive e↵ects if CI= 1 and synergy if CI< 1. Data
represent the mean of 3 independent experiments carried out in sextuplicate.
2.30 Surface Plasmon Resonance
This experiment was carried out by Syngene Inc. and data provided by GE Healthcare.
Human, rhesus and rat HER2-ECD-Fc (SINO Biological, Cat. Nr: 10004-H02H, 90020-
K02H, and 80079-R02H), as well as human HER2-ECD-Fc-6XHis (R&D Systems, Cat.
Nr: 1129-ER) and p95HER2 ECD-Fc-6XHis (Syngene) were diluted with 50 mM sodium
acetate pH 4.5 (Biacore coupling bu↵er; GE Healthcare) to a final concentration of 10
µg/mL. Antigen coupling to sensor chip CM5 (GE Healthcare; Cat. Nr: BR-1005-30)
was done according to manufacturer’s amine coupling protocol. HBS-EP bu↵er (10 mM
HEPES pH 7.4,150 mM NaCl, 3 mM EDTA and 0.005% surfactant P20; GE Healthcare;
Cat. Nr: BR-1006-69) was used as running bu↵er and as solvent for isotopically unmodified
GE-226. The a nity studies were performed using a Biacore T100 (GE Healthcare). GE-
226 was injected over the surface in concentration range of 0.05–50 nM followed by HBS-
EP to monitor dissociation. The chip was regenerated with 50 mM sodium hydroxide
followed by a 60 seconds run of HBS-EP to stabilise the surface. Kinetic calculations were
performed using Langmuir 1:1 binding model and simultaneous calculation of association
and dissociation phase.
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2.31 Cells and treatments for evaluation of [18F]GE-226
For siRNA-mediated HER2 knockdown, SKOV-3 cells were transfected with 25 nM scram-
ble control or HER2-targeting siRNA (Invitrogen ERBB2 Silencer Select Validated siRNA;
Cat. Nr: 4457298) by reverse transfection with Lipofectamine RNAiMAX (Invitrogen) ac-
cording to manufacturer’s instructions. 3× 105 cells were seeded in 12-well plates 48 hours
prior to uptake experiment. Target knockdown was verified by western blotting on cells
that were transfected in parallel.
For all uptake studies in response to drug treatment, 2.5× 105 SKOV-3 cells were
seeded in complete medium 48 hours prior to uptake experiments. Cells were incubated
with indicated doses of NVP-AUY922 (LC Laboratories) for 24 hours and 10 µg/mL
trastuzumab (Roche) for 1 or 24 hours prior to addition of radiotracer.
2.32 In vitro [18F]GE-226 uptake assay
For baseline uptake, 3× 105 cells were seeded in complete media in 12-well plates and
allowed to recover overnight. Cells were washed twice with serum-free medium and pulsed
with 370 kBq in 500 µL serum-free medium for 1 hour. For blocking studies, cells were
co-incubated with tracer and 0.5 mg/mL cold, isotopically unmodified GE-226.
Cells were washed with PBS, trypsinised, neutralised with complete medium and cen-
trifuged. The pellet was washed three times with PBS and lysed in 120 µL RIPA bu↵er.
The radioactivity of 100 µL lysate was counted on a Packard Cobra II gamma counter
(Perkin Elmer). Radioactivity was normalised to applied radioactivity and protein con-
tent, as determined by BCA assay.
2.33 Small animal experimental models and treatments for
[18F]GE-226 PET studies
For all but SKOV-3 xenografts, mice were s.c. implanted with 0.72 mg/60 day release
oestradiol pellets (Innovative Research of America) approximately 2 days before cell in-
oculation. Xenografts were established by s.c. injection of 100 µL MCF7-vector, MCF7-
p95HER2 and MCF7-HER2 cells (1.5× 107 cells in PBS mixed 1:1 with Matrigel, BD
Bioscience), MDA-MB-361 cells (5× 106 cells in PBS mixed 1:1 with Matrigel) or SKOV-3
cells (5× 106 cells in PBS) on the back of mice. Tumour dimensions were measured fre-
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quently by calliper measurements, as described in section 2.23. When tumour volumes
reached approximately 50–100 mm3 (MCF7 models ca. 4 weeks post injection, MDA-
MB-361 xenografts ca. 3 weeks post injection and SKOV-3 xenografts ca. 6 weeks post
injection), mice were used for subsequent studies.
For blocking studies, SKOV-3 xenograft bearing mice were administered 500 µg (ca. 25
mg/kg) cold isotopically unmodified GE-226 i.v. through the tail vain 20 minutes before ad-
ministration of radiotracer. To assess interaction of radiotracer with trastuzumab, SKOV-3
xenograft-bearing mice were treated with 50 mg/kg trastuzumab i.p. 2 hours prior to the
scan. Animals were recovered, treated twice more with 25 mg/kg trastuzumab i.p. and
re-scanned 7 days after initial dose. To investigate response to HSP90 inhibition, SKOV-3
xenograft-bearing mice were treated with 50 mg/kg NVP-AUY922 or equivalent volume
of vehicle (ca. 5 µL/g body weight; 10% DMSO and 5% Tween-20 in PBS) once a day
i.p. for three days. 24 hours after the last treatment, animals were used for PET imaging.
2.34 [18F]GE-226 PET-CT imaging
Mice were anesthetised through isoflurane inhalation and 60 minute dynamic emission
scans acquired on a Siemens Multimodality Inveon small animal PET-CT scanner, as
described in section 2.25. Where indicated, cumulative images of the dynamic data (30 to
60 minutes) were iteratively reconstructed (OSEM3D) for qualitative image visualisation.
2.35 ELISA
Excised and snap frozen tumour tissue samples were homogenised in RIPA bu↵er with
the PreCellys 24 homogenizer and CK14 beads-containing tubes (two cycles of 25 seconds
at 6 500 rpm). HER2 expression was determined by ELISA (Calbiochem, c-ErbB2/c-Neu
Rapid Format ELISA Kit, Cat. Nr: QIA10-1EA) according to manufacturer’s instructions.
2.36 Metabolic stability of [18F]GE-226
Metabolic stability of the radiotracer was assessed by GE Healthcare. Male Wistar rats
were administered 20 MBq [18F]GE-226 i.v. through the tail vein. At 10, 30 and 60
minute post injection, rats were exsanguinated via cardiac puncture and plasma obtained
by centrifugation. Radioactive plasma metabolites were trapped on a tC2 SPE cartridge
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(Oasis), washed with water and eluted in a mixture of 50% of 100 mM ammonium acetate
(mobile phase A) and 50% of acetonitrile (mobile phase B). The eluate was diluted 1:4
with mobile phase A and 1 mL analysed by radio-HPLC (Gilson) equipped with a BGO
dual coincidence detector. Metabolites were separated using a Luna C5 5µ 4.6×150 mm
analytical column (Phenomenex) at 1 mL/min with a gradient of 95% A for 2 minutes,
95–5% A for 12 minutes, 5–0% A for 4 minutes, 0% A for 4 minutes, 0–95% A for 2
minutes, and 95% A for 8 minutes.
2.37 Biodistribution
Tumour-bearing BALB/c nude mice were administered ca. 3.7 MBq [18F]GE-226 i.v.
through the tail vein. Mice were sacrificed at di↵erent time points by exsanguination.
Tissues were excised, weighed and radioactivity counted using a Packard Cobra II gamma
counter and decay corrected. Data were expressed as percent injected dose per gram of
tissue (%ID/g).
2.38 Kinetic modelling of [18F]GE-226
Kinetic analysis of PET data was performed by Dr. Giampaolo Tomasi applying a standard
two-tissue irreversible compartmental model to fit each tumour TAC with the correspond-
ing image-derived plasma TAC as input function (IF) to estimate K 1 (mL/cm
3/min), k2
(1/min) and k3 (1/min) and the blood vascular component V b (mL blood/mL tissue; unit-
less). The irreversible uptake rate K i (mL/cm
3/min) was computed as K 1 × k3 / (k2+ k3).
To estimate the kinetic parameters the measured tumour TAC (tTAC) was modelled as
tTAC(t) = (1 − Vb)h(t)⊗ pIF (t) + VbIF (t) (2.3)
with h(t) indicating the unknown tissue impulse function and ⊗ the convolution operator.
The parameter vector p = [K 1,k2,k3,V b] was estimated with the standard Weighted Non-
Linear Least Squares (WNLLS) by minimizing the Weighted Residual Sum of Squares
(WRSS) function
WRSS(p) = N￿
i=1wi[tTAC(ti, p)MODEL − tTAC(ti)]2 (2.4)
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with tTAC(ti) and ti indicating the measured concentration in the tumour and mid-time
of i-th frame, respectively, and N denoting numbers of frames. Weights were set to
 i
C(ti) exp( ti) (2.5)
with Di and l representing the duration of the i-th frame and decay-constant of 18F
Ref. [172]. The two-tissue irreversible model was chosen after visual assessment of the
tumour TACs, which showed clear irreversible uptake in most cases. Furthermore, when
a two-tissue reversible compartment model was used, non-physiological estimates of the
parameters characterised by high variance were obtained.
2.39 Synthesis of fluorescein labelled GE-226
Synthesis of fluorescein labelled GE-226 was carried out by Dr. Susan Hoppmann, GE
Healthcare. It was prepared by mixing 5 mg ZHER2:2891 with 1.5 mg fluorescein-5-maleimide
(Pierce, Cat. Nr: 46130) in 1.5 mL 33% acetonitrile/water. The solution was adjusted to
pH 6 by adding ammonium acetate and the reaction mixture shaken for 2 hours. Dimethyl-
formamide (0.5 mL) and water (3 mL) were added and the mixture was shaken for another
hour, diluted with 4 mL water/0.1% trifluoroacetic acid. The product was purified by
semi-preparative HPLC (gradient: 20–35% acetonitrile over 50 minutes) and lyophilised.
2.40 Small animal model for fluorescent GE-226 experiment
This experiment was carried out by Dr. Susan Hoppmann, GE Healthcare. The bilateral
A431/NCI-N87 model was established by s.c. injection of A431 (1× 107 cells) and NCI-N87
cells (2× 106 cells) in 100 µL PBS mixed 1:1 with Matrigel in the lower flanks of 4–6 week
old male CD-1 nude mice (Charles River Laboratories). Tumour volumes were monitored
frequently as described in section 2.23 and when they reached 50–100 mm3 (approximately
3–4 weeks), mice were administered a mixture of Hoechst (ca. 20 mg/kg) and fluorescein-
conjugated GE226 (ca. 15 mg/kg) in 100 µL PBS i.v. through the tail vein. Tumours
were excised 120 minutes post injection, immediately fixed in formalin and embedded
in para n. Sections were sliced and stored in the dark at –80°C. Immunofluorescent
images were acquired at 400× magnification using a Leica DMRB microscope with a
Nikon DS-Ri1 camera and Nikon NIS-Elements D 3.2 software. Fluorescent images were
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acquired by keeping exposure times constant across all slides. Adjacent tumour sections
were immunohistochemically stained with HercepTest.
2.41 Immunohistochemistry
Analysis of HER2 protein expression in excised tumours was carried out by GE Healthcare
using the HercepTest (Dako, Cat. Nr: K5204) according to manufacturer’s instructions.
2.42 Sequencing
Genomic DNA of SKOV-3 cell line and indicated tumour samples were extracted us-
ing PureLink Genomic DNA extraction kit (Invitrogen). Exon 8 was PCR amplified, as
previously described [173], using the following primers: forward, TCAGATCCTGGCT-
GACTGTG; reverse, AACAGCCACATGAGCATCAG (synthesised by Invitrogen). PCR
products were purified using ExoSAP-IT (A↵ymetix) and sent for bi-directional sequenc-
ing at the MRC CSC Genomics Laboratory. Sequences were analysed using Sequencher
software version 5.2.3.
2.43 Statistical analysis
Data were expressed as mean ± standard deviation (SD) or standard error of the mean
(SEM). Unless otherwise specified, the significance of comparison between two data sets
was determined using unpaired, two-tailed Student’s t test (GraphPad Prism version 5.1)
and P < 0.05 defined as significant.
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Chapter 3
Design and Evaluation of Choline
Kinase Inhibitors
This work is associated with [1]:
Trousil S, Carroll L, Kalusa A, Aberg O, Kaliszczak M, Aboagye EO. Design of symmetri-
cal and nonsymmetrical N,N -dimethylaminopyridine derivatives as highly potent choline
kinase alpha inhibitors. MedChemComm. 2013;4:693–6.
Inhibition of CHKA is thought to be a promising intervention for tumours with deregu-
lated choline metabolism. Most results have been achieved by posttranscriptional silencing
or with inhibitors that are di cult to synthesise and not commercially available. In order
to develop accessible inhibitors with drug-like properties and new sca↵olds the CHKA
crystal structure was examined.
3.1 Analysis of CHKA crystal structure
The CHKA crystal structures solved by Malito et al. [71] and Hong et al. [174] were taken
as basis to analyse the binding sites of choline and ATP to rationally design novel inhibitors
(Figure 3.1). The ATP binding site shares similarities with all CHK isoforms, eukaryotic
protein kinases and aminoglycoside phosphotransferases [71]. It comprises of many highly
conserved amino acids, including Asn122, Leu124, Leu144, Arg146 and Leu313, where
induced mutations lead to a loss of function [71]. The choline-binding site contains a deep
hydrophobic groove with negatively charged residues on its rim (Glu215, 217, 218, 309, 349,
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Figure 3.1: Crystal structure of CHKA. A, The structure was derived from RCSB Protein Data
Bank (accession code 3F2S) and analysed in PyMOL. CHKA is in complex with HC-3 (left co-
crystallised structure occupying the choline pocket) and ADP (right). Regions in blue indicate
negatively charged amino acids and red represent lipophilic amino acids. B, Close-contact interac-
tions of HC-3 with the deep end of the choline pocket. Green dashed lines refer to intermolecular
interactions. C, Structure of choline. D, Structure of N,N -dimethylaminopyridine.
357, 434 and Asp353) and at the deep end of the groove (Asp306, Asp330 and Glu349; [71];
Figure 3.1A). It appears that the negatively charged residues on the outside attract the
positively charged choline to guide it into the binding pocket, where it is fixed by Asp306,
Asp330 and Glu349 (Figure 3.1B). The long hydrophobic groove contains aromatic amino
acids (Tyr333, Tyr354, Tyr440 and Trp420, Trp423), which further stabilise the positively
charged amine [71]. Choline phosphorylation occurs through a double displacement mech-
anism, whereby in two discrete steps the g-phsophate of ATP is transferred to choline via
a phospho-enzyme intermediate [147].
Due to the structure of CHKA it was concluded that small-molecule inhibitors should
have the following features: (i) a positively charged quaternary amine group, which mim-
ics choline and (ii) an aromatic moiety adjacent to the amine, which allows p-p interac-
tion with the hydrophobic groove, in particular with Tyr354 (Figure 3.1B). Therefore,
N,N -dimethylaminopyridine (DMAP) was employed as cationic choline-mimicking moiety
(Figure 3.1C–D), as this had been shown in previous work to be a highly e↵ective pharma-
cophore [144]. Although the charge of DMAP is formally on the pyridine nitrogen, it is in
fact delocalised and interacts with the aromatic ring and the nitrogen of the dimethylamino
group. It therefore possesses good balance of charge, lipophilicity and aromaticity.
It was intended to create two di↵erent sca↵olds (Figure 3.2). Symmetrical bis-DMAP
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Figure 3.2: Overview of designed choline kinase inhibitor sca↵olds. Symmetric inhibitors (left)
with di↵erent linker lengths were designed to only interact with the choline pocket. Additionally,
nonsymmetrical inhibitors (right) aimed to inhibit both choline and ATP pockets were designed.
compounds with di↵erent aliphatic linkers would be tested in anticipation to interact with
the negatively charged amino acids and therefore solely inhibit the choline pocket. It was
further attempted to exploit the proximity of the ATP and choline pockets by creating
novel sca↵olds that — for the first time — would permit simultaneous inhibition of both
catalytic sites. These compounds would comprise of a DMAP and the introduction of an
ATP-mimicking moiety in ca. 14 A˚ distance, which corresponds to a chain of ca. 12 car-
bons. Such molecules could potentially have high a nity towards CHKA, while avoiding
the promiscuity of ATP-competitive kinase inhibitors. Furthermore, the decreased over-
all charge could potentially enhance its pharmacological properties. A focused chemical
library comprising 13 compounds was designed and synthesised by Dr. Laurence Carroll
and Dr. Andrew Kalusa, Imperial College London.
3.2 Development and validation of CHKA inhibition assay
In order to evaluate the potency of choline kinase inhibition, an assay was developed to
facilitate (i) accurate IC50 determination, (ii) establishment of the mode of inhibition, thus
revealing interactions with choline or ATP pockets, and ideally, (iii) rapid and simulta-
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neous screening of multiple compounds. Several assays, based on various principles, were
evaluated.
3.2.1 Radioactive assays using [18F]D4-FCH
Due to the initial unavailability of purified CHKA, two assays using the PET radiotracer
[18F]D4-FCH were investigated. The conversion of tracer, mimicking choline, to its phos-
phorylated form, resembling PCho, was monitored by radio-HPLC. HCT116 cells, that are
known to express CHKA [112], were used in in assays involving whole cells (incorporating
transport and phosphorylation) or cell lysates (incorporating only phosphorylation).
3.2.1.1 Whole cell CHK activity assay
HCT116 cells, grown in 15 cm dishes, were pulsed with 5.5 MBq [18F]D4-FCH for 1
hour. Cells were scraped into PBS, washed, and lysed in methanol. Soluble metabolites,
containing the radiotracer, were separated and analysed by radio-HPLC (Figure 3.3A).
In untreated cells, the tracer was almost completely converted to its phosphorylated
analogue and the formation of betaine, the oxidation product of choline, was negligible
(Figure 3.3B). It was then tested whether this method would be suitable to detect the
modulation of CHKA. To this end, as the designed inhibitors were not available at that
time, cells were pre-treated for 24 hours with 1 mM HC-3, a weak CHK inhibitor that also
inhibits choline transporters, or 1 µM MAPK/ERK (MEK) kinase inhibitor PD0325901,
that was previously shown to downregulate CHKA protein expression [112]. Radioactivity
was normalised to protein content and ratios of choline to PCho plotted (Figure 3.3C-E).
Total tracer incorporation and PCho formation was significantly reduced by both treat-
ments. Dual inhibition of CHKA and transporters abolished cell-associated radioactivity
by more than 90%. In contrast, CHKA downregulation by MEK inhibition reduced PCho
formation by 65% and increased the free choline fraction, indicating, that reduced CHKA
expression inhibited PCho synthesis, resulting in an accumulation of free choline.
The assay proved to be of very slow throughput and, importantly, the results are a
combination of choline transport and phosphorylation. Therefore, a cell lysate-based assay
was developed, that would only measure choline phosphorylation.
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Figure 3.3: Cell-based inhibition assay using [18F]D4-FCH. A, HCT116 cells were incubated with
[18F]D4-FCH, harvested and lysed in methanol and radioactive metabolites separated and analysed
by radio-HPLC. Representative radio-HPLC chromatograms of untreated (B), HC-3 (1 mM for 24
hours; C), or PD0325901 (1 µM for 24 hours; D) samples. Western blot in D shows CHKA expres-
sion after treatment with 1 µM PD0325901 for 24 hours. E, Peak areas of indicated metabolites
were normalised to total protein content and are expressed as radioactivity per µg protein. Mean
of n =3 in triplicate±SD; **P < 0.01.
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Figure 3.4: Representative radio-HPLC chromatogram of cell lysate-based assay, demonstrating
< 1% conversion of choline to PCho in cell lysates.
3.2.1.2 Cell lysate-based CHK activity assay
Cytosolic fractions of HCT116 cells were isolated in order to enrich for CHKA. In the first
step, varying amounts of lysate were tested in order to determine the lowest concentration
of CHKA-containing lysate required to catalyse the enzymatic reaction. Lysates with a
total protein content of 10–1500 µg were tested and supplemented with 10 mM ATP and
100 mM magnesium chloride (MgCl2), a co-factor required for catalytic activity. Samples
were incubated with 740 kBq [18F]D4-FCH for 30 minutes at 37°C with occasional mixing
and reactions were stopped by placing samples on ice and by addition of mobile phase
containing acetonitrile. The mixture was filtered, separated and analysed by HPLC. Even
at high total protein concentrations (> 500 µg), the cell lysates showed almost no CHK
activity (Figure 3.4). While it is possible that the extraction process compromised en-
zymatic integrity, the assay bared additional disadvantages; extraction e ciencies might
have varied across di↵erent batches and the ATP concentration could not be fully con-
trolled, as the decomposition of endogenous ATP in the lysate was unknown. Therefore,
this assay proved to be unsuitable and alternatives were investigated.
3.2.2 Assays using purified CHKA2
The initially tested assays were not able to fulfil the set criteria to accurately determine
IC50 and mode of inhibition and in addition were expensive and time consuming. Therefore
it was necessary to develop an assay using purified CHKA. The enzyme was kindly provided
by Arnon Lavie, University of Illinois at Chicago, in form of D49N hCHKA2, an N-
terminally truncated construct, as published elsewhere [71]. Di↵erent luminescent and
UV-spectrophotometric assays were tested. In all assays, purified CHKA2 was incubated in
83
1 10 100 1000 10000 100000
0
5.0u106
1.0u107
1.5u107
2.0u107
2.5u107
CTR
(- CHKA)
CHKA (ng)
Lu
m
in
es
ce
nc
e 
(R
LU
)
Time dependency
-4.5 -4.0 -3.5 -3.0 -2.5
0
1.0u107
2.0u107
3.0u107
4.0u107
5 min RT
15 min RT
30 min RT
60 min RT
Log Drug Conc (M)
Lu
m
in
es
ce
nc
e 
(R
LU
)
Temperature dependency
-4.5 -4.0 -3.5 -3.0 -2.5
0
1.0u107
2.0u107
3.0u107
4.0u107
30 min 37qC
30 min RT
60 min 37qC
60 min RT
Log Drug Conc (M)
Lu
m
in
es
ce
nc
e 
(R
LU
)
A
ED
B
N+
N
N+
N
C
Figure 3.5: Kinase Glo assay. A, assay principle. A kinase reaction uses ATP to phosphorylate a
substrate (i.e. choline). After completion of the enzymatic reaction, the Kinase Glo mix containing
luciferase is added, which converts remaining ATP to light. Figure by Promega. B, Determination
of the amount CHKA2 needed to alter luminescent signal (mean of n =2). C, Structure of com-
pound 8. D–E, The reaction was carried out in presence of inhibitor 8 and reaction progress curve
monitored. A strong time-dependency (D) and temperature-dependency (E) was observed. Each
data point represents mean of n =3±SD.
presence of choline, ATP and Mg2+. The assay optimisation was conducted in accordance
with NIH guidelines [175] and key literature [176].
3.2.2.1 Kinase Glo assay (Promega)
This assay is an endpoint measurement, where addition of a proprietary reaction mix
terminates the enzymatic reaction. It measures ATP that has not been used up during
a kinase reaction (Figure 3.5A). Remaining ATP gives a luminescent signal and high
luminescence therefore corresponds to enzymatic inhibition.
In the first step, it was determined how much enzyme is required to su ciently convert
choline into PCho (Figure 3.5B). Di↵erent concentrations of enzyme were added and 80 ng
per reaction found to be the smallest amount of enzyme capable of completely converting
exogenous choline at room temperature within the 30-minute duration of the assay. Ambi-
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ent temperature was chosen, as recommended by the manufacturer, to avoid experimental
variations induced by varying substrate temperatures.
Next, one of the new inhibitors, which has already been synthesised at that point
(compound 8, Figure 3.5C) was added to the reaction. Di↵erent concentrations ranging
from 58 µM to 1.5 mM showed dose-dependent inhibition of the enzymatic reaction, how-
ever, the signal proved to be time- and temperature dependent (Figure 3.5D–E). It was
unclear whether this e↵ect was due to assay instability or rapid reaction kinetics. The
main drawback, however, was that the maximal possible ATP concentration of 10 µM for
this assay was significantly below CHKA’s reported KM of 450 µM [71]. Therefore, the
ADP Glo assay was used instead.
3.2.2.2 ADP Glo assay (Promega)
In this assay, ADP, which is formed during the enzymatic reaction, generates the lumines-
cent signal. This means, that high luminescence correlates with high enzyme activity (or
low pharmacological inhibition) and vice versa. The assay permits ATP concentrations
up to 1 mM. To validate the assay, the linearity of the signal was assessed against a stan-
dard curve of ADP and showed a large dynamic range up to 1 mM ADP (Figure 3.6A).
Next, the smallest amount of kinase that generates an adequate signal-to-noise ratio and
that produces luminescence within the linear range of the titration curve was determined.
When 50 ng CHKA was used, a signal-to-noise ratio of ca. 130 was achieved (Figure 3.6B).
Determination of IC50 has to be be carried out in the initial linear phase of the reaction
progress curve, which plots the amount of product generated over time. At 50 ng CHKA,
the linearity was only maintained in the first minutes of the assay (Figure 3.6C). As this
assay is an end-point measurement, it was di cult to retain accuracy at very short incuba-
tion times. Therefore, the amount of kinase was reduced, in hope that it would slow down
the reaction time. This should result in delayed reaction progress curves, where the max-
imal luminescence remains the same. This is, because with less enzyme the same amount
of substrate can be converted, just at a slower rate. However, less enzyme resulted in a
flatter slope, indicating enzyme instability [175]. Therefore, the 50 ng reaction was further
characterised and the reaction stopped at di↵erent time points (Figure 3.6D). Linearity
was only given in the first 3 minutes and determination of KM of both substrates (choline
and ATP) were not accurately possible without real-time kinetic measurements (data not
shown).
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Figure 3.6: ADP Glo assay. A, The linearity of the signal was determined using an ADP standard
curve in presence of ATP. E.g., 20% conversion corresponds to 20% ADP and 80% ATP. B, Di↵erent
concentrations of CHKA2 were added to the reaction in order to optimise the amount enzyme
needed for the reaction. The red line indicates 50 ng CHKA per reaction, which gave a signal-to-
noise ratio of 130 and was in the linear range of the assay. C, Reaction progress curve, showing the
amount of signal derived from di↵erent enzyme concentrations over time. The curves were fitted
by GraphPad Prism version 5.01 using Michaelis-Menten kinetics. The line indicates the maximal
velocity. D, The reaction was repeated with 50 ng CHKA and linearity in the first minutes of the
reaction observed. Mean of n = 3±SD.
Kinase and ADP Glo assays were employed, as they are non-radioactive, of high
throughput and commonly used for screening [177]. However, both assays were unsuitable
for CHKA, and therefore focus put on the development of an assay with robust readouts
and that could determine reaction progress kinetics.
3.2.2.3 Phosphoenolpyruvate kinase / lactate dehydrogenase-coupled assay
A phosphoenolpyruvate kinase / lactate dehydrogenase (PK/LDH) coupled assay was
adapted from one published by Maltio and colleagues [71] that indirectly measures the
accumulation of ADP (Figure 3.7). The reaction can be carried out in a temperature-
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Figure 3.7: Assay principle of PK/LDH coupled kinase activity assays. The generated ADP
during the CHKA reaction is used to form pyruvate from phosphoenolpyruvate (PEP) by pyruvate
kinase (PK). Lactate dehydrogenase (LDH) then converts pyruvate to lactate under consumption
of NADH. This decrease of NADH can be spectrophotometrically monitored, as NADH, but not
NAD+ is UV active at 340 nm.
controlled plate reader, where kinetic measurements are taken. Furthermore, half-area 96-
well plates can be used allowing parallel processing of several compounds, while minimising
sample volumes.
Most commonly used multiwell plates are not UV light translucent and therefore give
low readings at this 340 nm, which is the maximal absorbance of NADH. Di↵erent 96-
well plates were tested and Greiner Bio-One UVStar plates found to be most suitable
(Figure 3.8). The detection limit for NADH was low (1 µM) and the signal linear over a
broad concentration range (1–750 µM) and therefore the detection system proved suitable
for NADH assay concentration of 250 µM. The reported maximal absorption was confirmed
to be at 340 nm.
Next, the stability of the NADH signal was investigated and the absorbance of 250 µM
NADH in 100 mM Tris monitored at 37°C over 30 minutes, which was anticipated to be
the maximal assay duration. The loss of NADH signal over 30 minutes was only 1.6%,
suggesting su cient stability (Figure 3.9).
The assay components were chosen as recommended by Malito et al. [71] and scaled
to a total volume of 50 µL. The assay composition can be found in Table 3.1. Choline and
ATP were used at their respective KM of 72 and 450 µM, as previously reported for this
enzyme [71].
In order to determine the optimal CHKA concentration per reaction, several reactions
were run using di↵erent quantities of enzyme and decrease of NADH monitored over 30
87
 
Greiner UVStar - Spectrum
280 320 360 400
0.0
0.1
0.2
0.3
0.4
0.5
CTR (Tris)
NADH (250 µM)
340
Wavelength (nm)
A
bs
or
ba
nc
e
Greiner UVStar - Lineraity
Detection Limit < 1 µM NADH
0 200 400 600 800
0.0
0.5
1.0
1.5
r² 0.9999
Conc (µM)
A
bs
or
ba
nc
e
Corning - Spectrum
280 320 360 400
0.0
0.1
0.2
0.3
0.4
0.5
CTR (Tris)
NADH (250 µM)
340
Wavelength (nm)
A
bs
or
ba
nc
e
Corning Linearity
Detection Limit ~3 µM NADH
200 400 600 800
-0.1
0.0
0.1
0.2
0.3
0.4
r² 0.9997
Conc (µM)
A
bs
or
ba
nc
e
A
DC
B
Figure 3.8: Identification of suitable microplates. UV-Vis spectra of 250 µM NADH in 100 mM
Tris bu↵er or bu↵er alone in di↵erent 96-well plates are shown. While commonly used lab ware was
not su ciently UV translucent (C, D), Greiner UVstar plates (A, B) showed a good signal-to-noise
ratio and high linearity.
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Figure 3.9: Stability of NADH in 100 mM Tris bu↵er was determined by monitoring the signal
intensity at 340 nm over 30 minutes at 37°C. Time t0 refers to start of measurement.
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Table 3.1: CHKA2 enzyme kinetics assay components at a total volume of 50 µL.
Stock 
Concentration
Volume per 
reaction (µL)
Final 
Concentration
Tris pH 7.5 1 M 5 100 mM
KCl 1 M 5 100 mM
MgCl2 100 mM 5 10 mM
PEP 5 mM 5 500 μM
Pyruvate kinase 900-1400 U/mL 4 units
Lactate dehydrogenase 600-1000 U/mL 5 units
ATP 4.5 mM 5 450 μM
Choline chloride 965.02 μM* 5 96.5 μM*
NADH 2.5 mM 5 250 μM
Δ49N CHKA 1 μg/μL 5 Variable
Inhibitor 40 mM 5 Variable
Total 50 µL
* 96.5 μM choline chloride for a final concentration of 72 μM choline (=KM).
5
minutes (Figure 3.10). An enzyme concentration of 20 ng CHKA per reaction showed
favourable velocity of enzymatic reaction and good linearity in the first 15 minutes.
The assay was then employed for screening. MN58B proved too di cult to synthesise
as a reference compound and due to the lack of a literature compound, one of the first
synthesised inhibitors, compound 8) was used. The reaction was carried out in presence
of 9 di↵erent concentrations of inhibitor (4.5 nM–300 µM) and compared to untreated
controls (Figure 3.11). The reaction was highly linear within the first 10 minutes of the
reaction, during which, su cient amounts of NADH were available. After 10 minutes,
the raw data curves started shifting to the right (data not shown for clarity), indicating
substrate depletion. The IC50 was determined in the phase, where untreated controls show
linearity of the NADH signal and where < 20% substrate are depleted [175].
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Figure 3.10: A, Reaction progress curves of di↵erent CHKA quantities. B, Linearity of NADH
depletion in the first 15 minutes. Mean of n = 3 ± SD.
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Figure 3.11: Determination of IC50. A, Inhibition curves of compound 8 over time (in min) showing
an increase of signal-to-noise ratio, as NADH is depleted during this phase. B, Absorbance of
NADH in controls over time showed linearity in the first 10 minutes. This is the phase before all
NADH has been used up in non-treated controls. C, Time-dependence of IC50 of 8. In the first 10
minutes, IC50 was stable, which was followed by an increase (right shift of curves) due to substrate
depletion. Mean of n =3± SD.
3.3 Evaluation of choline kinase inhibitors
3.3.1 CHKA enzymatic inhibition
A summary of all tested structures is shown in Figure 3.12. Elongation of the alkyl chain
in the symmetrical bis-DMAP compounds successively increased potency against recombi-
nant CHKA2 (Table 3.2 and Figure 3.13A–B). The C8 linker compound 3 had an IC50 of
2.7 µM, which decreased to 150 nM when the two pharmacophores were separated by an
additional 6 carbons. As expected, these compounds were found to be competitive with
choline, but not with ATP, as exemplified by Lineweaver-Burk plots of 8 (Figure 3.14A
and B), where the lines intersect at the ordinate when choline concentrations are varied
and at the abscissa when ATP concentration are altered.
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Figure 3.12: Structures of all tested compounds.
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Table 3.2: Inhibitory activity against recombinant D49N CHKA2 (IC50) or human HCT116 and
A549 cancer cell lines (GI50).
Compound Linker IC50 (µM) SD GI50 (µM) SD GI50 (µM) SD
1 PEG n/d > 1 mM n/d
2 PEG n/d > 1 mM n/d
3 C8 2.7 0.6 2.5 0.3 3.3 2
5 C9 1.3 0.1 2.6 0.5 4.0 0.3
6 C10 0.67 0.08 2.8 0.2 4.2 0.6
7 C11 0.29 0.02 2.0 0.05 1.6 0.3
8 C12 0.27 0.06 0.64 0.05 0.38 0.04
9 C12 5.1 1 0.69 0.03 1.3 0.5
10 C12 0.34 0.009 1.1 0.05 0.75 0.07
12 C12 0.80 0.08 4.1 1 5.3 3
13 C14 0.15 0.04 0.29 0.01 0.33 0.009
HCT116 A549Δ49N CHKA2
In the series of nonsymmetrical inhibitors (9–12), substitution of one DMAP resulted
in loss of activity, although this was less severe when charges were retained on both phar-
macophores, as exemplified by compound 10. Compound 11 was found to be unstable and
therefore not investigated. While the benzimidazole derivative 9 had low activity, intro-
duction of an adenine (12) was associated with a significant increase in inhibitory activity
(IC50=803 nM). As expected, 12 displayed mixed inhibition, as shown by Lineweaver-
Burk plots, where the lines intersect at the second quadrant above the x-axis (Figure 3.14C
and D).
3.3.2 Molecular Modelling
Molecular modelling was employed to further characterise possible binding modes. The
model was validated by docking HC-3 into the empty pocket, which superimposed with
the co-crystallised structure (Figure 3.15A–B). In addition, the estimated free energy of
binding (MM-GBSA) highly correlated with the experimental IC50 values of bis-DMAP
compounds (Figure 3.15C).
When the bis-DMAP compounds 3, 5–8 and 13 were docked, none of these inter-
acted with the ATP cassette in their most stable poses and instead had a binding mode
resembling the co-crystallised inhibitor HC-3. The inner cationic DMAP interacted with
the positively charged Asp306 in the choline pocket while the carbon linker interacted
with the hydrophobic side chains of Tyr333, Trp423, Trp420, Tyr354 and Tyr437 (Fig-
ure 3.16). The second DMAP was more solvent exposed and interacted predominately
with the hydrophobic residues at the rim of the pocket. Altogether the biochemical and
modelling data suggest that 8 and most likely also the other bis-DMAP compounds are
choline-competitive inhibitors and solely interact with the choline active site.
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Figure 3.13: Inhibition of D49N CHKA2 and growth of human HCT116 cancer cell lines. A, IC50
was determined using a pyruvate kinase/lactate dehydrogenase-coupled assay that measures NADH
depletion at 340 nm. High NADH levels reflect complete enzymatic inhibition. B, Structure activity
relationship between linker length and IC50 of symmetrical compounds. C, GI50 in HCT116 cells
was determined by sulforhodamine-B assay. For A and C, half-maximal inhibitory concentrations
were determined by fitting of a sigmoidal curve with variable slope in GraphPad Prism version
5.01. D, confirmation of high CHKA protein expression by western blot in HCT116 and A549 cells
in comparison with St-T1b cells.
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Figure 3.14: Lineweaver-Burk plots of compounds 8 (A and B) and 12 (C and D) against D49N
CHKA2. Reaction kinetics were measured without inhibitor (•) or in presence of 0.1 (￿), 1 (▲)
or 10 µM (▼) 8 or 12. In A and C, choline concentrations were varied and ATP kept constant at
KM, while in B and D choline was kept constant at KM and ATP concentrations altered.
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Figure 3.15: Validation of molecular model. A, The applied docking algorithm could successfully
dock HC-3. The docked molecule (green) superimposes with the co-crystallised ligand (yellow).
B, Close-contact interactions of HC-3 with CHKA2. C, Correlation for compound 3, 5, 6, 7, 8
and 13 between experimental pIC50 against D49N CHKA2 and estimated free energies of binding
(kcal/mol) obtained by Glide XP docking and MM-GBSA scoring. D, Di↵erent scoring functions
applied to SP and XP docked poses. aDocks simultaneously in the choline site and the pocket
rim in the highest ranked pose bDocks simultaneously in the choline site and in the ATP site
in the highest ranked pose. cThe calculated pKa of the benzimidazole moiety is 5.62. dNeutral.
eProtonated. fXP docking resulted in an unrealistic pose, instead the XP refined SP docked pose
was used. Molecular modelling was carried out by Dr. Ola A˚berg.
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Figure 3.16: Proposed binding modes of bis-DMAP compounds. A, 8 (green) solely interacted with
the choline pocket in its most stable pose. ADP (yellow) is shown as reference. B, Interactions of
8 in its most stable pose with the choline pocket and rim of CHKA2. Molecular modelling was
carried out by Dr. Ola A˚berg.
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Figure 3.17: Proposed binding modes of nonsymmetrical inhibitors. A, 12 had two stable confor-
mations, where DMAP was always interacting with the deep end of the choline pocket. The adenine
moiety could either interact with the solvent exposed rim or the ATP cassette. B, Interactions of
12 in its most stable pose with the ATP cassette and the choline pocket. Molecular Modelling was
carried out by Dr. Ola A˚berg.
Compounds 9-12 on the other hand were designed with an adenine mimic to interact
specifically with the ATP pocket. For example, when docked in the absence of ADP,
12 showed two predominant conformations (Figure 3.17). In its most stable pose, it
simultaneously interacted with the ATP and choline binding sites. The adenine moiety of
12 almost completely superimposed with the co-crystallised adenine moiety of ADP and
interacted with Glu206 via a water bridge in addition to hydrogen bonding to Ile209 and
Gln207. Alternatively, in a lower ranked binding mode the adenine moiety of 12 pointed
towards the solvent and hydrogen bonded to the backbone carbonyl of Ser355 at the rim of
the enzyme without any interaction with the ATP cassette (Figure 3.17). Compound 12
can interact with both cavities, however, when docked in the presence of ATP, resembling
physiological ATP concentrations, the adenine moiety is forced out of the ATP cassette
and instead binds to the pocket rim in a fashion resembling HC-3 and compounds 3, 5–8
and 13. Therefore, docking studies together with the kinetic experimental data suggested
a mixed type of binding.
3.3.3 Fragment-based screen of ATP mimics
It was then attempted to increase the potency of the ATP-mimicking component through
a fragment-based approach. A small library of ATP mimics was designed by Dr. Andrew
Kalusa, Imperial College London (Figure 3.18). Such an approach required probing of the
fragments at relatively high concentrations, as only minor interaction with the enzyme
could be anticipated. The CHKA activity assay was designed to test each fragment at
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Figure 3.18: ATP mimicking fragments included in screen against CHKA2.
two concentrations (10 and 30 µM) in hope to detect dose-dependence and with two
concentrations of ATP [450 µM (=KM) and 1.3 mM (=3×KM)], as decreased inhibitory
properties at high ATP concentrations could indicate ATP competitiveness. None of
the investigated compounds could e ciently inhibit CHKA at the tested concentrations
(Table 3.3) and therefore this approach was not further pursued.
3.3.4 Antiproliferative activity
Anti CHKA activity of symmetrical and nonsymmetrical compounds translated well into
antiproliferative activity against HCT116 colorectal adenocarcinoma and A549 lung cancer
cell lines, which express CHKA at high levels (Table 3.2 and Figure 3.13C–D). In accor-
dance with the cell-free assay, linker elongation in the symmetrical compounds strongly in-
creased cellular e cacy and resulted in compounds with submicromolar growth inhibitory
Table 3.3: Inhibitory activity of ATP mimicking fragments against CHKA2. Mean of n =3.
Compound Mean SD Mean SD Mean SD Mean SD
DMSO CTR 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
107A 6.94 11.72 3.29 7.28 5.36 4.04 4.67 0.91
107B -2.68 14.30 1.19 10.93 6.28 6.20 2.21 7.35
107C 3.06 11.48 6.81 7.26 9.54 5.28 13.78 9.77
107D -9.28 5.93 2.35 2.38 7.05 5.01 -2.44 4.36
107E -4.68 8.67 5.52 9.43 3.91 1.37 3.38 3.90
107F -13.16 11.58 -0.17 3.38 2.16 13.77 0.09 9.60
107G -11.58 11.98 0.70 7.50 -0.63 1.95 2.70 5.62
107H -8.31 14.38 1.71 5.25 5.93 4.91 1.93 2.60
107I -7.34 9.78 4.02 10.71 0.46 6.99 1.20 5.94
107J -13.73 11.86 3.63 13.14 1.88 12.39 3.89 3.63
107K -5.23 9.98 6.32 5.66 3.14 3.95 -2.15 3.89
Fragment [30 μM]
ATP [1.35 mM]
%inhibtion%inhibtion
Fragment [10 μM]
ATP [450 μM]
Fragment [30 μM]
ATP [450 μM]
%inhibtion
Fragment [10 μM]
ATP [1.35 mM]
%inhibtion
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concentrations. The nonsymmetrical compound 9 showed higher cellular than enzymatic
activity, suggesting that growth inhibition is mediated by e↵ect on targets other than
CHKA. The PEGylated compounds 1 and 2 showed no activity up to a concentration of
1 mM. The growth inhibitory properties were assessed in a larger panel of cancer cell lines
(Table 3.4). Compounds 8 and 13 were most e↵ective with a median GI50 of 620 and 330
nM, respectively.
3.3.5 Inhibition of CHK in HCT116 cells
Next, the ability of the several compounds to inhibit the CHK reaction in whole cells was
assessed. To this end, HCT116 cells were incubated with [3H]choline in the presence of
varying concentrations of inhibitors and [3H]PCho formation was measured. [3H]PCho was
e ciently separated from [3H]choline using a modified Bligh and Dyer extraction method
(Figure 3.19), Ref. [164]. The fundamental principle of this assay is, that choline with
one positive charge can be scavenged by negatively charged tetraphenylborate (TPB, see
Figure 3.19 for structure). The TPB-bound choline is lipophilic and can be isolated by
phase separation. In contrast, the zwitterionic PCho has a net charge of zero and therefore
Table 3.4: Growth inhibition (GI50 in µM) of indicated compounds in various cancer cell lines.
Mean of n =3; n/d, not determined.
1. PEGylated 2. C8 Linker
Compound
cell line GI50 (μM) SD GI50 (μM) SD GI50 (μM) SD GI50 (μM) SD
HCT116 > 1mM > 1mM 2.5 0.28 40 12
MCF7 n/d n/d 4.6 1.3 25 6.9
A431 n/d n/d 2.9 0.76 48 14
A549 n/d n/d 3.3 2.3 38 6.1
A2780 n/d n/d 3.3 0.64 15 4.7
Ishikawa n/d n/d 3.2 0.16 39 4.5
median 3.2 38
3. C9 Linker 4. C10 Linker 5. C11 Linker
Compound
cell line GI50 (μM) SD GI50 (μM) SD GI50 (μM) SD
HCT116 2.6 0.5 2.8 0.2 2.0 0.1
A2780 5.9 0.4 4.2 0.6 1.6 0.4
A549 4.0 0.3 4.2 0.6 1.6 0.3
median 4.0 4.2 1.6
6. C12 Linker 7. C14 Linker
Compound
cell line GI50 (μM) SD GI50 (μM) SD GI50 (μM) SD GI50 (μM) SD GI50 (μM) SD
HCT116 0.64 0.052 0.69 0.030 1.1 0.046 4.1 1.3 0.29 0.01
MCF7 1.6 0.60 0.71 0.20 2.4 1.1 3.7 2.5 n/d
A431 2.7 0.46 1.1 0.40 2.1 0.54 7.5 2.7 n/d
A549 0.38 0.035 1.3 0.47 0.75 0.074 5.3 2.8 0.33 0.01
A2780 0.54 0.11 0.60 0.030 0.86 0.54 1.6 0.11 0.33 0.05
Ishikawa 0.59 0.040 2.9 0.65 1.4 0.13 5.0 0.29 n/d
median 0.62 0.88 1.3 4.6 0.33
12
5 6
13
1 2
8 9 10
3 4
7
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Table 3.5: Inhibition of [3H]PCho formation in HCT116 cells.
Compound EC50 (µM) SD
8 0.67 0.28
9 5.2 1.9
10 0.93 0.34
12 2.5 1.5
13 0.52 0.15
does not interact with TPB. The e ciency of the [3H]choline and [3H]PCho extraction was
tested and typically 13.7± 1.6% [3H]choline detected in the PCho fraction, while 1± 0.6%
[3H]choline was present in the PCho fraction.
All compound e ciently inhibited the choline kinase reaction in whole cells (Table 3.5).
Compounds 8 and 13 were highly e↵ective and associated with an EC50 of 0.67± 0.3 µM
and 0.52± 0.2 µM, respectively, and inhibited [3H]PCho formation > 75% at concentrations
above 6.5± 4 and 2.4± 1 µM, respectively.
B-
Cho Cho
Cho
[3H]Cho [3H]-PCho
N+
N
N+
N
B-
Figure 3.19: Assay principle of Bligh and Dyer extraction. The negatively charged tetraphenylb-
orate (TPB) preferentially binds to choline (net positive charge) over PCho (net neutral) and the
TPB-choline complex can be extracted by phase separation with organic solvents. PCho remains
in the lower aqueous phase. Cho, choline; PCho, phosphocholine.
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3.4 Discussion
The increased expression and activity of CHKA in many di↵erent solid tumours together
with the growth-promoting role of choline metabolites make CHKA an attractive target for
anticancer therapy. Previously designed inhibitors, such as MN58B, have the disadvantage
of a challenging synthesis, which could be part of the reason why such inhibitors are not
commercially available. The short ethyl chain between the benzyl moieties of MN58B, for
example, is relatively di cult to functionalise, and therefore only gives poor yields.
Here, the evaluation of highly e↵ective CHKA inhibitors, which are synthetically read-
ily available is presented. The symmetrical inhibitors 8 and 13 potently inhibited CHKA,
which translated well into high cellular e cacy in di↵erent cancer cell lines. Furthermore,
these compounds were able to fully inhibit the CHK reaction in whole cells, which is a
key requirement for further development, as CHKA inhibitors need to compete with high
endogenous choline concentrations of 10–50 µM [178]. By comparison to other compounds
published in the literature and summarised in Table 1.2, the inhibitors presented here
are — with the caveat of di↵erent assays used — among the most e↵ective compounds
described to date with respect to their IC50 and GI50.
It was further aimed to develop novel sca↵olds of CHKA inhibitors, which simulta-
neously inhibit the choline and ATP pockets. It was demonstrated through biochemical
evaluation backed by computational modelling that this binding mode may exist but the
inability of these compounds to elicit ATP-competitiveness at higher ATP concentrations
suggests that symmetrical inhibitors may be more favourable candidates. A similar ap-
proach was since attempted by another group [150]. Although the structures of this report
are related to the nonsymmetrical inhibitors presented here, these molecules were relatively
inactive (GI50> 50 µM, IC50 6–10 µM).
With respect to the bis-DMAP compounds, the inhibitory activity against CHKA
strongly depended on the linker length. Molecular modelling elucidated that both DMAPs
interacted with negatively charged amino acids in the deep end of the pocket and the
rim. Therefore su cient space and flexibility is required to maximise the charge-charge
interactions.
Di↵erent linker types were tested, however, the PEGylated compounds were unstable
in solution and inactive in cell systems, which is why this approach was not further pur-
sued. Given the time and resources of this project it was unfortunately not possible to
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diversify the linkers. Based on these data, however, it appears that the charge interactions
were essential for biological activity. Sca↵old modifications would need to be done with
careful consideration and ideally jointly with X-ray crystallography in order to maximise
intermolecular interactions, while trying to minimise increases in lipophilicity. TCD-717,
which is an evolution of MN58B and therefore likely to have higher a nity to CHKA, is
characterised by a large molecular weight of 878 g/mol and a cLogP of 3.3, suggesting
that the enhanced interaction is likely to be driven by size and lipophilicty, which there-
fore might not translate into potent inhibition in an in vivo context. Furthermore, the
combination of high molecular weight and 6 aromatic ring systems make it more prone to
be a substrate for drug resistance transporters.
To improve the pharmacologic properties of CHKA inhibitors, it would be desirable
to reduce the overall charge of the compounds. CK37 is an uncharged CHK inhibitor
and lack of charge–charge interactions at the deep end of the pocket make it relatively
ine↵ective in cell-free assays (IC50 ca. 25 µM), Ref. [149]. The ATP-competitive inhibitor
V-11-0711 possesses good inhibitory properties in cell-free assays (IC50 against CHKA
20 nM; CHKB 220 nM), which does not translate into e↵ective growth inhibition or in-
duction of apoptosis [148]. It remains unclear why V-11-0711 does not phenocopy the
e↵ect of CHKA knockdown, as demonstrated in the same study. It is possible that due to
similarities between the ATP cassettes of CHKA with CHKB, eukaryotic protein kinases
and aminoglycoside phosphotransferases [71], cross reactivity with other targets prevents
biological activity. A recent report highlighted that simultaneous inhibition of CHKA and
CHKB indeed prevents cells to undergo apoptosis [65].
Due to unavailability of purified CHKB, it was not possible to determine isoform se-
lectivity for the inhibitors presented here. Although the overall di↵erences between the
CHKA and CHKB binding pockets are only subtle, it can be anticipated that the com-
pounds presented have higher a nity towards CHKA than CHKB. The loop connecting
helices a9 and a10 (La9a10) at the deep end of the hydrophobic groove is folded inwards
in CHKA, allowing interaction of the quaternary amine with Glu434. In CHKB this loop
is positioned away from the groove, potentially negatively a↵ecting binding [174].
Synthesis of non-isoform selective ATP competitive inhibitors might not form the most
suitable strategy to reduce the charge of these inhibitors. Alternative approaches could
be to employ a pro-drug mechanism, where a charge-masking moiety is removed in the tu-
mour, or to create compounds that imitate PCho instead of choline. Such phosphocholine-
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mimetics would potentially have a neutral overall charge while retaining selectivity to the
enzyme. These approaches, however, would be challenging from a chemistry perspective
and have not been attempted to date.
Chapter 4
Use of ICL-CCIC-0019 to
elucidate CHKA biology in cancer
Symmetrical bis-DMAP compounds emerged as most potent CHKA inhibitors from the
focused library screen. Compounds 8 and 13 were most promising with IC50 values of
270 and 150 nM, respectively, and GI50 values of 640 and 290 nM, respectively, against
HCT116 cells and 380 and 330 nM, respectively, against A549 cells. These results, paired
with e cient inhibition of CHK in whole cells at physiological choline concentrations,
demonstrated that these compounds were among the most potent and promising evaluated
to date and warrant further characterisation. While 13 had slightly higher inhibitory
properties than 8, unforeseeable reasons led to limited availability of chemistry facilities,
which prevented synthesis of larger amounts of 13. Due to comparable qualities of both
compounds, 8 was further evaluated, as su cient quantities were already available at that
point. Compound 8 was subsequently named ICL-CCIC-0019. Slight variations between
data acquired in the initial screen compared to results in this chapter account to di↵erent
batches used.
4.1 Selection of cancer cell lines
Prior to the pharmacologic evaluation of ICL-CCIC-0019, the expression of CHKA in
di↵erent cancer cell lines was investigated to identify models, which are suitable to study
the e↵ects of CHKA inhibition.
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4.1.1 The Cancer Cell Line Encyclopaedia (CCLE)
The Cancer Cell Line Encyclopaedia comprising 1037 cell lines across a wide array of dif-
ferent cancer types was analysed for CHKA mRNA expression levels [179]. While cancers
of the biliary tract, liver, pancreas, stomach and breast showed highest median expression,
certain lung cancer samples were also characterised by elevated CHKA expression (Fig-
ure 4.1A). All 1037 analysed cell lines were then ranked from highest to lowest expression
and CHKA mRNA levels of several lineages, which were commonly used in the literature
to study choline metabolism, are indicated in Figure 4.1B.
DNA copy number variations were not responsible for mRNA expression profiles (Fig-
ure 4.1C), suggesting that intrinsic regulatory mechanisms drive CHKA expression rather
than genetic alterations. Across all cancer cell lines derived from CCLE, no CHKA muta-
tion could be identified, although common polymorphisms, allelic fraction less than 10%
and putative neutral variants were excluded from the analysis. Data for CHKB does not
exist, due to overall low expression in cancer.
For subsequent experiments, HUH-7, MDA-MB-468 and HCT116 cell lines were used.
While HUH-7 and MDA-MB-468 cells represent highly CHKA expressing cell lines, HCT116
cells were employed in most assays, due to their sensitivity to ICL-CCIC-0019, as estab-
lished in the initial screen, and the capacity to readily form xenografts, allowing rapid
translation from in vitro to in vivo.
4.1.2 Validation of HCT116 model by siRNA
The e↵ects of transient siRNA-mediated knockdown of CHKA and CHKB were assessed in
HCT116 cells. CHKA silencing resulted in reduced cell proliferation (–38%, Figure 4.2A)
and increased caspase 3/7 activation (2.3-fold, Figure 4.2B) 72 hours post transfection.
However, silencing of CHKB or double knockdown of CHKA and CHKB did not alter
proliferation or induction of apoptosis compared to scramble transfected control. CHKA
knockdown unexpectedly increased Akt phosphorylation in HCT116 cells (Figure 4.2 C),
which is in contrast to reports of other cell lines [132]. Erk phosphorylation or the ex-
pression of the apoptosis-related proteins Bcl-2 and Bax were not altered. Furthermore,
reduced CHKA expression increased the sub-G1 population, representing apoptotic cells
(72 h post transfection; Figure 4.2D).
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Figure 4.1: CHKA mRNA expression in di↵erent cancer cell lines. A, Box plot of quantile nor-
malised mRNA expression in cell lines derived of indicated tumours. B, All 1037 cell lines were
ranked from highest to lowest expression and selected cell lines are highlighted. C, CHKA mRNA
expression was plotted against DNA copy number variation. Data derived from the Cancer Cell
Line Encyclopaedia [179].
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Figure 4.2: E↵ects of CHKA knockdown in HCT116 cells. Cells were exposed to non-targeting
scramble control siRNA (SCR) or siRNAs targeting CHKA, B or both for 48 hours. A, Proliferation
was measured by SRB assay and (B) apoptosis assessed by caspase 3/7 Glo assay. Mean of
n =3 in quadruplicate±SD; ** P < 0.01; *** P < 0.001. C, Lysates were analysed by western
blot for expression and phosphorylation of indicated proteins. CTR, untreated control. D, After
exposure to indicated siRNAs for 48 or 72 hours, cells were fixed and cell cycle analysed by flow
cytometry using propidium idodine staining. E, Total mRNA was extracted from lysates collected
after 48-hour incubation with CHKA siRNA and expression of indicated enzymes compared to
SCR controls. ENTK, ethanolamine kinase; PCYT1A, cytidyltransferase alpha; CHPT1, choline
phosphotransferase 1; PLD, phospholipase; GPCPD1, glycerophosphocholine phosphodiesterase.
Mean of n =3 in duplicate±SD; * P < 0.05.
Knockdown of CHKA caused compensatory elevated expression of genes involved in
choline biochemistry. Ethanolamine kinase 1 and 2 expression was significantly upregu-
lated, potentially to countervail reduced PtdCho formation by activation of the PEMT
pathway. In addition, expression levels of members of the Kennedy pathway (PCYT1A
and CHPT1) and the catabolic deacylation pathway (PLD1, PLD2 and GPCPD1) were
also non-significantly higher compared to scramble controls.
4.1.3 Establishment and evaluation of isogenic CHKA and CHKB over-
expressing U2OS cells
Knockdown of CHKA evoked response of the apoptotic machinery and imparied pro-
liferation. To cross validate these findings, a CHKA and CHKB overexpressing model
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Figure 4.3: U2OS cells were transfected with GFP-tagged CHKA and CHKB and selected by G418.
Individual clones were picked and green fluorescence was quantified by FACS. Data represent per
cent GFP positive cells compared to wild-type.
was generated. U2OS osteosarcoma cell lines, which express CHKA at endogenously low
levels, were stably transfected with GFP-tagged isoforms and individual clones selected.
Clones with highest fluorescence were identified by FACS (Figure 4.3) and subsequently
characterised by western blot and functional assays. While no clones with su cient high
expression of CHKA could be identified in the initial screen, further clones were evaluated,
and clones CHKA16, CHKA18 and CHKB4 identified to have highest expression of the
two isoforms (Figure 4.4A). CHKB expression could not be quantified due to poor quality
of CHKB antibodies.
Increased CHKA expression, however, was only associated with a marginal increase in
[3H]choline uptake (+22%) and no changes in proliferation (Figure 4.4 B, C). To explore
why the vast expression of CHKA did not translate into functionally active enzyme com-
plexes, it was tested whether the GFP tag potentially prohibited the formation of active
dimers. Clone CHKA18 was analysed by native gel electrophoresis, which demonstrated
that overexpressed CHKA dimerised (Figure 4.4D). However, the GFP tag possibly inter-
fered with the enzymatic activity and therefore, this model was not further pursued.
4.2 ICL-CCIC-0019 has low o↵-target e↵ects
The pharmacological properties of ICL-CCIC-0019 were then characterised. To assess
kinase specificity, ICL-CCIC-0019 was tested against a panel of 131 human kinases (Fig-
ure 4.5, Dundee Kinase Screen, for full results table see Appendix B). The compound
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Figure 4.4: Characterisation of isogenic U2OS CHKA and CHKB model. A, Western blot against
CHKA in wild-type, two CHKA-GFP overexpressing clones and one CHKB overexpressing clone.
Molecular weight CHKA: 52 kDa; CHKA-GFP: 79 kDa. B, [3H]choline uptake in U2O2 model
and (C) impact on proliferation as determined by SRB assay. Mean of n =3 in triplicate±SD; for
statistical analysis all 9 data points were pooled; ** P < 0.01. D, Homogenates of U2OS-CHKA18
were obtained in passive lysis bu↵er to maintain integrity of protein complexes. Samples were
analysed by native gel electrophoresis (BN-PAGE) and purified CHKA2 in its native condition or
pre-treated with SDS to dissociate CHKA complexes used as controls.
showed low o↵-target e↵ects as only 5 kinases were inhibited more than 20% at a concen-
tration of 10 µM (< 35% in all 131 kinases). Inhibition greater than 20% was attained
for insulin-like growth factor 1 (IGF-1R, 35± 7% inhibition), mitogen-activated protein
kinase-activated protein kinase 3 (MAPKAP-K3, 33± 6%), extracellular signal regulated
kinase 8 (ERK8, 31± 4%), ribosomal S6 kinase 1 (RSK1, 22± 6%), v-erb-a erythroblastic
leukemia viral oncogene homolog 4 (HER4, 21± 7%).
4.3 ICL-CCIC-0019 has potent antiproliferative activity
Determination of antiproliferative activity was incorporated in the screening and com-
pound selection phase and was subsequently expanded for ICL-CCIC-0019 in the context
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Figure 4.5: Selectivity of ICL-CCIC-0019. The compound was screened against 131 kinases at a
concentration of 10 µM. Screen was carried out by MRC Kinase Screen, Dundee University.
of inhibition of cellular proliferation in normal cells. In an initial screen comprising 8
cancer and 3 normal cell lines, cancer-derived lineages were preferentially inhibited with
a median GI50 of 1.09 µM, while normal cells were not a↵ected at these concentrations
(GI50 30–120 µM; Figure 4.6A–B).
The key role of CHKA is to ensure the availability of membrane lipid precursors, while
its involvement in oncogenesis is less well understood. Intriguingly, the antiproliferative
activity did not correlate with the population doubling time (Figure 4.6 C). The higher
sensitivity of cancer cells to CHKA inhibition suggests that hyperactivation of CHKA
could be indicative of a malignant phenotype. Due to its bolaamphiphilic character com-
parable to surfactants, ICL-CCIC-0019 was investigated for its potential to non-specifically
lyse cells. Cell lysis, as caused by surfactants, would trigger formation of pores in the cell
membrane and subsequent release of cytosolic proteins into the supernatant [187]. Activ-
ity of lactate dehydrogenase (LDH), an exclusively cytosolic protein with high stability
[188], in the medium can be measured as a surrogate of cell membrane integrity. Incuba-
tion of HCT116 cells with 1–25 µM ICL-CCIC-0019, did not elevate LDH release to the
supernatant (Figure 4.6 D).
The compound was then screened against a larger panel of cancer cell lines of diverse
histopathologic origin, the NCI-60 screen [189]. The median GI50 across all cell lines was
1.29 µM (range 0.0389–16.2 µM, Figure 4.7A–B). Breast and non-small lung cancer cell
lines were most sensitive (median GI50 0.627 and 0.751 µM, respectively, Figure 4.7C),
which is line with evidence in the literature of particularly deregulated choline biochem-
istry in those cancers [30, 78]. Twelve cell lines were found to have a GI50 below 0.5 µM,
with MDA-MD-468 being most sensitive (38 nM). The least sensitive cell line, NCI/ADR-
RES (16.2 µM), an adriamycin-resistant OVCAR-8 variant, is characterised by high ex-
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Figure 4.6: ICL-CCIC-0019 preferentially inhibits growth of cancer cells. A, Comparison of its
antiproliferative activity in cancer (black) and normal cells (grey). B, GI50 values in tested cell
lines and population doubling times (PDT) of cell lines in hours. PDT were obtained from the
literature [162, 180–186]. C, Relationship between PDT and antiproliferative activity. D, Lactate
dehydrogenase (LDH) release to the supernatant was measured as a surrogate of cell membrane
integrity. HCT116 cells were incubated with indicated concentrations of inhibitor for 4 hours and
LDH activity measured in the supernatant. Triton X-100 was used as positive control. Mean of
n =3±SD; P < 0.001 for untreated control and treated samples in comparison to triton X-100, as
determined by one-way ANOVA.
pression of the multidrug resistance transporter MDR1 (also known as P-glycoprotein)
[190–193], suggesting a potential role of ABC transporters in mediating resistance to bis-
pyridinium CHK inhibitors. Surprisingly, antiproliferative activity did not correlate with
CHKA mRNA expression (Figure 4.7D). The data of the NCI-60 screen correlated well
with the GI50 data generated in house and displayed in Figure 4.6B (r
2=0.87; data not
shown), although only three of the cell lines were part of both screens.
As previous literature indicates that CHKA could be regulated by activating mutations
of kinases, such as Ras [120], the sensitivity of NCI60 cell lines was correlated to the
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Figure 4.7: NCI-60 screen. A, Mean bar graph and GI50 values of all tested cell lines. Bars depict
the deviation of individual tumour cell lines from the overall mean value for all the cells tested. B,
Summary graph of all growth inhibitory curves. C, Median GI50 of cell lines grouped by tumour
type. N LOG GI50, negative logarithmic GI50 in mol/L. D, Relationship between GI50 (µM) and
CHKA mRNA expression, as derived from the Cancer Cell Line Encyclopaedia [179]. Growth
inhibition data was obtained and analysed by NCI using ICL-CCIC-0019 at a concentration range
between 10 nM and 100 µM.
presence of mutations commonly detected in cancer (Table 4.1). With the limitation
that some mutations were either absent or only present in a small subset of lineages,
no correlation existed between sensitivity against the inhibitor and investigated genetic
alterations, when analysed by binary logistic regression (r2=0.36; P =0.52) using SPSS
version 21.
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Table 4.1: Growth inhibitory properties of ICL-CCIC-0019 and mutation analysis of NCI-60 panel.
Highlighted are sensitive cell lines with GI50< 1 µM; Y indicates presence of mutation, as published
elsewhere [194].
Cell line Tumor type N
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I 5
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A
PC
BR
A
F
BR
CA
1
BR
CA
2
CD
KN
2A
CT
N
N
B1
ER
BB
2
H
RA
S
EG
FR
FL
T3
KI
T
KR
A
S
M
A
P2
K4
M
ET
N
RA
S
PD
G
FR
A
PI
K3
CA
PT
EN
RB
1
RE
T
SM
A
D
4
ST
K1
1
TP
53
VH
L
786-0 Renal 5.5 3.162 Y Y Y Y
A498 Renal 6.14 0.724 Y Y
A549 Lung 6.65 0.224 Y Y Y
ACHN Renal 5.53 2.951 Y
BT-549 Breast 6.25 0.562 Y Y
CAKI-1 Renal 4.99 10.233 Y
CCRF-CEM ALL 6.18 0.661 Y Y Y Y Y
COLO205 Colorectal 6.14 0.724 Y Y Y Y
DU-145 Prostate 5.86 1.380 Y Y Y Y
EKVX Lung Y
HCC-2998 Colorectal 5.75 1.778 Y Y Y
HCT-116 Colorectal 6.42 0.380 Y Y Y Y Y
HCT-15 Colorectal 5.45 3.548 Y Y Y Y Y
HL-60 AML 5.75 1.778 Y Y Y
HOP62 Lung 5.76 1.738 Y Y Y
HOP-92 Lung 5.75 1.778 Y Y
HS578T Breast 5.54 2.884 Y Y Y
HT29 Colorectal Y Y Y Y Y
IGROV1 Ovarian 5.64 2.291 Y Y Y Y
K-562 CML 6.69 0.204 Y Y Y
KM12 Colorectal 6.16 0.692 Y Y Y
LOXIMVI Melanoma 5.91 1.230 Y Y
M14 Melanoma 5.7 1.995 Y Y Y
MALME-3M Melanoma 5.77 1.698 Y Y
MCF7 Breast 6.16 0.692 Y Y
MDA-MB-231 Breast 5.68 2.089 Y Y Y Y
MDA-MB-435 Melanoma 5.92 1.202 Y Y Y
MDA-MB-468 Breast 7.41 0.039
MOLT-4 ALL 5.65 2.239 Y Y Y Y Y
NCI/ADR-RES Ovarian 4.79 16.218
NCI-H226 Lung 6.3 0.501 Y
NCI-H23 Lung 6.84 0.145 Y Y Y
NCI-H322M Lung 5.36 4.365 Y
NCI-H460 Lung 6.35 0.447 Y Y I Y
NCI-H522 Lung 6 1.000 Y
OVCAR3 Ovarian 5.8 1.585 Y
OVCAR-4 Ovarian Y
OVCAR-5 Ovarian 5.66 2.188 Y Y
OVCAR-8 Ovarian 5.98 1.047 Y Y
PC-3 Prostate 5.96 1.096 Y Y
RPMI-8226 Myeloma 6.5 0.316 Y Y Y
RXF393 Renal 5.7 1.995 Y Y Y
SF-268 Glioma 5.6 2.512 Y Y
SF-295 Glioma 6.15 0.708 Y Y Y
SF-539 Glioma 5.87 1.349 Y Y Y
SK-MEL-2 Melanoma 5.85 1.413 Y Y
SK-MEL-28 Melanoma 5.69 2.042 Y Y Y
SK-MEL-5 Melanoma 6.68 0.209 Y Y
SK-OV-3 Ovarian 6 1.000 Y Y Y Y
SN12C Renal 6.49 0.324 Y
SNB19 Glioma 6.29 0.513 Y Y Y
SNB-75 Glioma 5.97 1.072 Y
SR NHL 5.77 1.698 Y
SW620 Colorectal 5.73 1.862 Y Y Y
T47D Breast 6.63 0.234 Y Y
TK-10 Renal 5.55 2.818 Y
U251 Glioma Y Y Y
UACC-257 Melanoma 6.37 0.427 Y
UACC-62 Melanoma 5.96 1.096 Y Y Y
UO-31 Renal 5.04 9.120 Y
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4.4 E↵ect of ICL-CCIC-0019 on CHKA dimerisation
As dimerisation is required to exert CHKA activity, it was tested whether as part of the
mechanism of action, the inhibitor could destabilise CHKA complexes. Treated HCT116
cell lysates were analysed by native gel electrophoresis, which showed that dimer integrity
was not compromised by treatment (Figure 4.8).
CH
KA
 +
 S
D
S
CH
KA
 n
at
iv
e
Co
nt
ro
l
1 10 10
0
HCT116
ICL-CCIC-0019 (µM)
CHKA (dimer)
CHKA (monomer)
Actin
Figure 4.8: ICL-CCIC-0019 does not destabilise CHKA dimers. HCT116 cells were treated with
indicated doses for 24 hours and proteins separated by BN-PAGE. Purified CHKA (D49N CHKA2;
expected molecular weight: 48kDa) treated with or without SDS were used as controls. CHKA
dimers were detected at ca. 100 kDa.
4.5 ICL-CCIC-0019 reduces membrane lipid formation
It was then investigated, whether the inhibition of CHKA translated not only into reduced
PCho (as demonstrated in Table 3.5), but also PtdCho formation. In a pulse-chase exper-
iment, HCT116 cells were incubated with inhibitor for 1 hour and pulsed with 18.5 kBq
[3H]choline for an additional hour in presence of drug. The media was replaced with fresh
RPMI and cells incubated for additional six hours (chase period). Cells were washed and
choline-containing metabolites separated.
Consistent with initial screening experiments, ICL-CCIC-0019 dose-dependently re-
duced the formation of PCho, while free [3H]choline concentrations were comparable to
untreated controls (Figure 4.9). Importantly, the incorporation of [3H]choline into the
lipid-containing fraction was reduced at similar levels to PCho, suggesting that the ICL-
CCIC-0019 not only deplete the intracellular PCho pool, but also inhibits the synthesis of
choline-containing lipids, like PtdCho.
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Figure 4.9: ICL-CCIC-0019 treatment decreases formation of choline-containing lipids. A, experi-
mental outline of pulse-chase experiment. B, Quantification of choline metabolites. Cho, choline;
PCho, phosphocholine. Mean of n =3 in triplicate±SD; *** P < 0.001.
4.6 ICL-CCIC-0019 induces cell death via endoplasmic retic-
ulum stress mechanism
Depletion of PtdCho has previously shown to induce ER stress [155]. Therefore, it was
investigated whether ICL-CCIC-0019 causes expression of ER stress response markers in
HCT116 cells. The compound dose- and time-dependently increased the expression of
ATF4, a transcription factor for target proteins that resolve ER stress, and to lesser ex-
tent IRE1a (Figure 4.10A). This increased the expression and nuclear localisation of the
transcription factor CHOP (Figure 4.10B). This was independent of total protein ubiq-
uitination and HSP70 expression. Moderate increases in HSP90 expression further con-
tributed to the ER stress phenotype. Tunicamycin, an inhibitor of N-linked glycosylation
and well-characterised inducer of ER stress, was used as positive control.
4.7 ICL-CCIC-0019 arrests cells in G1 phase of cell cycle
The e↵ects of ICL-CCIC-0019 on cell cycle progression were evaluated by flow cytometry.
The inhibitor caused dose-dependent arrest of cell populations in the G1 phase of the
cell cycle after 24 hours of treatment (2-fold increase at 10 µM; Figure 4.11 A). After
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Figure 4.10: CHKA inhibition induces ER stress. A, HCT116 cells were treated with ICL-CCIC-
0019 and expression of key regulators of ER stress assessed by western blot. B, HCT116 cells
were treated with 1 or 10 µM ICL-CCIC-0019 for 24 hours and stained for CHOP (red), actin
(green) and nuclei with DAPI (blue). Immunofluorescent microscopy images were acquired at
400× magnification. For A and B, 2 µg/mL tunicamycin was used for 4 hours as positive control.
48 hours, 1 µM inhibitor also yielded in 2-fold increased G1 population, whereas 10 µM
resulted in a 3.7-fold increased sub-G1 population, representing apoptotic and dead cells
(Figure 4.11B).
4.8 ICL-CCIC-0019 prompts caspase 3/7 activation
Incubation with varying concentrations of ICL-CCIC-0019 for 48 hours induced activa-
tion of caspase 3/7 mediated apoptosis in HCT116, HUH-7 and MDA-MB-468 cells (Fig-
ure 4.12A). The e↵ect was more prominent in MDA-MB-468 cells (5-fold increase at 10 µM)
than HCT116 and HUH-7 cells (2.9 and 3.7-fold, respectively, at the same concentration).
While cell viability decreased dose-dependently (Figure 4.12B), caspase 3/7 activation was
not dose related.
4.9 In vitro pharmacology
In addition to cellular potency, satisfactory pharmacological properties are crucial to
achieve in vivo e cacy. Administration, distribution, metabolism and excretion (ADME)
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Figure 4.11: ICL-CCIC-0019 induces G1 arrest and increases sub-G1 population. HCT116 cells
were incubated with inhibitor for 24 (A) or 48 (B) hours and cell cycle populations quantified by
flow cytometry using propidium iodine staining. C, Quantification of populations in various states
of the cell cycle, as evaluated in A and B. Mean of n =3±SD. Statistical significance compared to
control: * P < 0.05, ** P < 0.01, *** P < 0.001.
define the duration and extend to which a compound can be biologically active. While a
compound’s pharmacokinetic profile cannot be predicted in vitro or in silico, individual
parameters can be estimated to avoid in vivo evaluation of compounds that are likely to
have insu cient characteristics. Therefore, experiments to determine metabolic stability,
cell permeability, multidrug resistance transporter substrate activity and plasma protein
binding were conducted.
4.9.1 Microsomal stability
The predominant organ of metabolism is the liver, where the majority of approved drugs
are cleared. Metabolism usually occurs in at least two steps. In phase I, a compound
is enzymatically modified by oxidation, reduction or hydrolysis. The cytochrome P-450
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Figure 4.12: ICL-CCIC-0019 activates caspases 3 and 7 and reduces cell viability. HCT116 cells
were incubated with indicated doses of ICL-CCIC-0019 for 48 hours. A, Caspase 3/7 activity
was determined by caspase Glo assay and normalised to protein. B, Cell viability was measured
by SRB assay. Mean of n =6˙±SD Statistical significance was analysed by one-way ANOVA with
Bonferroni’s multiple comparison test; *** P < 0.001.
system is the predominant catalyst for these reactions. In phase II, the compound is
further modified by conjugation with endogenous substances, such as glucoridonic acid,
amino acids, glutathione, acetate or sulphate.
ICL-CCIC-0019 was highly stable in human microsomes and S9 fractions. In the
respective mouse preparations, 40% and 70% parent compound were detected at the end
of the experiment (Figure 4.13A). The metabolic stability of verapamil was comparable
to values reported in the literature [195].
4.9.2 Cell permeability and ABC transporter substrate specificity
The ability of a compound to permeate cell membranes is important for oral absorption
and transport into tissues and cells. This was assessed in a transwell system, where Caco-2
colon adenocarcinoma cell lines form a tight monolayer that separates two compartments
with media. Caco-2 cells resemble the orientation of the gut lining, with an apical (A) and
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Figure 4.13: Microsomal stability, cell permeability and plasma protein binding of ICL-CCIC-0019.
A, Metabolism of ICL-CCIC-0019 was predicted by incubating human and mouse microsomes and
S9 fractions with 10 µM ICL-CCIC-0019. Metabolites were quantified by HPLC and amount parent
compound normalised to controls without microsomes. B, Cell permeability was determined using
Caco-2 transwell system by determining the rate of migration of 10 µM ICL-CCIC-0019 from the
apical to the basal compartment (A–B). Propranolol and vinblastine were used as controls. Drug
e✏ux was determined by the ratio of (B–A)/(A–B) transport. The red line indicates a ratio of
3, which is commonly used as an indicator of multidrug resistance transporter substrate activity.
Vinblastine was used as positive and propranolol as negative control. C, Plasma protein binding
was determined at a concentration of 10 µM using Rapid Equilibrium Dialysis (RED) method
(Pierce). For all assays: mean of n =3±SD; ** P < 0.01, ***P < 0.001.
basal side (B). ICL-CCIC-0019 was added to the apical media and the rate of transport to
the basal compartment determined (Papp A–B). Propranolol and vinblastine were used as
controls, which are known to have high and low cell permeability, respectively. ICL-CCIC-
0019 had a permeability of 3.5± 0.74× 10-6 cm/s, which was comparable to vinblastine
(Figure 4.13B). Transport of propranolol was significantly higher and values for both
control compounds were in line with values reported in the literature [196, 197].
In addition, multidrug resistance transporter substrate activity was measured in this
assay. Many cancer drugs fail to demonstrate clinical e cacy, due to their e✏ux from can-
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cer cells by ATP-binding cassette (ABC) transporters, preventing the drugs from reaching
their intracellular targets [198]. In this Caco-2 transwell system, P-glycoprotein is located
on the apical side. Therefore, if a compound is not substrate to P-glycoprotein, flux
from A–B and B–A will be equal. However, if a compound possesses substrate specificity,
there will be significantly stronger flux from B–A than A–B. A ratio of B–A/A–B greater
than 3 is generally considered to be indicative of substrate specificity [198]. In separate
wells, the rate of transport from A–B and B–A was determined and ICL-CCIC-0019 found
to have similar permeability coe cients for both directions of transport. Vinblastine’s P-
glycoprotein substrate specificity was confirmed by a B–A/A–B ratio of 6.3 (Figure 4.13B).
4.9.3 Plasma protein binding
While circulating in the blood, drug molecules can either be bound to proteins or lipids
in the plasma or are free [199]. Only unbound drug can di↵use to its target and ex-
ert pharmacological activity. While the free drug concentration in the plasma does not
necessarily correlate with in vivo e cacy, as this is dependent on the free drug concentra-
tion surrounding the target, it has profound influence on the pharmacokinetic properties
and potential toxicity [199]. Plasma protein binding (PPB) was 64%, as determined by
equilibrium dialysis method (Figure 4.13C), indicating a satisfactory balanced profile. Ve-
rapamil (high PPB) and acebutolol (low PPB) were used as positive and negative controls,
respectively [200].
4.10 Pharmacokinetics of ICL-CCIC-0019
Encouraged by the cellular potency and the predicted pharmacologic parameters, ICL-
CCIC-0019 was further examined in vivo. To this end, initial experiments were carried
out to assess its tolerability.
4.10.1 Tolerability
Tolerability was assessed in BALB/c mice by monitoring body weight changes in response
to di↵erent dosing regimens. Mice were randomised into groups of three and treated with
vehicle (PBS) or subsequently escalating, i.p. administered doses of ICL-CCIC-0019. A
starting dose of 1 mg/kg was chosen, as comparable bis-pyridinium compounds were shown
to be tolerated at doses 5 mg/kg [146]. No alterations in body weight were detected after
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Figure 4.14: Body weight changes in response to ICL-CCIC-0019. A, BALB/c mice were admin-
istered a single dose of vehicle (PBS) or indicated doses of ICL-CCIC-0019 i.p. and body weight
monitored for seven days (n =3 per group). B, As in A, however, with three subsequent doses of 5
mg/kg i.p. once a day. Dosing days are indicated by red arrows. C, As in A, however, three doses
of 2.5 or 5 mg/kg i.p. once a day (red arrows) followed by four doses of 1 mg/kg i.p. once a day
(green arrows) were administered. Mean of n =3±SD.
single doses up to 5 mg/kg (Figure 4.14A). 10 mg/kg ICL-CCIC-0019 caused a mean
decrease of 4% body weight after 24 hours. The mean body weight further decreased up
until 72 hours post injection, after which 2 out of 3 mice recovered and regained their
initial body weight within a week of the initial dose. One mouse maintained a reduced
body weight for the duration of the experiment (Figure 4.14A).
Subsequently, tolerability of multiple doses of 5 mg/kg was assessed. Three doses of
5 mg/kg i.p. once a day time-dependently decreased the mean body weight by 8% within
72 hours, but mice regained their initial weight within a week of treatment initiation
(Figure 4.14B).
Finally, two continuous dosing schemes were tested. They comprised three doses of
2.5 or 5 mg/kg i.p., followed by four maintenance doses of 1 mg/kg i.p. No significant
body weight changes were observed and therefore, 3× 5 mg/kg followed by 4× 1 mg/kg
was identified as tolerated. For short-term experiments, a single dose of 10 mg could
alternatively be used.
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Figure 4.15: Plasma and tissue pharmacokinetics of ICL-CCIC-0019. A, BALB/c mice were ad-
ministered 10 mg/kg ICL-CCIC-0019 p.o. or i.p. and plasma obtained 5, 15, 30, 60 minutes and 2,
4, 6 and 24 hours post injection. Figure insert displays first 120 minutes only. Compound plasma
concentrations were determined by LC-MS. B, Plasma pharmacokinetic variables derived from A.
C, Tissue distribution of ICL-CCIC-0019. HCT116 xenograft bearing BALB/c nude mice were
treated with 10 mg/kg ICL-CCIC-0019 and plasma, tumour, liver and kidney harvested after 5
min, 2, 6 and 24 hours. D, Same data as C, but only displaying plasma and tumour for clarity.
Tissue concentrations were determined by LC-MS. For all graphs, lines indicate GI50 in HCT116
cells; mean of n =3 per time point±SD.
4.10.2 Pharmacokinetics
Plasma and tissue pharmacokinetic profiles were established following a single injection
of 10 mg/kg ICL-CCIC-0019. Plasma variables were derived in BALB/c mice at 5, 15,
30, 60 minutes and 2, 4, 6 and 24 hours post administration. As tissue distribution was
expected to be less erratic, compound concentrations were determined at 5 minutes, 2, 6
and 24 hours only. BALB/c nude mice bearing HCT116 xenografts were employed and
tumour, liver, kidney and plasma analysed.
The compound was rapidly cleared from the plasma following i.p. administration (Fig-
ure 4.15A) and plasma concentrations above the GI50 of HCT116 cells were maintained
for ca. 50 minutes. The compound was not orally bioavailable, as plasma concentrations
did not reach concentrations of the GI50, which would be necessitated to exert antitumour
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Table 4.2: Plasma metabolites of ICL-CCIC-0019. Plasma samples of BALB/c mice treated with
10 µM ICL-CCIC-0019 for 2 hours used for tissue PK experiments were pooled and analysed for
parent peak and metabolites by LC-MS. Analysis was performed by Cyprotex Inc.
Mass
Metabolite 
name Formula
Mass difference 
from parent m/z found Ion
Retention 
time (min)
Metabolite 
reference Abs area
Area 
percentage
412 Parent C26H44N4 - 206 [M]2+ 7.38 - 7.17E+07 41.3
246 Loss of 166 - -166 246 [M]+ 2.58 M1 1.02E+07 5.88
246 Loss of 166 - -166 246 [M]+ 2.73 M2 1.22E+07 7.03
305 Loss of 107 - -107 305 [M]+ 2.78 M3 7.54E+06 4.35
305 Loss of 107 - -107 305 [M]+ 3.45 M4 1.31E+07 7.55
338 Loss of 74 - -74 338 [M]+ 3.54 M5 1.01E+07 5.82
538 Gain of 126 - 126 538 [M]+ 10.46 M6 1.12E+07 6.46
563 Gain of 151 - 151 563 [M]+ 7.47 M7* 3.74E+07 21.6
All remaining peaks in the sample were either in the control sample or not believed to be related
to test compound. Percentages have been calculated assuming that each metabolite is equally as
sensitive as parent.
activity. Plasma pharmacokinetic variables are shown in Figure 4.15B.
The compound was quickly extracted by the examined tissues and tumour concentra-
tions above the GI50 were maintained throughout the study (Figure 4.15C–D). Extensive
accumulation in liver and kidneys were observed, although clearance from liver was more
rapid than from tumour.
4.10.3 In vivo metabolism
In conjunction with the pharmacokinetic characterisation, the metabolites of ICL-CCIC-
0019 in plasma were characterised. The 2-hour plasma samples of BALB/c nude mice were
pooled and ICL-CCIC-0019-derived metabolites compared to untreated plasma samples.
Seven metabolites could be identified (Table 4.2), of which five represented breakdown
products and two conjugates to biomolecules. The metabolites were matched against a
database of commonly detected drug metabolites (Table 4.3), but no similarities were
obtained.
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Table 4.3: List of expected metabolites. Data provided by Cyprotex, Inc.
4.11 ICL-CCIC-0019 inhibits CHK activity in vivo
4.11.0.1 [18F]D4-FCH PET imaging
To determine whether ICL-CCIC-0019 could attenuate CHK activity in vivo, [18F]D4-FCH
PET imaging was performed. Tracer and compound compete for the same target, thus
permitting non-invasive assessment of competitive antagonism in the physiological and
complex milieu of the tumour.
24 and 48 hours after a single dose of 10 mg/kg, a marked reduction in tracer uptake was
observed in treated HCT116 xenografts compared to the vehicle-treated cohort [AUC0–60
control: 191.9 (%ID/mL)*min; AUC0–60 24 hours: 145.8 (%ID/mL)*min; AUC0–60 48
hours: 139.4 (%ID/mL)*min; Figure 4.16 and Figure 4.17]. Interestingly, despite the rapid
tissue distribution, where ICL-CCIC-0019 concentrations in the tumours peaked at 2 hours
post injection, PET imaging at 6 hours post administration did not result in significant
reduction of [18F]D4-FCH uptake [AUC0–60 6 hours: 187.7 (%ID/mL)*min]. Reductions of
tumour tracer accumulation were most prominent within the first 20 minutes of dynamic
scans, reflecting the early delivery and retention phase. While cardiac TACs were not
influenced by treatment, liver and kidney tracer retentions were diminished, comparably
to tissue pharacokinetics data (Figure 4.17).
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Figure 4.16: ICL-CCIC-0019 inhibits choline kinase activity in vivo. Representative [18F]D4-FCH
PET images of HCT116 xenograft bearing BALB/c nude mice, treated with vehicle (PBS; A) or
10 mg/kg ICL-CCIC-0019 i.p. for 24 hours (B). Images show summed frames from 30–60 minutes
and tumours are indicated by white arrowheads.
4.11.0.2 Pharmacokinetic modelling of CHK inhibition
To further characterise ICL-CCIC-0019 mediated choline kinase inhibition in vivo, kinetic
modelling was employed. Whereas normalised tissue uptake values reflect tracer concentra-
tion in a three-dimensional region of interest, kinetic modelling accounts for tissue uptake
relative to plasma. A two-tissue irreversible compartmental model, as previously reported
[110], was employed with the hypothesis that k3 would represent the rate by which the
tracer is phosphorylated by choline kinase (see Introduction and Figure 1.6). Although
this enzymatic reaction is in principle reversible, it was assumed that the high dependency
of cancer cells to incorporate choline made it unlikely that catalytic hydrolysis of PCho
prevails. Best fits and more physiological parameters were obtained with a 3k (excluding
k4) instead of 4k model.
ICL-CCIC-0019 treatment significantly decreased K 1, denoting the flux from blood
to tissue, at all investigated time points in the tumour (73% decrease compared to con-
trol after 24 hours, 75% decrease after 48 hours) and to a lesser extent in kidneys and
liver (Figure 4.18A). The opposing flux from tissue into the blood stream, k2, was not
significantly influenced by treatment across all tissues (Figure 4.18B). Interestingly, the
rate constant k3, which represents intracellular tracer trapping, was also non-significantly
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Figure 4.17: Tumour TACs of HCT116 xenograft-bearing mice in groups of four were treated with
a single dose of 10 mg/kg ICL-CCIC-0019 i.p. and imaged at indicated times post injection in
comparison to untreated control mice. A, Tumour; B, heart; C, liver; D, kidney TACs. E, time
course of [18F]D4-FCH uptake in tumour, liver and kidney; data represent NUV60 as a function of
time, where 0 represents the NUV60 of control mice. Mean of n =4±SEM.
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Figure 4.18: Pharmacokinetic modelling of competitive inhibition of CHKA by ICL-CCIC-0019
using [18F]D4-FCH in HCT116 xenograft-bearing mice. Statistical significance was determined by
one-way ANOVA and Bonferroni’s Multiple Comparison Test; * P < 0.05; ** P < 0.01; *** P < 0.001.
Kinetic modelling was performed by Dr. Giampaolo Tomasi.
altered (Figure 4.18C). In consequence to these micro parameter changes, the macro pa-
rameter K i denoting the irreversible uptake rate was decreased, however, not significantly
(Figure 4.18D). Unexpectedly, changes in kinetic flux were predominantly driven by al-
terations in K 1. In all examined tissues, the blood volume V b decreased initially after
treatment (Figure 4.18E). These perfusion deficits were more pronounced and persistent
in tumour compared to liver and kidney.
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Figure 4.19: Antitumour activity of ICL-CCIC-0019. HCT116 xenograft-bearing mice were treated
with vehicle (PBS) or 5 mg/kg i.p. once a day on indicated days (red arrows). A, Antitumour
activity; B, body weight changes compared to day 1. Line indicates 85%. Mean of n =6±SEM;
*** P < 0.001.
4.12 Antitumour activity
Antitumour activity was assessed in HCT116 xenograft bearing mice (Figure 4.19). It was
intended to apply the initially optimised dosing scheme, however, body weight loss was
more profound in BALB/c nude compared to BALB/c mice (maximal decrease 15%) and
the schedule had therefore be intermitted. Mice were treated on days 1–3 with 5 mg/kg
i.p. once a day followed by a 11 day recovery period. ICL-CCIC-0019 resulted in potent
antitumour activity.
4.13 [18F]FLT PET
To determine whether the antiproliferative response could be predicted non-invasively and
at early time points, treatment response of [18F]FLT uptake was assessed. Thymidine
is a vital metabolite for DNA synthesis and therefore in demand in proliferating tissues.
Reduction of abnormally high proliferation was shown to frequently reduce FLT uptake
[201]. Surprisingly, three doses of 5 mg/kg increased FLT uptake by 33% in HCT116
xenografts (Figure 4.20).
4.14 Inducible CHKA shRNA model
Given the multitude of e↵ects observed with ICL-CCIC-0019 it was necessary to further
verify the pharmacologic e↵ect by alternative - genetic - means. Therefore, an inducible
shRNA targeting CHKA was created in HCT116 cells. In contrast to transient siRNA
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Figure 4.20: ICL-CCIC-0019 treatment increased [18F]FLT uptake in vivo. HCT116 tumour-
bearing BALB/c nude mice were treated with 5 mg/kg once a day i.p. for 3 days and imaged 24
hours after the last dose. A, Representative PET images; white arrows indicate tumour. B, NUV60
values of control and treatment groups. Mean of n =6±SEM; * P =0.0403.
transfection, it bears the advantage of stable incorporation of the shRNA into the host
DNA. The employed pTRIPZ vector contains a hairpin consisting of 22 nucleotides and
a TurboRFP sequence under the control of a tetracycline-inducible promoter sequence
(Figure 4.21). The Tet-On configuration provides expression of the shRNA and TurboRFP
in the presence of doxycycline (DOX).
4.14.1 Identification of shRNA sequence that su ciently silences CHKA
Three di↵erent shRNA sequences were tested to identify one that produces the strongest
knockdown. Induction was carried out by incubation with 0.5 µg/mL DOX, which was
found to be non-toxic in HCT116 cells (Figure 4.22A). Transduced cells under DOX in-
duction were FACS sorted to isolate a pool that contains the 90th percentile with the
highest TurboRFP expression. The resulting lines were further characterised. While all
3 sequences su ciently knocked down CHKA by western blot, sequence 3 elicited lowest
[3H]choline uptake and strongest antiproliferative activity as well as caspase 3/7 activation
(Figure 4.22B–E). Therefore, this lineage was further characterised.
4.14.2 Characterisation of HCT116-shCHKA3 cell line
HCT116-shCHKA3 was evaluated in greater detail. Onset of CHKA knockdown occurred
two days post DOX induction and protein expression was almost completely diminished 4
days post induction (Figure 4.23A). Choline uptake decreased by 50% after 7 days of DOX
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Vector Element  Utility
TRE Tetracycline-inducible promoter
tRFP TurboRFP reporter for visual tracking of transduction and shRNA expression
shRNA microRNA-adapted shRNA (based on miR-30) for gene knockdown
UBC Human ubiquitin C promoter for constitutive expression of rtTA3 and puromycin resistance genes
rtTA3 Reverse tetracycline-transactivator 3 for tetracycline-dependent induction of the TRE promoter
PuroR Puromycin resistance permits antibiotic-selective pressure and propagation of stable integrants
IRES Internal ribosomal entry site allows expression of rtTA3 and puromycin resistance genes in a single transcript
5' LTR 5' long terminal repeat
3' SIN LTR 3' self-inactivating long terminal repeat for increased lentivirus safety
ƻ Psi packaging sequence allows viral genome packaging using lentiviral packaging systems
RRE Rev response element enhances titer by increasing packaging efficiency of full-length viral genomes
WPRE Woodchuck hepatitis posttranscriptional regulatory element enhances transgene expression in the target cells
Figure 4.21: Scheme of pTRIPZ vector. Figure from [202].
treatment, while control cells were not a↵ected by DOX treatment (Figure 4.23B). The
onset of shRNA expression could further be monitored by fluorescent microscopy detecting
TurboRFP expression (data not shown).
4.14.3 [18F]D4-FCH PET imaging of CHKA shRNA model
The model was then evaluated in vivo. BALB/c nude mice were inoculated with shCTR or
shCHKA3 cells and xenografts of ca. 40 mm3 allowed to form. Mice were then randomised
into two groups per cell line and treated for seven days with or without DOX-supplemented
diet. IVIS fluorescent imaging confirmed induction of the shRNA in the DOX-induced co-
horts (Figure 4.24A–B). No changes in tumour volume were observed from the time of
induction (data not shown). Mice were then imaged with [18F]D4-FCH, but no di↵erences
in tumour uptake observed among the groups (Figure 4.24C–E). Some degree of hetero-
geneity was observed and therefore tumours were further analysed by their highest voxel
intensity. No di↵erences were observed in the intensities of the 90th percentile of voxels
across all cohorts (Figure 4.24F). Tumours were then analysed for CHKA expression and
no significant reduction in the shCHKA group fed with DOX diet observed (Figure 4.24G).
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Figure 4.22: Selection of HCT116 cells transduced with CHKA targeting shRNA. A, HCT116 wild
type cells were exposed to varying concentrations of DOX for 72 hours and 0.5 µg/mL identified
to be non-toxic. B–D, Cells transduced with indicated shRNAs were incubated with 0.5 mg/mL
DOX for 7 days. The day before initiation of experiments, untreated wild type cells and shRNA-
induceld cells were seeded at equal cell numbers. B, western blot against CHKA. C, Uptake of
[3H]choline was determined for each DOX-induced cell line and compared to wild type cells. D,
Relative proliferation was measured by SRB assay and absorbance normalised to cell density at day
1. E, Apoptosis was measured 24 hours post seeding by caspase 3/7 Glo assay. Mean of n =3±SD;
* P < 0.1, ** P < 0.01, *** P < 0.001.
4.15 E↵ects of combined CHK and HDAC inhibition
E↵ective inhibition of CHK by ICL-CCIC-0019 diminished the intracellular accumulation
of PCho and PtdCho, which resulted in potent antiproliferative activity. Combination
therapies with histone deacetylase (HDAC) inhibitors were examined, as these drugs in-
crease choline kinase expression and intracellular PCho accumulation.
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Figure 4.23: Characterisation of HCT116-shCHKA3 cell line. A, Indicated cell lines were treated
with or without DOX and at after 2, 4 and 6 days, cells were harvested and knockdown confirmed
by western blot. B, [3H]choline uptake was determined in cells treated with or without DOX for
seven days. Mean of n =3±SD. Statistical significance was determined by one-way ANOVA with
Bonferroni’s multiple comparison test (see table).
Depending on the transcriptional requirements of a cell, DNA alternates between
“open” and “closed” conformations. This process, called chromatin remodelling, mod-
ulates the accessibility and the sensitivity of regulatory proteins to DNA [203, 204]. Post-
translational modifications of histones, most notably acetylation, orchestrate these changes
[205, 206]. Acetylation occurs through histone acetyltransferases (HATs) to result in a
transcriptionally repressed conformation. This process is reverted by HDACs leading to a
transcriptional active state [207]. Therefore these enzymes have profound implications for
development and diseases, such as cancer.
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Figure 4.24: In vivo characterisation of HCT116-shCHKA model. BALB/c nude mice were in-
oculated with HCT116-shCTR and HCT116-shCHKA3 cells and randomised into two groups per
xenograft model after tumour reached 40 mm3. Groups of each model were fed for seven days ei-
ther normal diet or chow supplemented with DOX (n =6 per group with the exception of shCHKA
on normal diet: n =5) A, Representative IVIS fluorescent images depicting TurboRFP, which is
co-expressed with the shRNA upon DOX induction. B, Quantification of IVIS-derived average of
radiance obtained from two-dimensional ROIs drawn over the tumours. C, Representative [18F]D4-
FCH PET images of cumulative 30–60 minute frames of dynamic scans. Tumours are indicated by
white arrows. D, Dynamic tumour TACs of indicated groups and their respective NUV60 values
(E) are shown. F, Summed 40–60 minute scans were histogrammed and highest intensity voxels
analysed. The 90th percentile for each tumour is shown. Note that Y-axis scales vary in between
panels E and F. G, Western blot analysis of CHKA expression in tumours excised directly after
imaging.
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Table 4.4: E↵ects of combined treatment of HCT116 cells with ICL-CCIC-0019 and HDAC in-
hibitors C1A or vorinostat, as determined by combination index (CI). CI> 1 indicates antagonism,
CI=1 additive e↵ects and C< 1 synergy. Mean of n =3 in sextuplicate±SD.
ICL-CCIC-0019 plus
0.1 µM C1A 1.75 ± 0.12
0.5 µM C1A 0.91 ± 0.31
1 µM C1A 0.4 ± 0.16
5 µM C1A 3.36E-08 ± 3.71E-08
0.01 µM vorinostat 1.11 ± 0.15
0.05 µM vorinostat 1.24 ± 0.19
0.1 µM vorinostat 1.17 ± 0.084
0.5 µM vorinostat 0.18 ± 0.056
Combination index at 
In recent years, HDACs have been intensively investigated for their potential as cancer
therapeutics. 18 di↵erent HDACs, subdivided into four subclasses, have been identified
and two pan-inhibitors (vorinostat or SAHA, and romidepsin) gained FDA approval [208].
In addition, specific HDAC6 inhibitors are currently in development [3, 209]. In contrast to
other HDACs, this isoform exists in the cytoplasm and is also responsible for deacetylation
of non-histone targets. Therefore HDAC6 inhibitors have limited involvement in epigenetic
regulation, while controlling the activity of multiple client proteins.
Elevated PCho intracellular concentrations have been detected in response to pan-
HDAC inhibitors vorinostat and LAQ824 and are driven by increased expression of CHKA
and choline transporters [100, 101, 210, 211]. The relevance of this pharmacodynamic
marker in the context of selective HDAC6 inhibition is unknown.
As elevated CHKA expression is linked to proliferation, it was hypothesised, that
HDAC inhibitor-driven PCho changes could be part of a feedback mechanism to maintain
cell survival. Therefore combined CHKA and HDAC inhibition was evaluated. Four doses
(ranging between GI20 and GI80) of a pan-HDAC (vorinostat) or HDAC6 specific inhibitor
(C1A) were added, while assessing cell survival in response to 9 di↵erent doses of ICL-
CCIC-0019 in HCT116 cells.
In combination with ICL-CCIC-0019, both HDAC inhibitors were antagonistic at low
and synergistic at high concentrations (Table 4.4). Synergy was particularly strong in
combination with the HDAC6 selective inhibitor C1A. Interestingly, both HDAC inhibitors
did not elevate incorporation of [3H]choline after 24 hours drug treatment, as expected in
response to the described elevated expression of CHKA. In contrast, both drugs and more
profoundly C1A decreased its uptake (Figure 4.25).
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4.16 Discussion
CHKA is a valid drug target
By means of pharmacologic inhibition and posttranscriptional silencing, it was demon-
strated that inhibition of CHKA is viable strategy for treatments of cancers with hyper-
activated choline biochemistry.
Previous attempts to create drug-like CHKA inhibitors, either yielded compounds
with a disconnect of cellular and enzymatic activity or lacked detailed pharmacologic
data on metabolic stability, pharmacokinetics, pharmacodynamic response or o↵-target
e↵ects. It was a key objective of this project to develop new synthetically readily available
CHKA inhibitors with detailed pharmacological characterisation, permitting investiga-
tions of choline metabolic handling in the complex milieu of the tumour. Interference with
essential nutrient utilisation, such as of choline, glutamine or glucose, forms a new trend
in cancer therapy to exploit the striking di↵erences in metabolic handling of cancer cells
versus normal tissues to accumulate biomass and satisfy the demand for energy equivalents
[212]. CHKA indeed features several characteristics that make it a putative and druggable
target. Analysis of the Cancer Cell Line Encyclopaedia revealed consistently high expres-
sion of CHKA, but not CHKB, in most human lineages, underpinning the global relevance
of this gene in malignancy. Furthermore, it contains a distinct, hydrophobic pocket allow-
ing intervention with small-molecule inhibitors. Lack of mutations and regulation by copy
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Figure 4.25: [3H]choline uptake normalised to protein content in HCT116 cells treated with HDAC
inhibitors vorinostat (A) and C1A (B) for 24 hours. Mean of n =3±SD; * P < 0.1, ** P < 0.01,
*** P < 0.001.
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number variations are ground for optimism that — in contrast to most other currently
targeted kinases — genetic alterations might not impede response.
The validity of the target was confirmed by RNA interference, whereby transient
knockdown induced apoptosis and reduced proliferation HCT116 cells. This is in line
with previous reports, indicating comparable responses in a variety of cancer cell lines
[136, 139]. Double knockdown of CHKA and CHKB did not induce apoptosis or deceler-
ate proliferation. This has been previously reported by Gruber et al. [65] and highlights
the importance of balanced CHKA and CHKB expression. Assuming equal transfection
e ciencies for CHKA and CHKB, knockdown of CHKA decreased protein levels to or
below those of CHKB, resulting in cell death due to the lack of CHKA. In case of double
knockdown, however, both CHKA and CHKB expression equally decreased, and relatively
higher CHKA than CHKB expression can still contribute to the oncogenic cell survival
mechanism [65]. While this hyporthesis requires further investigations, it highlights the
importance of selective CHKA inhibitors.
The growth inhibitory e↵ect of CHKA siRNA was not mediated by alteration of Akt
or Erk phosphorylation, which has been previously shown to be a downstream marker of
CHKA inhibition in MDA-MB-468 and HeLa cells [132, 136]. The mechanism of this inter-
action is unclear, but occurs downstream of PI3K. Furthermore, CHKA does not directly
interact with Akt, as shown by co-immunoprecipitation experiments and indicated by a lag
time of 8 hours between CHKA inhibition by MN58B and changes in Akt phosphorylation
[132]. Di↵erent results regarding Akt dephosphorylation in this and previous studies might
be due to genetic di↵erences of cell lines, such as PTEN or Akt phosphorylase PHLPP
expression. The profound antiproliferative e↵ect of ICL-CCIC-0019 in a great variety of
lineages with heterogeneous genetic backgrounds (NCI-60 screen) might infer that Akt is
— although a↵ected in some cases — not essential to mediate the cytotoxic response.
The importance of CHKA in PtdCho metabolism was further substantiated by the
compensatory expression of enzymes of the PEMT pathway, namely ethanolamine kinase
1 and 2 upon CHKA knockdown. Additionally, non-significant upregulation of enzymes
of the Kennedy pathway underline the importance for HCT116 cells to have a functional
choline-PtdCho axis, to provide enough lipids for proliferation and signalling. Elevated
choline catabolic activity in response to CHKA downregulation might suggest a high turn-
over of lipid second messengers, as some of these enzymes would be involved in generation
of DAG and phosphatidic acid.
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It was attempted to relate the e↵ects of gene knockdown to a CHKA overexpressing
system, which could have also served as a model to test compound selectivity for CHKA
over CHKB in a biological context. However, transfection of c-terminally GFP-tagged
CHKA or CHKB did not result in functionally active enzymes. While in comparable
studies, untagged CHKA was used, c-terminally His-tagged CHKA showed full activity
in toxoplasma gondii [213]. Due to the steric involvement of sequences close to the C
and N terminal sites in formation of both catalytic cavities [71], it is possible that the
GFP tag prevented accurate protein folding, as it was ruled out that the C-terminal tag
prevented CHKA dimerisation. Considering the potential formation of complexes with
c-Src or EGFR, future studies should explore overexpression without GFP tag.
ICL-CCIC-0019 e↵ectively inhibits CHK
Based on these findings, ICL-CCIC-0019 underwent further pharmacological evaluation
to permit its use to elucidate choline biochemistry. Several lines of evidence suggest that
the inhibitor is selective for CHK: (i) a kinase screen against 131 human kinases showed
minimal inhibition of other kinases, (ii) IC50 in enzyme-based assays, EC50 measuring
depletion of PCho formation in whole cells and GI50 determining antiproliferative activity
are comparable, and (iii) CHKA is e ciently inhibited in vivo, as measured by CHK-
specific tracer [18F]D4-FCH.
For the first time, a detailed kinase screen has been carried out for a choline-competitive
inhibitor and ICL-CCIC-0019 showed low o↵-target e↵ects against the panel of 131 human
kinases. CHKA and CHKB were not available as part of the panel at the time of the screen,
and therefore isoform selectivity could not be determined. As indicated above, it can be
anticipated that ICL-CCIC-0019 has greater a nity towards CHKA than CHKB due to
the conformational di↵erences in the loop connecting helices a9 and a10 (La9a10) at the
deep end of the hydrophobic groove. This loop is folded inwards in CHKA, allowing
interaction of the quaternary amine with Glu434, whereas it is positioned away from the
groove in CHKB, potentially negatively a↵ecting binding [174].
There is a lack of compound selectivity data of previously published compounds, how-
ever, the disparity between IC50 in enzymatic assays, EC50 measuring PCho depletion in
cell-based assays and GI50 data suggests o↵-target e↵ects for these compounds. For exam-
ple, the most-published inhibitor, MN58B, has an IC50 of 22 µM against yeast CHK, an
EC50 of 4.2 µM to deplete [3H]PCho formation in HT-29 cells after 14 hours of incubation
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with drug and a GI50 of 0.5 µM against HT-29 cells [144, 146]. Similarly, CK37 was shown
to have an IC50 of around 25 µM, EC50 of around 7 µM and GI50 of 5–10 µM [149]. While
the kinase screen conducted here cannot rule out o↵-target e↵ects apart from the selected
proteins, the tight relation between IC50 (0.27 µM), EC50 (0.67 µM after 1 hour incubation
in HCT116 cells) and GI50 of 0.34 µM against HCT116 cells, are indicative of on-target
e↵ects.
ICL-CCIC-0019 showed potent antiproliferative activity against the NCI-60 panel of
cell lines, while three normal cell lines were not a↵ected. The superior e↵ect on malignant
cells paired with the independence of doubling time and antiproliferative activity suggests
that the inhibitor is specific to an oncogenic phenotype and that CHKA has greater roles
in malignancy than simply to satisfy cell membrane synthesis requirements. Similar obser-
vations were previously made in breast cancer cells [33] and gives hope that this strategy
could selectively target tumour cells.
The antiproliferative activity did not correlate with CHKA mRNA expression. While
mRNA provides a robust and easily quantifiable parameter, it does not always translate
into protein expression and cannot take activating or inhibitory posttranslational modifi-
cations in consideration.
CHK inhibition induces cell death via ER stress response
ICL-CCIC-0019 did not rupture cell membranes, as could be expected by structurally
related surfactants. This was demonstrated by absence of spillage of cytosolic LDH to the
supernatant as a surrogate. A short incubation time of 4 hours and relatively high inhibitor
concentrations were chosen, as extracellular pH of the medium or extended culture periods
are known to compromise LDH stability [214]. Additionally, it could be shown that ICL-
CCIC-0019 did not inhibit CHKA activity by destabilisation of the enzyme complex.
Antiproliferative activity subsequent to CHK inhibition by ICL-CCIC-0019 was trig-
gered by decreased PtdCho synthesis that caused cells to arrest in the G1 phase of the cell
cycle and induction of ER stress. The connection between PtdCho synthesis and cell cycle
regulation is apparent, as increased availability of membrane lipids is necessary for cell
division [215]. Small changes in PtdCho by uncontrolled synthesis would rapidly result
in cells with either excess amounts of or deficient membrane surface [215]. In light of the
regulation of PtdCho synthesis during the G1 phase of the cell cycle by cyclins A and
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E in conjunction with CDK2, a checkpoint for G1/S transition [216–218], CHKA inhibi-
tion appears to prevent cells from correct transitioning through this cell cycle checkpoint.
Microarray studies have confirmed deregulated expression of genes involved in cell cycle
progression upon CHKA overexpression [137] or knockdown [32].
Furthermore, pharmacological CHK inhibition induced ER stress response mechanisms.
ER stress is typically caused by accumulation of unfolded proteins or depletion of PtdCho
synthesis [155, 156] and culminates in unfolded protein response (UPR). UPR is initi-
ated by activation of at least one of the three e↵ector proteins inositol-requiring protein-1
(IRE1), activating transcription factor-6 (ATF6) or protein kinase RNA (PKR)-like ER
kinase (PERK) [156]. PERK promotes the phosphorylation of eukaryotic translation ini-
tiation factor-2 alpha (eIF2a) to suppress general protein synthesis, but induction of the
transcription factors ATF4 and its downstream target CHOP. ICL-CCIC-0019 activated
this branch of the UPR with marked dose- and time-dependent increases of ATF4. This
enhanced transcriptional activity of CHOP, as confirmed by its nuclear localisation. The
temporal evolution of di↵erent UPR triggers orchestrates the fate of the response. While
concurrent activation of IRE1a and PERK pathways promote cell survival with the aim of
stress resolution, attenuation of the IRE1a signal and persistent activation of the PERK–
CHOP axis commits to cell death via apoptosis or autophagy [219–221]. IRE1a-mediated
UPR was only mildly activated at 24 and 48 hours continuous treatment of ICL-CCIC-
0019, but it remains to be elucidated whether apoptosis or autophagy account for cell
death response seen at these time points. A complex switch depending on timing and
strengths of ATF4 and CHOP signals determines the commitment to either of these cell
death pathways [221]. If apoptotic pathways are involved, it is unlikely to be mediated
by caspases 3 and 7, as their modest activation was not in proportion to the profound
antiproliferative activity. No changes in total protein ubiquitination were observed, but a
more detailed characterisation of autophagic e↵ectors are required to further understand
possible implications of ICL-CCIC-0019 on this cell death mechanism.
As part of ER stress resolution, chaperon molecules such as HSP70 and HSP90 can be
expressed to counteract misfolding of proteins [222]. HSP70 expression was not influenced
by ICL-CCIC-0019, while a small increase in HSP90 expression was observed. It is possible,
that this response could be profound enough to permit synergistic interaction of combined
CHKA and HSP90 inhibition.
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CHK inhibition yields in potent antitumour activity
The compound was then tested for key pharmacological properties that could a↵ect its
behaviour in vivo. Using human and mouse liver microsomes predicted good compound
metabolic stability. The positive charges of ICL-CCIC-0019 restrain its cell permeability,
however it was found to have su cient capabilities to cross membranes with a comparable
range to other approved drugs [196]. Plasma protein binding of 64% indicated a balanced
equilibrium of bound and free drug fractions [199]. Additionally, ICL-CCIC-0019 did not
possess ABC drug resistance transporter substrate activity. Nonetheless, it seems likely
that resistance could arise through upregulation of these transporters, as NCI/ADR-RES,
an adriamycin-resistant OVCAR-8 variant with high MDR1 expression was least sensitive
to the inhibitor. This is further supported by a ca. 10-fold higher sensitivity of HCT116
cells, that express low levels of ABC transporters, compared to HCT15 cells with high
ABC transporter expression.
The results obtained to that point warranted further in vivo evaluation. Initial dose
finding studies revealed that 5–10 mg/kg ICL-CCIC-0019 were tolerated. This is compa-
rable to previously described bis-cationic CHK inhibitors, especially MN58B, for which
2–5 mg/kg 3 times a week were described as tolerated doses. [146]. The occurring toxicity
was characterised by body weight loss followed by relatively quick recovery in BALB/c
mice. BALB/c nude mice displayed greater body weight loss and therefore the initially
optimised dosing scheme could not be completed and treatment had to be intermitted.
Pharmacokinetic variables demonstrated rapid clearance from the plasma and accumula-
tion in tissues, such as tumour, liver and kidneys. This was also detected by [18F]D4-FCH
PET imaging and reflected by a relatively large volume of distribution. In spite of the
low cellular permeability, the compound was selectively retained in tissues. Potentially,
physicochemical properties of ICL-CCIC-0019, such as pKa, favour cellular trapping by
virtue of di↵erences in ionisation that may not be obvious in the case of an in vitro assay
with a relatively high extracellular pH of 7.4. Pharmacokinetic data support the notion
that dosing schedules to lower Cmax and increase exposure are required to achieve the
optimal therapeutic index. Mechanisms to reduce liver and kidney retention, e.g. via ap-
propriate formulation, would be helpful for future investigations, although recovery in liver
appears to be rapid within 48 hours.
High accumulation in the liver and kidneys was observed in both pharmacokinetic
and PET studies, which could account for the body weight changes. Liver accumulation
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is unlikely to be related to the intrinsic, charged chemical structure of ICL-CCIC-0019.
Neuromuscular blocking agents, which comprise a class of approved drugs that are denoted
by bis-cationic moieties of quaternary amines, are both renally and hepatically cleared.
Importantly, the route of excretion depends on their lipophilicity, with hydrophilic com-
pounds favouring renal and lipophilic compounds hepatic clearance [223]. The structural
similarity of ICL-CCIC-0019 to this drug class, suggests that the main route of excretion
could be via kidneys and that the compound accumulation in liver may be attributed to
specific interaction with choline metabolic pathways in this organ. Unlike neuromuscular
blocking agents, ICL-CCIC-0019 is not expected to interact with nicotinic acetylcholine re-
ceptors, due to subtle but important structural di↵erences. Neuromuscular blocking agents
mimic acetylcholine and therefore usually contain a quaternary amine in proximity to an
ester [224]. More specifically, depolarising neuromuscular blockers, like suxamethonium
chloride, require a choline ester to be exposed to the receptor as part of their mechanism
of action [225]. Non-depolarising neuromucular blockers, like tubocurarin and atracurium,
comprise of larger and more lipophilic quaternary moieties and encompass a more rigid
often ester-containing linker [226]. However, if ICL-CCIC-0019 proceeds into clinical eval-
uation, it would be imperative to assess the interaction with acetylcholine receptors as
part of experimental preclinical toxicology studies.
CHKA expression and activity is particularly high in the liver, as this organ is one
of the key metabolic sites for lipid — including choline — metabolism and the formation
of betaine [41]. As indicated above, strong retention of ICL-CCIC-0019 in liver could
therefore be related to specific interactions with CHKA and arrest its physiological roles. If
this was the case, this form of on-target toxicity could have profound implications for CHK
inhibitors in general. To better understand the e↵ect of CHKA inhibition in hepatic tissues,
it will be necessary to monitor the changes in choline-containing metabolites (especially
choline, PCho, PtdCho and betaine) and relate them to liver function perturbations.
Testing the antiproliferative activity in cell normal liver cell lines could provide preliminary
evidence of toxicity in cells with high endogenous choline turnover. It is plausible, however,
that if a suitable therapeutic window for the liver can be identified, CHK inhibition could
be a viable therapeutic strategy for hepatocellular carcinomas or liver metastasis. The
former have been recently shown to have elevated CHKA expression that adversely a↵ect
overall survival [227].
PET imaging confirmed the target inhibition in vivo by a marked decrease of [18F]D4-
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FCH uptake compared to controls. Interestingly, despite the rapid tissue distribution, in-
hibition was strongest after 24–48 hours post single treatment. Potentially, the bis-cationic
structure required time to homogenously penetrate areas of a tumour that are further away
from vascularisation. Additionally, a lag time might be required to inhibit CHKA and re-
duce the relatively high intracellular PCho concentrations. The PET imaging-derived data
reflected the tissue pharmacokinetic behaviour. In future drug development programs,
[18F]D4-FCH PET could therefore serve as a valuable tool to rank compounds according
to their a nity to the target in vivo, while predicting the tissue biodistribution of major
organs. This has advantages over MRS, where only changes in total choline containing
metabolites (choline, PCho, GPC) can be detected in vivo. Furthermore, PET permitted
deeper analysis of the enzymatic modulation by fitting of a kinetic model. Changes in
tumour-associated radioactivity were mostly driven by K 1, the perfusion-dependent rate
constant describing flux from the plasma to the tissue. It was anticipated based on previ-
ous experiments [110], that k3 would reflect CHKA inhibition. It appears plausible that
because of the very rapid tissue distribution of [18F]D4-FCH, where all tumour-associated
tracer is delivered within the first two minutes of imaging, CHKA-mediated retention is
indeed more reflected by the initial delivery phase. Potentially, however, the fairly rapid
metabolisation of the tracer — albeit lower than [11C]choline — could adversely impact the
input function of the kinetic model. The higher rate of metabolism in mice compared to
humans may limit the accuracy of the model. Interaction of ICL-CCIC-0019 with choline
transporters can also not be ruled out and further studies will be required to fully address
choline transporter inhibition.
Target inhibition in vivo translated into potent antitumour activity, but not tumour
regression. This is comparable to other inhibitors targeting metabolic handling, such as
IDH1 inhibitor AGI-5198 [228], the AMP-activated protein kinase (AMPK) agonist phen-
formin [229], or FASN inhibitor orlistat [230]. As metabolic pathways are very interlinked,
alternative routes are likely to compensate. During CHKA inhibition, for example, PEMT
pathway via ENTK1 and 2 could take over the roles of PtdCho synthesis or potentially the
membrane lipid composition could change with higher content of non-choline containing
lipids. This stresses the importance of understanding the metabolic consequences caused
by inhibition of a specific pathway to rationally develop combination therapy approaches.
The changes in proliferation could not be predicted at early time points by [18F]FLT.
In contrast, treatment increased tracer retention, which is referred to as ‘flare e↵ect’. This
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temporal elevation is usually detected upon inhibition of de novo DNA synthesis as a
consequence of redistribution of the human equilibrative nucleoside transporter type 1
(hENT1) to the cell membrane [231]. The causal link between CHKA and flare [18]FLT
uptake remains to be elucidated.
These results of pharmacological CHK inhibition were aimed to be cross validated by
an inducible shRNA model. While siRNA is a useful tool for in vitro research, its short
duration of action of about one week makes it unsuitable for in vivo experiments. By com-
parison to constitutive shRNA expression, this approach as the advantage that tumours
can be grown without interfering with oncogenic targets before treatment initiation, re-
sembling a clinical scenario. Additionally, engraftment of the cells is not influenced by
inhibition of potentially essential targets.
The model showed good knockdown in vitro after exposure to DOX, which yielded
in about 50% reduction of PCho formation. Previous reports using gene silencing have
provided similar results [138, 142, 232]. Residual amounts of kinase appear to be able
to generate considerable quantities of PCho, which favours pharmacological inhibitors
with high a nity and good pharmacokinetic properties over RNAi, as pharmacological
intervention is more likely to result in complete target inhibition.
While shRNA expression was confirmed in vivo, it did not downregulate CHKA protein
levels and therefore no di↵erences in [18F]D4-FCH uptake were seen. While 1 week of
DOX dietary supplementation was su cient to activate RFP expression, it was probably
too short to mediate CHKA knockdown. Longer exposures to DOX would be required,
but the rapid growth of HCT116 xenografts (tumours reach 50–100 mm3 ca. 10 days post
inoculation) might prove this lineage to be unsuitable.
E↵ects on combined treatment with HDAC inhibitors
Metabolic pathways are profoundly interlinked and understanding of their connections
could permit the rational design of highly e↵ective combination therapies. Combined
inhibition of CHK and HDAC was tested due to the activation of CHKA upon pan-HDAC
inhibition [100, 101, 210, 211] and found to be synergistic, particularly in the setting of
HDAC6-selective inhibition by C1A. The HDAC inhibitors used in this study exert their
antiproliferative activity through di↵erent mechanisms. In contrast to the pan-HDAC
inhibitor vorinostat, which induces G1 arrest and subsequently apoptosis, C1A rapidly and
potently triggers apoptosis [3]. The earlier onset of C1A-mediated e↵ects could explain
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why this combination was more favourable than with pan-HDAC inhibition.
Previously reported PCho increases in response to pan-HDAC inhibition could not be
confirmed. Importantly, past studies were based on MRS, which represents the sum of
catabolic and anabolic events, that could confound the e↵ects of CHK activity. Future
studies will be required to examine the molecular relationship between CHKA and HDACs.
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Chapter 5
A body PET Imaging of HER2
Expression
This work is associated with [2]:
Trousil S, Hoppmann S, Nguyen Q-D, Kaliszczak M, Tomasi G, Iveson P, Hiscock, Duncan,
Aboagye, Eric O. Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891
A body for Detection of HER2 Expression and Pharmacodynamic Response to HER2-
Modulating Therapies. Clin Cancer Res. 2014;20:1632-43.
5.1 Introduction
Choline metabolism and the consequences of its inhibition have been mainly examined in
breast and lung cancer. Both diseases are characterised by frequent overexpression of the
epidermal growth factor receptor family members EGFR and HER2 (also referred to as
HER2/neu or ErbB-2) [233]. EGFR and HER2 exert at least part of their transforming
capabilities through interaction with the non-receptor tyrosine kinase c-Src, which is over-
expressed in > 60% of breast cancers [234–236]. As highlighted on page 44, c-Src is the only
interaction partner that has been identified to date to directly phosphorylate and activate
CHKA [122]. Consequently, human mammary epithelial cell lines that are engineered to
express HER2 exhibit increased levels of PCho and total choline containing metabolites
compared to their wild-type counterparts, without changes in their doubling times [33].
HER2 expression also dramatically increases the PCho:GPC ratio, a surrogate for ma-
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Figure 5.1: Functional interaction between HER2 and CHKA. A, Cell lines of the Cancer Cell
Line Encyclopaedia were analysed and ranked by HER2 mRNA expression. The 25 lowest and 25
highest expressing cell lines were investigated for CHKA expression (P =0.0005). Data derived
from Cancer Cell Line Encyclopaedia [179]. B, Antiproliferative activity of ICL-CCIC-0019 against
MCF7-vector (HER2 negative) and MCF7-p95HER2 (transfected with the truncated but signalling
remnant p95HER2) and MCF7-HER2 (transfected with full-length HER2) cells was measured.
lignant transformation [33]. Furthermore, HER2 positive cancer cell lines — including
commonly studied BT474, SKBR-3 and SKOV-3 cells — exhibit higher CHKA expression
than HER2 negative lineages (Figure 5.1A, P < 0.001). As a result, HER2 positive cell
lines are more sensitive to CHKA inhibition than HER2 negative lineages (Figure 5.1B).
In an isogenic model comprising of HER2 negative MCF7 cells transfected with empty
vector (MCF7-vector), truncated but signal remnant p95HER2 (MCF7-p95HER2) or full-
length HER2 (MCF7-HER2), treatment with ICL-CCIC-0019 impaired proliferation more
in cell lines with functional HER2 signal transduction (GI50 MCF7-p95HER2: 2.54 µM
and MCF7-HER2: 2.19 µM) than in the HER2-negative line (GI50: 6.05 µM, P < 0.001
compared to both positive lines). Conversely, patients responding to pharmacologic in-
hibition of HER2 display reduced [11C]choline uptake by PET imaging [237]. Therefore,
patients with HER2 amplification are more likely respond to CHKA inhibition. To iden-
tify such patients more readily, and permit the hypothesis to be clinically tested, a novel,
non-invasive, PET-imaging-based HER2-targeting diagnostic tool, [18F]GE-226, was de-
veloped.
HER2 is a 185 kDa transmembrane receptor and its gene amplification and protein
overexpression play pivotal roles in the pathogenesis and progression of many types of
cancer. HER2 is overexpressed in around 20% of breast, 15-35% of gastric and 9-32% of
ovarian cancers and is correlated with poor survival [238–240]. The protein has conse-
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quently emerged in recent years as an important predictive biomarker and target of cancer
therapy [241]. Homo- or heterodimerisation with other members of its family prompts
activation of the intracellular tyrosine kinase domain and triggers cell survival and prolif-
eration mediated through MAPK and Akt signalling pathways [242, 243].
Available HER2-targeted therapies in the clinic include antibodies, such as trastuzumab
(Herceptin, Genentech) and pertuzumab (Perjeta, Genentech), which prevents receptor
dimerisation, antibody–drug conjugates, such as T-DM1 (Kadcyla, Genentech) or small
molecule inhibitors targeting the tyrosine kinase domain (e.g., lapatinib, Tyverb, Glaxo-
SmithKline; a dual HER2 and EGFR inhibitor). Proteolytic shedding of the extracel-
lular domain or alternative splicing in limited cases can generate a truncated, signalling
remnant p95HER2 domain, which presents one potential mechanism of resistance to anti-
HER2 therapies [244]. Although trastuzumab forms the mainstay of anti-HER2 targeted
therapies, it does not reverse HER2 protein expression in patients [245, 246]. Inhibitors of
the molecular chaperone HSP90, which elicit HER2 proteasomal degradation, are there-
fore currently under investigation in this context. A phase II clinical trial of one such
inhibitor, NVP-AUY922 (Novartis), has recently been completed in patients with HER2
or ER positive locally advanced or metastatic breast cancer (NCT00526045).
Accurate testing of HER2 status is crucial for patient stratification to identify individ-
uals that may benefit most from such targeted therapies. However, this can be intricate
as HER2 expression may vary through progression from primary to secondary disease
with locoregional and distant recurrences often not being amenable to biopsy [247]. Fur-
thermore, recent studies have highlighted spatial heterogeneity as a potential source of
incorrect assessment [248]. The vast majority of FDA-approved diagnostics are based on
immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH). IHC deter-
mines the HER2 protein expression in formalin-fixed para n embedded (FFPE) tumour
biopsies, while FISH detects HER2 gene amplifications, which are considered a legitimate
surrogate as HER2 overexpression is generally caused by copy number variations [249].
The utility of serum-based alternatives by detecting soluble extracellular domains is also
under investigation [250].
Tumour marker-targeted molecular imaging using radiolabeled A bodies, which are
non-immunoglobulin-derived a nity proteins, might provide an accurate and non-invasive
alternative to HER2 molecular diagnostics. A bodies are engineered as three-helix bundle
Z proteins derived from the staphylococcal protein A [251]. They are characterised by
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nano- to picomolar binding a nities, small size of ca. 6.5 kDa compared to antibodies or
antibody fragments (ca. 20–150 kDa), and short plasma residence time, thus permitting
rapid and homogenous tissue distribution. Consequently, high contrast images can be
obtained within the first hour or two of administration [252, 253]. Due to their favourable
pharmacokinetic properties, these molecules are suitable for radiolabeling with short-lived
radioisotopes by comparison with full IgG antibodies.
Here, it is demonstrated that the HER2-targeting A body [18F]GE-226 provides a
viable strategy to determine di↵erential HER2 expression irrespective of lineage or pre-
treatment with trastuzumab within one hour after injection. Insights into the kinetic
characteristics of the A body interaction with HER2 are provided using full length versus
p95HER2 transfected cells and siRNA HER2 as controls, or HSP90 inhibitor treatment to
degrade HER2.
5.2 A body-HER2 binding properties
To ensure the fluorinated prosthetic group does not adversely influence the A body bind-
ing kinetics, the receptor interaction of the isotopically unmodified A body analogue was
measured using surface plasmon resonance and compared to binding of human full-length
and truncated p95HER2, as well as rhesus and rat full-length HER2 (Figure 5.2). While
the tracer showed very strong binding to human (KD=76 pM) and rhesus HER2 (KD=67
pM), it did not interact with p95HER2 or rat HER2 (Table 5.1).
Table 5.1: Summary of GE-226 binding kinetics to human and rhesus HER2.
Kinetic properties Human HER2 Rhesus HER2 
On-rate kon  1.73u107 M-1s-1 6.37u106 M-1s-1 
Off-rate koff 1.31u10-3 s-1 4.25u10-4 s-1 
Affinity KD 7.58u10-11 M 6.67u10-11 M 
Rmax 133.5 138.1 
Chi-Square ƺ2 0.607 1.12 
U-value 3 7 
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Figure 5.2: Interaction of GE-226 with HER2 as determined by surface plasmon resonance. GE-
226 binds with high a nity to human (A) and rhesus (B) HER2, but not to human p95HER2 (C)
or rat HER2 (D). Data were obtained from Syngene.
5.3 [18F]GE-226 exhibits specific and lineage-independent
HER2 binding
The tracer retention was tested in 10 di↵erent cell lines derived from breast, upper gas-
trointestinal tract and ovarian cancer, of which half were HER2 negative and the other
half HER2 positive. The panel included an isogenic model comprising of HER2 nega-
tive MCF7 cells, which were transfected with empty vector (MCF7-vector), p95HER2
(MCF7-p95HER2) or full-length HER2 (MCF7-HER2). While all HER2 negative and
p95HER2 transfected cell lines had only marginal background uptake (1.2 ± 0.5% ap-
plied radioactivity per mg protein across all lines), all HER2 positive cell lines retained
the tracer at high levels (between 13.6± 3.4 and 79.9± 12.1% applied radioactivity per
mg protein) and in good agreement with endogenous HER2 expression. Tracer binding
was, however, independent of expression of another epidermal growth factor receptor fam-
ily member, EGFR. Figure 5.3A shows one representative uptake experiment, as initial
experiments revealed that the uptake was dependent on the specific activity. In com-
parison to freshly prepared [18F]GE-226, the same radiotracer preparation yielded only
39.5± 8.5 and 24.9± 3.8% tracer uptake if incubation was initiated 70 and 140 minutes
later (Figure 5.3B). Transient siRNA-mediated knockdown of HER2 decreased tracer up-
take compared to non-targeting scramble control (Figure 5.3C, 100± 12% versus 18± 9%,
P < 0.0001). Target knockdown was confirmed by western blot. To further investigate
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the specificity of the signal, SKOV-3 cells were co-incubated with tracer and large excess
(ca. 2 000 fold) of its non-radioactive 19F-labelled analogue (Figure 5.3D). This reduced
uptake to 3.1± 2.6% compared to control cells (100± 12%; P < 0.0001).
5.4 [18F]GE-226 exhibits a di↵erent binding site than tras-
tuzumab and predicts detection of HER2 degradation
by NVP-AUY922
An important question when developing a HER2-targeting imaging probe is whether the
tracer can correctly determine the HER2 status of a patient independently of potential
trastuzumab treatment. Pre-treatment of SKOV-3 cells with 10 µM/mL trastuzumab for
1 hour did not alter tracer binding, however, incubation for 24 hours prior to uptake exper-
iment reduced tracer binding by 32± 11% compared to drug-na¨ıve controls (Figure 5.4A;
P < 0.0001).
It was investigated, whether HER2 degradation consequent to HSP90 inhibition (HER2
is a client protein of HSP90 [254]) would result in detectable changes in tracer uptake.
The HSP90 inhibitor NVP-AUY922 caused a dose-dependent decrease of HER2 protein
expression compared to untreated controls, which consequently translated into reduced
tracer uptake, further supporting its specificity (Figure 5.4B; P < 0.0001 for all tested
concentrations compared to control).
5.5 [18F]GE-226 discriminates di↵erential HER2 expression
in vivo
Based on the in vitro data, the ability of the tracer to distinguish varying degrees of
HER2 expression in the complex tumour milieu in vivo was investigated. Figure 5.5A
shows representative small-animal [18F]GE-226 PET images of SKOV-3 and MCF7-vector
xenograft-bearing mice. High tumour uptake contrasts the low non-specific retention in
the body. Across di↵erent tumour models, the tracer discriminated well between HER2
positive and negative xenografts. Both tumour-specific distribution and retention kinetics
accounted for these di↵erences. While HER2 negative MCF7-vector and MCF7-p95HER2
xenografts exhibited low tumour retention and a steady-state tissue radioactivity after
initial delivery, HER2 positive xenografts had increased uptake and followed a pattern
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Figure 5.3: [18F]GE-226 binds with high selectively and sensitivity to HER2. A, Cell lines of diverse
lineages and di↵erential HER2 status were exposed to [18F]GE-226 for 60 minutes and retained
radioactivity measured as percent applied radioactivity normalised to total protein (mean of n =1
with 5–6 replicates±SD). Full-length and truncated p95 HER2 protein expression as determined
by western blot is shown for the same cell lines in the panel above. B, SKOV-3 cells were pulsed
with 740 kBq/mL [18F]GE-226 either immediately upon receipt of tracer (t0; typically 2–3 h
after synthesis), 70 min (t70) or 140 min (t140) after first incubation and cell-bound radioactivity
measured. The amount of cold GE-226 A body per well was ca. 50 ng at the start of the experiment
and ca. 80 and ca. 130 ng at 70 and 140 min, respectively. Mean of n =1 in at least duplicate.
Error bars: SD. C, HER2 expression was transiently abrogated by siRNA and tracer retention
after 60 minutes compared to non-targeting scramble control (mean of n =3 in triplicate on three
di↵erent days±SD, P < 0.0001); knock-down confirmed by western blot. D, SKOV-3 cells were
incubated with [18F]GE-226 in the presence or absence of 0.5 mg/mL blocking dose of isotopically
unmodified GE-226 for 60 minutes and cell-bound activity measured (mean of n =3 in triplicate
on three di↵erent days±SD, P < 0.0001).
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Figure 5.4: [18F]GE-226 possesses a di↵erent binding site than trastuzumab and detects HER2
degradation upon HSP90 inhibition. A, SKOV-3 cells were treated with 10 µM/mL trastuzumab
for 1 or 24 hours and incubated for an additional hour with [18F]GE-226 and retained activity
compared to untreated controls (*** P < 0.0001; mean of n + 5 in triplicate on five di↵erent days± SD). E↵ect on HER2 protein expression is shown in the panel below. B, E↵ect of HSP90 inhibitor
NVP-AUY922 on HER2 expression and consequent impact on tracer uptake (P < 0.0001 for all
concentrations compared to control; mean of n + 3 in triplicate on three di↵erent days ± SD).
of net irreversible binding (Figure 5.5B–C). Thus [18F]GE-226 PET was able to distin-
guish HER2-negative (MCF7-vector and MCF7-p95HER2) from low (MCF7-HER2) and
moderately (MDA-MB-361) HER2-expressing xenografts. However, tissue radioactivity
was comparable in tumours with moderate and highly (SKOV-3) HER2-expression when
simple measures of uptake were employed for PET analysis (Figure 5.5B–C). Nonetheless,
radiotracer uptake correlated well with HER2 protein expression as determined by ELISA
(r2=0.78; Figure 5.5D–E).
The tracer was metabolically stable and predominately and rapidly excreted via the
renal route (Figures 5.6 and 5.7).
It was hypothesised that kinetic modelling, which accounts for tissue uptake relative
to plasma as opposed to tissue uptake alone, could further help discern the various HER2
groups. A two-tissue irreversible compartmental model was employed to derive the net
irreversible uptake rate constant, K i (Figure 5.8A). No metabolite correction was necessary
as the tracer was stable in vivo (Figure 5.6A). With this model, all groups could be
distinguished, even MDA-MB-361 from SKOV-3 xenografts (Figure 5.8A). As expected,
K i highly correlated with NUV60 among all groups (r
2=0.82; P =0.008; Figure 5.8B).
Figure 5.8C–F shows other pharmacokinetic parameters.
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Figure 5.5: Tumour profiles of [18F]GE-226 in di↵erentially HER2 expressing xenograft models. A,
Representative OSEM3D reconstructed PET-CT images of SKOV-3 and MCF7-vector xenograft-
bearing mice. White arrow indicates tumour, orange arrow kidney. B, Comparison of tumour time
versus radioactivity curves in indicated xenograft models (mean of n =6±SEM with exception of
MCF7-p95HER2 n =3±SEM). C, Box plot representing NUV60 values of [18F]GE-226 in various
xenograft models. NUV60 is a measure of retained radioactivity in a defined region of interest
(tumour) 60 minutes after tracer administration. The box extends from the 25th to 75th percentile,
with the line in the middle representing the median. The whiskers indicate the highest and the
lowest value. D, HER2 expression in various xenograft models as determined by ELISA on tumour
samples that were excised post imaging. E, Correlation between NUV60 and HER2 expression as
determined by ELISA on tumour samples.
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Figure 5.6: Plasma metabolite profile and tissue pharmacokinetics of [18F]GE-226. A, Rats were
administered 20 MBq [18F]GE-226 i.v. and metabolites quantified by radio-HPCL 10, 30 and 60
minutes post injection. Metabolic stability was assessed by comparison of parent peak (retention
time (RT) ca. 10.6 minutes) with metabolites (RT ca. 29 minutes) and is represented as percent
radiochemical purity (RCP). Data provided by GE Healthcare. B, Time versus radioactivity curves
derived from PET data for uptake in heart, tumour and kidneys in SKOV-3 xenograft bearing mice
(mean of n =6±SEM).
To lend further support to the specificity of the A body, blocking studies were carried
out by injecting 30 mg/kg isotopically unmodified GE-226 i.v. 20 minutes prior to PET
scan (ca. 100-fold mass equivalent of hot tracer). The cold ligand, by blocking specific
binding sites, resulted in significantly reduced tracer uptake (NUV60 18.7± 2.4 versus
7.1± 1.6 in controls and blocked tumours, P =0.0003) andK i (Figure 5.9). It is noteworthy
that the kinetics of tracer uptake were distinctly di↵erent between controls and blocked
samples, in that the latter share characteristics of HER2 negative tumours.
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Figure 5.7: Biodistribution of [18F]GE-226 in tumour-bearing BALB/c nude mice. Tissues were ex-
cised at indicated time points and associated radioactivity measured on a gamma counter. Uptake
is expressed as %ID/g tissue±SD (n =3 per time point).
5.6 Localisation and intensity of fluorescein-labelled GE-226
correlates with DAKO HercepTest
To examine tissue localisation, GE-226 was labelled with fluorescein and its localisation and
fluorescent intensity in tumour sections compared with FDA approved DAKO HercepTest.
In contrast to PET experiments, normalisation to injected dose is not possible with fluo-
rescent compounds. To eliminate inter-subject variability, experiments were performed in
bilateral tumour-bearing mice. Because HER2 positive and negative xenografts described
in Figure 5.5 have greatly varying growth rates and require di↵erential hormonal treat-
ments, A431 (HER2 negative) and NCI-N87 (HER2 positive) xenografts were employed
as previously described [160]. A mixture of 20 mg/kg Hoechst and 15 mg/kg fluorescein-
conjugated GE-226 in PBS were injected i.v. and two hours post injection, tumours were
excised, formalin fixed and para n embedded and adjacent tumour sections prepared for
HercepTest staining or fluorescent microscopy. Tissue processing for immunofluorescence
microscopy removed any unbound tracer and signal therefore accounts only for specific
HER2-A body interaction. Figure 5.10 shows that fluorescent staining co-localised with
regions that are HER2 positive in NCI-N87 tumours and that both HercepTest and fluo-
rescent staining in A431 tumours were negligible.
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Figure 5.8: Tissue pharmacokinetic analysis using a single input 2-tissue 3k model. A, K i, the
rate constant for the net irreversible retention of the tracer in the tumour. B, Correlation between
NUV60 and K i to support validity of the kinetic model. C–F, Kinetic parameters of [
18F]GE-
226 binding in these xenografts. Graph shows mean of n =6 per group with exception of MCF-
P95HER2 n =3±SD. Statistical significance was determined by one-way ANOVA with Bonferroni’s
Multiple Comparison test. * P < 0.05; ** P < 0.01; *** P < 0.001. Mathematical modelling was
carried out with help of Dr. Giampaolo Tomasi.
5.7 [18F]GE-226 can correctly assess HER2 status indepen-
dently of prior trastuzumab treatment and predicts for
response to NVP-AUY922 in vivo
SKOV-3 tumour bearing mice were treated with three doses of trastuzumab and imaged 2
hours post initial dose and re-imaged 48 hours after last treatment (i.e. 7 days after initial
scan). Neither treatment adversely a↵ected tumour tracer retention (Figure 5.11A), albeit
7 days of continuous treatment reduced K i by 24% (P =0.025) as a consequence of elevated
arterial input function and altered renal excretion (Figure 5.11B–F). This confirmed by
comparison to trastuzumab, that the A body possesses di↵erent HER2 binding sites.
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Figure 5.9: Specificity of [18F]GE-226 receptor interaction was determined by blocking studies.
SKOV-3 xenograft bearing mice were treated with 30 mg/kg cold isotopically unmodified GE-226
in PBS i.v. 20 minutes before PET scan and compared to untreated controls. A, Representative
axial PET-CT images of mice treated with or without blocking dose. B, Graph shows mean
tumour time versus radioactivity curves of n =6 per group±SEM. C, Kinetic analysis of blocking
experiment. P < 0.0001. Mathematical modelling was carried out with help of Dr. Giampaolo
Tomasi.
DAKO HercepTest Fluorescein GE-226 
NCI-N87
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Figure 5.10: GE-226 co-localises with HER2 protein expression in tumours with spatial heterogene-
ity. GE-226 was labelled with fluorescein and injected in mice bearing both NCI-N87 and A431
tumours, which express high and low levels of HER2, respectively. Tumours were sectioned and
adjacent slides either stained with DAKO HercepTest or used for immunofluorescent microscopy.
Staining was conducted at GE Healthcare.
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Figure 5.11: [18F]GE-226 binding does not interfere with trastuzumab treatment. A, Mice bearing
SKOV-3 xenografts were treated with 50 mg/kg trastuzumab i.v. 2 hours prior to scan. Animals
were recovered, treated twice more with 25 mg/kg trastuzumab and re-imaged 7 days after initial
scan (mean of n =6±SEM). One mouse, which was an outlier with low tracer uptake both on
early and late scan, is displayed separately. B, Pharmacokinetic analysis of A (P =0.025). TACs
and AUC0-60 for uptake in heart (C, D) and kidney (E, F) of drug-na¨ıve or trastuzumab-treated
SKOV-3 xenograft bearing mice (*** P = 0.0004). Mathematical modelling was carried out with
help of Dr. Giampaolo Tomasi.
Interestingly, one mouse had significantly reduced uptake on both scans and was viewed
separately for analysis. Tracer uptake could not be correlated with ELISA-derived HER2
expression values, as one of the ELISA antibodies interfered with bound trastuzumab.
Therefore, western blot confirmed that trastuzumab treatment did not substantially alter
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Figure 5.12: HER2 expression analysis and genomic DNA sequencing in relation to uptake rate
constants in trastuzumab-treated or control xenografts. A, HER2 protein expression in SKOV-3 tu-
mors after 7 days of treatment with trastuzumab. C1–4, representative controls, T1–6, trastuzumab
treated samples, T4, outlier PET imaging. B, Aligned sequences of exon 8 of HER2 surrounding the
region coding for amino acids 309 and 310. Samples include untreated control SKOV-3 xenograft
(C1), parental SKOV-3 cell line, trastuzumab-treated xenograft with normal [18F]GE-226 uptake
(T1) and outlier sample (T4, outlier). C–G, Kinetic parameters K 1, k2, k3, K i and V b of controls
and trastuzumab-treated SKOV-3 tumors in comparison to HER2-negative, drug-na¨ıve xenografts
(grey bars). Statistical significance was determined by comparison of each group to untreated
SKOV-3 controls; * P < 0.05, ** P < 0.01, *** P < 0.001. Mathematical modelling was carried out
with help of Dr. Giampaolo Tomasi.
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Figure 5.13: [18F]GE-226 can predict response to HSP90 inhibition. A, Comparison of NVP-
AUY922 treatment (mean of n =5±SEM) to vehicle treated controls (mean of n =4±SEM) in
the SKOV-3 xenograft model and B, kinetic analysis of inhibition constants (P =0.011). C, Box
plot representing NUV60 values. The box extends from the 25
th to 75th percentile, with the line
in the middle representing the median. The whiskers indicate the highest and the lowest value.
D, HER2 expression in SKOV-3 tumours after treatment with 3 doses of 50 mg/kg NVP-AUY922
in comparison to vehicle (10% DMSO and 5% Tween-20 in PBS). Mathematical modelling was
carried out with help of Dr. Giampaolo Tomasi.
HER2 expression nor resulted in expression of truncated P95HER2 in the outlier sample
(Figure 5.12A). Sequencing exon 8 of HER2, which has been previously described as a site
for mutations on the extracellular domain of HER2 [255], indicated no sequence alterations
in the outlier sample compared to controls (Figure 5.12B). Furthermore, kinetic modelling
revealed increased tissue e✏ux (k2) of the outlier with similarities to HER2 negative
tumours, suggesting a loss of interaction of the A body with its target (Figure 5.12C-G).
Finally, it was assess whether [18F]GE-226 is responsive to HSP90 inhibitor treatment
in vivo. SKOV-3 xenograft bearing mice were treated with 3 doses of 50 mg/kg NVP-
AUY922 or vehicle. This led to reduced HER2 expression with consequently decreased
tracer uptake (Figure 5.13).
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5.8 Discussion
With aid of kinetic modelling, it was demonstrated that the ZHER2:2891 A body, [
18F]GE-
226, quantitatively discriminates between HER2 negative and positive tumours within 1
hour, independent of lineage and prior treatment with trastuzumab. A body radiotracers
have been developed to overcome the shortcomings of large (150 kDa) antibodies. To date
most of the reported studies of radiolabeled A bodies in the literature have employed ana-
logues of ZHER2:342 labelled with radiometals or radiohalogens [252, 256–262]. Recently,
re-engineering of this A body by Feldwisch and co-workers [263] led to an optimised
sca↵old containing 11 amino acid substitutions in the nonbinding surface of the A body
removing similarity to the original protein A domain — ZHER2:2891 . Further to potential
for automated site-specific good manufacturing practice-grade (GMP [264]) manufacture
on FASTlab to allow broad clinical access to a HER2 imaging agent, ZHER2:2891 has
improved thermal and chemical stability by avoiding deamidation, as well as increased
hydrophilicity of the non-binding surface; positive attributes for ease of peptide synthe-
sis and in vivo pharmacokinetics. The latter property is desirable to permit conduct
of imaging studies within 1 or 2 hours post-radiotracer injection. However, within this
early period non-specific uptake could contribute to tissue signal. Therefore the specificity
of 18F-radiolabeled ZHER2:2891 A body, [
18F]GE-226, was assessed for early imaging (1
hour) using both intrinsic cellular uptake and in vivo dynamic imaging to quantitatively
discriminate between HER2 negative and positive tumours.
Optimisation of contrast is pivotal to successful development of imaging agents. High
contrast results largely from high a nity of radiotracers and rapid pharmacokinetics. By
comparison with other molecular imaging probes, A bodies benefit from a short blood
circulation time and high target a nity resulting in high contrast images within a rel-
atively short time after injection, and slower internalisation rates [259, 265, 266]. This
permits utilisation of more widely available short-lived radioisotopes, such as 18F and
68Ga, minimizing the patient’s dosimetry. In comparison with nanobodies, A bodies ex-
cel through lower KD, higher kon and slower ko↵ rates [267]. Regarding a nity, Surface
Plasmon Resonance experiments with isotopically unmodified GE-226 revealed high a n-
ity binding to human and rhesus HER2-ECD-Fc comparable to the binding of parent
ZHER2:2891 A body to human HER2-ECD-Fc (76 pM, Ref. [263]). In contrast, GE-226
did not interact with rat HER2-ECD-Fc or human p95HER2, demonstrating specificity
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to the ECD-containing human protein. Radiofluoridation to produce [18F]GE-226 did not
a↵ect radiotracer a nity either, as demonstrated by high specific cell intrinsic uptake in
HER2 positive versus negative human breast, upper-gastrointestinal and ovarian cancer
cell lines. Notably the lineage independence observed also lends support to the specificity
of the radiotracer for HER2 versus other targets like EGFR and potential utility in cancers
other than breast.
While preclinical imaging with ZHER2:2891 radiolabeled with
111In for single photon
computed emission tomography (SPECT) displays good tumour targeting in SKOV-3
xenografts [265], it is expected that [18F]GE-226 with the superior sensitivity, resolution,
and quantification of PET will provide improved contrast at the early time points.
This suggests that [18F]GE-226 could be used for detection of HER2 expression in
primary tumours and distant metastasis, including liver, lung and bone. In this study,
[18F]GE-226 did not cross the blood-brain-barrier so its utility for imaging of brain metas-
tases remain to be seen.
Regarding systemic tracer disposition, high renal accumulation is characteristic of ra-
diometal tracers due to loss of the radioactive ion and reabsorption in the proximal tubules
[268]. In this context previous A bodies labelled with 68Ga or 111In showed approximately
10-fold higher renal localisation than that seen in tumour [265, 266, 269], precluding imag-
ing of tumours in the region around the kidney, as well as having an impact on dosimetry.
Bioconjugation of the A body molecule with albumin, histidine containing tags or 18F
radiolabels have been proposed as alternative approaches to avoid tubular reabsorption
and permitting rapid glomerular filtration [159, 259, 270, 271]. The radiohalogen strategy
with 18F used in this study demonstrated rapid renal clearance of [18F]GE-226, without
substantial tracer accumulation in the kidneys; kidney radioactivity levels were compara-
ble to levels in tumours at 60 minutes. Uptake in other organs, including the liver, was
negligible and it remains elusive whether previously detected hepatic uptake of other A -
bodies in the clinical setting is attributed to A body disposition or the labelling strategy
[272].
Several lines of evidence indicated that the binding of [18F]GE-226 to HER2 is highly
specific: (i) the tracer discriminated between HER2 positive and negative cells and tu-
mours, (ii) siRNA knockdown of HER2 protein in cells reduced tracer uptake, (iii) pre-
treatment of cells or mice with isotopically unmodified GE-226 resulted in significant reduc-
tion in uptake and (iv) tumour distribution of fluorescein-labelled GE-226 co-localised with
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HER2 protein as determined by DAKO HercepTest. The latter also demonstrated that
tumour distribution of the A body was non-limiting in the heterogeneous tumour models
studied. The desirable a nity, specificity and pharmacokinetics properties of [18F]GE-226
led to very high contrast PET images, with the limitation that the high contrast is per-
haps due also in part to the lack of tracer binding to rodent HER2. Nonetheless, it further
substantiates the low non-specific binding of [18F]GE-226 as rodent data for A bodies
have been shown to translate well into human imaging profile.
An influence of specific radioactivity on A body uptake was observed in vitro where
receptor numbers are limited in part due the 2D properties of in vitro culture, compared to
a 3D system in vivo. It was hypothesised that with the higher amount of cold compound
associated with the same level of radioactivity over time, the limited specific binding sites
of an in vitro culture system are more readily blocked and result in a time-dependent
decrease of tracer uptake. As this e↵ect was not observed in vivo — potentially due to a
much greater overall availability of receptors — this finding is not anticipated to hamper
clinical development.
PET imaging demonstrated rapid tracer uptake in HER2 positive xenografts with net
irreversible binding kinetics over time. The irreversible uptake (over the time of imag-
ing) made it possible to distinguish between HER2 negative and HER2 positive tumours
within 1 hour. Time versus radioactivity curves revealed steady-state (limited-washout)
background uptake in HER2 negative xenografts, which was in keeping with the normal dis-
tribution kinetics of these types of peptides within the literature [259, 269, 273]. In HER2
negative xenografts (e.g., MCF7 and MCF7 p95HER2), uptake was rapid and remained
stable over the 60-minute scan period. As wash-out mechanisms are primarily determined
by size, tissue retention of A bodies is longer than of small-molecules nonetheless more
favourable than full immunoglobulins. Thus, the uptake observed in HER2 negative tu-
mours can be attributed to non-specific background tissue distribution. In contrast, all
HER2 positive models showed a continuous increased uptake throughout image acquisition
timeframe. It was confirmed that the net irreversible trapping of the tracer in tumour was
not due to di↵erences in tracer delivery (K 1) or blood volume (V b) but rather to specific
uptake. Tumour uptake correlated with HER2 expression, suggesting specific A body-
HER2 interactions and possibly some receptor internalisation [259, 265, 266]. Receptor
internalisation was not assessed in this study but localisation of the fluorescein-labelled
A body in vivo did not suggest substantial internalisation within the timeframe of the
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study. Importantly, kinetic modelling permits definition of a threshold for HER2 positivity
by determining the irreversible uptake in HER2 positive tumours. This concept requires
clinical evaluation, but preliminary data indicate reliable detection of HER2 positive and
negative lesions. Notably, a negative scan will be a clinically determined quantitative or
semi-quantitative uptake cut-o↵ value at a defined post-injection time, e.g. 1 hour, due
to A body tracer distribution kinetics, and not, an absolute negative signal as seen by
immunohistochemistry.
In view of trastuzumab being the most important HER2-targeting therapy, it was
confirmed that tracer and antibody did not compete for the same extracellular epitope.
X-ray crystallography revealed that ZHER2 A bodies bind the extracellular domain of
HER2 at the interface of domains III and IV, distinct from the trastuzumab binding site on
domain IV [274]. Both in vitro and in vivo experiments confirmed that uptake of [18F]GE-
226 was not obscured by the presence of trastuzumab. Minor, but significant, decreases
in uptake after 24 hours pre-treatment with trastuzumab in vitro are more likely related
to altered receptor internalisation or other dynamics due to the high concentration used
[275, 276]. Continuous exposure of SKOV-3 xenografts to trastuzumab resulted in a slight
downregulation of HER2 protein expression, as detected by western blot. This contrast
to clinical data has been previously reported for pre-clinical models [261], but further
validation would be required to investigate which of the complex dynamic changes upon
trastuzumab treatment — including receptor internalisation, changes in vascularisation,
immune response, cell death and selection of HER2 negative sub-populations — account
for these discrepancies. In the in vivo studies, one HER2 tumour bearing mouse was
characterised by low tumour tracer uptake. As HER2 was found not to be truncated in
this sample (western blot analysis), mutations in the extracellular domain of HER2 were
examined. Recent reports indicate that amino acids 309 and 310 on exon 8 are prone to
mutations (G309A/E, S310F [173, 255], a site that has previously not been identified to
contribute to the HER2-A body interaction [274]. No point mutations occurred in the
outlier samples. Higher tissue e✏ux kinetics (k2) paired with a lowered K 1 are indicative of
lack of retention or potential perfusion deficits, causing reduced tracer delivery. If perfusion
deficits are responsible for this unexpected finding, then an adverse implication on correct
assessment of HER2 positivity by this technology is envisaged; the comparable clinical
scenario is, however, unlikely to a↵ect treatment stratification, as poor perfusion would
potentially also reduce e cacy of trastuzumab. Finally it was confirmed that [18F]GE-
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226 is suitable as pharmacodynamic marker of HSP90 inhibition and perhaps as patient
enrichment tool for those likely to benefit from such therapies. The most promising of
these drugs, NVP-AUY922 [277] is currently in Phase II clinical trials and has previously
shown to downregulate HER2 expression [278], which was correctly confirmed in vitro and
in vivo by [18F]GE-226 PET. This is in accordance with the report by Smith-Jones and co-
workers who similarly demonstrated that the HSP90 inhibitor, 17-allylaminogeldanamycin,
degrades HER2 leading to reduction in the uptake of [68Ga]-labelled F(ab’)2 fragment of
trastuzumab [273, 279].
In conclusion, [18F]GE-226 PET imaging permits accurate discrimination of HER2
receptor expression, irrespective of tumour heterogeneity, cell lineage, or prior trastuzumab
treatment. The tracer is expected to have good safety and dosimetry profiles due to its low
nonspecific binding, the use of short-lived radiolabel and its favourable pharmacokinetic
properties. These data support the clinical development of this tracer in cancer patients,
which is planned. Furthermore, the strong specificity will allow use of this radiotracer for
selecting patients for treatment with choline kinase inhibitors to test the hypothesis that
patients with high HER2 will benefit from choline kinase inhibitor therapy.
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Chapter 6
Summary and concluding remarks
6.1 Summary of work
In this thesis, novel CHK inhibitors with potent antitumour activity were developed and
used to characterise choline biochemistry in cancer. The lead compound, ICL-CCIC-0019,
emerged from a focused library screen, that investigated strategies to create inhibitors that
solely interact with the choline pocket or simultaneously block the choline and ATP active
sites. Biochemical assays and molecular modelling proved the latter approach feasible,
however, with the caveat that the potency of these “hybrid” compounds was significantly
lower than of choline-competitive inhibitors. In particular, the high antiproliferative activ-
ity and the ability to reduce CHK activity at endogenously high choline concentrations in
whole cells, favoured the further characterisation and development of choline-competitive
inhibitors, like ICL-CCIC-0019.
One characteristic challenge in the development of kinase inhibitors is the putative
interaction with other kinases, attributed to the high evolutionary conservation of this
target class. By avoiding interaction with the ATP pocket, ICL-CCIC-0019 demonstrated
very low o↵-target e↵ects against a large panel of human kinases. The compound had high
antiproliferative activity against the NCI-60 panel of cell lines, while normal cell lines were
insensitive to treatment. Pharmacological intervention phenocopied the e↵ect of posttran-
scriptional silencing of CHKA in cancer cells. It was further demonstrated that the mecha-
nism of action is executed entirely by inhibition of the catalytic activity of CHKA and not
by destabilisation of dimer complexes. CHK inhibition decreased PCho accumulation and
subsequently formation of PtdCho, triggering cell death via ER stress pathways. Detailed
pharmacological profiling of ICL-CCIC-0019 was carried out, which considerably extended
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beyond previously published reports of comparable compounds. This permitted for the
first time the establishment of the connection between cellular potency, pharmacokinetics
and pharmacodynamics. The compound was stable in plasma, had a balanced plasma
protein binding, was a non-substrate for drug resistance transporters, but the intrinsic
cationic nature limited the capacity to rapidly cross cellular membranes. Nonetheless, the
latter feature was still within range of other currently approved anticancer drugs. PET
imaging using a target-competitive radiotracer, [18F]D4-FCH, demonstrated modulation of
the enzymatic reaction in vivo, which translated into potent antitumour activity. This re-
sponse, however, could not be predicted at early time points using the proliferation tracer
[18F]FLT. It was further aimed to validate the e↵ects of pharmacological inhibition by
genetic means. Therefore, an inducible shRNA model was created, that yielded su cient
CHKA knockdown in vitro, but failed to do so in vivo. The visualisation of co-expressed
TurboRFP using fluorescent in vivo imaging confirmed transcription of shRNA, but po-
tentially the relatively short study duration of one week prevented attenuation of protein
expression. Lastly, it was identified that combined CHKA and HDAC6 inhibition is highly
synergistic.
Figure 6.1 highlights the key findings, which were obtained by CHKA-selective inhi-
bition and contrasts them to e↵ects observed by combined CHKA and CHKB inhibition.
CHKA selective inhibition with ICL-CCIC-0019 deactivated the Kennedy pathway and
reduced PtdCho. Consequently, ER stress was induced via ATF4 and CHOP, which de-
creased via intermediate mechanisms cell viability. Additionally, pro-survival signal trans-
duction was reduced, leading to G1 arrest and apoptosis, which ultimately resulted in cell
death. In contrast, combined CHKA and CHKB inhibition, as shown by double siRNA
knockdown and exemplified by non-isoform selective ATP-competitive inhibitors [148],
has no e↵ect on cell viability, which could tentatively be mediated through mitophagy or
autophagy [280, 281].
In order to rapidly stratify patients that might benefit from CHK inhibitors, a HER2-
targeted PET tracer, [18F]GE-226, was developed, as HER2 expression is linked to hy-
peractivated choline metabolism. An A body-based approach was chosen, as this non-
immunoglobuline-derived a nity protein is characterised by very strong binding to HER2,
while its small molecular weight enables rapid and homogenous tissue distribution. Surface
plasmon resonance experiments confirmed that the radiolabel did not interfere with the
binding properties of the A body. High specificity was confirmed by di↵erential tracer
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Figure 6.1: Consequences of (A) selective CHKA or (B) combined CHKA and CHKB inhibition.
Black arrows indicate e↵ects of choline biochemistry in cancer cells, that are perturbed by CHKA
selective inhibiton (orange). Blue arrows represent impact of combined CHKA/CHKB inhibition,
as observed with siRNA double knockdown or current ATP-competitive inhibitors. Grey arrow and
circle indicate tentative mechanisms. Double arrows indicate that intermediate mechanisms are
involved to impact cell viability. ATF4, activating transcription factor-6; CHKA/B, choline kinase
alpha and beta; CHOP, CCAAT-enhancer-binding protein homologous protein; ER, endoplasmic
reticulum; PCho, phosphocholine; PtdCho, phosphatidylcholine.
retention in cell lines and xenografts with varying HER2 expression, decreased uptake
after blocking of the target with isotopically unmodified GE-226 and knockdown of HER2
by siRNA. A fluorophore-labelled GE-226 analogue co-localised with HER2 protein in tis-
sues with heterogeneous HER2 expression. Furthermore, tracer binding was not sterically
hindered by trastuzumab, demonstrating the applicability of this imaging modality for pa-
tients who already received this HER2-tagetting therapy. Finally, the pharmacodynamic
response to HSP90 inhibitor-mediated degradation of HER2 could be confirmed. High-
contrast images were obtained with [18F]GE-226 and for the first time, the A body-HER2
interaction could be characterised by kinetic modelling.
6.2 Advances to previous studies and future directions
One central aim of this thesis was to provide a detailed pharmacological characterisation of
ICL-CCIC-0019, as previous studies of CHK inhibitors failed to report data on selectivity,
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pharmacokinetics, pharmacodynamics or toxicity. The use of PET imaging formed the
centrepiece of this evaluation, as it quantitated the CHK inhibition in vivo and predicted
the compound tissue pharmacokinetics in major organs. The obtained results were the sum
of pharmacokinetic properties, cell permeability, target a nity and potential influences of
the tumour microenvironment. It therefore well described the overall behaviour of CHK
inhibitors in vivo and could easily be implemented in future drug discovery e↵orts. A
kinetic model was employed to further discern the physiological processes, but limitations
became apparent, as CHK inhibition was not predicted by changes in the irreversible
binding constant k3. Future studies will be required to validate this model. Genetically
engineered xenografts with knockdown of CHKA, CHKB or choline transporters could
assist to fully comprehend each pharmacokinetic parameter.
ICL-CCIC-0019 was associated with dose-limiting toxicity, depicted by dose-dependent
decrease of body weight in mice. Pharmacokinetic and PET data indicated high liver and
kidney accumulation, which is therefore a potential cause for body weight changes. For the
first time, consequences of CHK inhibitor-mediated choline metabolism on other tissues
than tumour were described. It remains to be understood, whether the e↵ects were related
to the compound or the high choline metabolic activity in liver and potentially also kidney.
Subsequent experiments will be required to study the implications of CHK inhibition in
malignant and benign settings of these organs. Diversification of inhibitor sca↵olds will
further contribute in understanding compound accumulation in various tissues. Recently
investigated uncharged, ATP-competitive inhibitors were ine↵ective in cell-based assays,
which is potentially due to the simultaneous inhibition of CHKA and CHKB. Further
studies will be required to understand why the associated decrease in PCho with ATP-
competitive inhibitors did not impact proliferation. Potentially, CHKA and CHKB have
sca↵olding properties that extend beyond their catalytic activity to generate PCho an
PtdCho and which give them additional roles for pro-survival signalling. Dependent on
which pocket is targeted, distinct conformational changes could influence the sca↵olding
properties for multi-protein complex formation. Additionally, the observed changes in
PCho could occur via PLC and PLD, which will require additional direct e↵ects on these
proteins to be verified. As the ATP cavities of both isoforms share great similarities,
it will require considerable e↵ort to design CHKA-specific, ATP-competitive inhibitors.
Therefore, development of novel — preferably uncharged — choline-competitive sca↵olds
are more likely to advance this class of compounds into an experimental clinical setting.
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The complexity of the required medicinal chemistry e↵orts is perhaps the biggest challenge
in future years.
In this study, an inducible shRNA models was created, but failed to repress CHKA
expression in vivo. HCT116 cells, which were used as a target cell line, were perhaps
too rapidly proliferating to allow su cient time to induce target knockdown. Subsequent
experiments should be aimed to identify suitable host cell lines, as inducible knockdown
models are highly valuable tools to mimic a clinical scenario where treatment commences
on already established lesions. Such models will be required to fully validate CHKA as
a target, provide a comparison to pharmacologic inhibition with respect to antitumour
activity verify kinetic models for PET imaging.
Future studies should aim to identify CHKA inhibition-related metabolic alterations
and the elucidation of their regulatory mechanisms. Potential pathways could include
glucose, amino acid and lipid biochemistry. This will highlight potential feedback loops
and resistance mechanisms but might equally open opportunities for targeted combination
therapies.
Lastly, an alternative approach to determine HER2 expression was proposed. Accu-
rate assessment of a cancer patient’s HER2 status remains a clinical challenge with up
to 20% of patients being potentially withdrawn from therapy or exposed to unnecessary
toxicity. Noninvasive imaging is widely seen as a viable alternative to current methods,
in particular within the setting of locoregional and distant recurrences not amenable to
biopsy, but clinical success by positron emission tomography has so far been hampered by
prolonged tracer retention in liver and kidneys obstructing detection on proximate metas-
tases. [18F]GE-226, overcame these limitations and demonstrated improved properties for
large-scale and good manufacturing practice–grade synthesis and enhanced pharmacoki-
netic characteristics. Lineage independence of these results extends application beyond
breast cancer. Future clinical studies will be required to determine patient dosimetry and
assess the feasibility to image multiple lesions simultaneously. Potential patient benefits
could arise by avoiding invasive procedures involving multiple biopsies. The kinetic model
proposed in this thesis could further increase the accuracy of the image interpretation.
Because of the specific annotation to HER2 and enhanced pharmacokinetic properties,
[18F]GE-226 is now transitioning into clinical development. A method has therefore been
developed that will permit the hypothesis that, patients with high HER2 will benefit from
treatment with CHK inhibitors, to be tested.
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Appendix A
Spectra of relevant compounds
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Appendix B
Kinase screen
Kinase Species Accession no. % activity remaining SD
ABL human NM_005157 112 5
AMPK rat Tissue purified 109 11
ASK1 human NM_005923 119 5
Aurora A human BC027464 98 1
Aurora B human NM_004217 102 9
BRK human NM_005975 117 10
BRSK1 human NM_032430 110 2
BRSK2 human AF533878 94 3
BTK human NP_00052.1 131 1
CAMK1 human NM_003656 110 11
CAMKKb human NM_153499 91 3
CDK2-Cyclin A human NM_001798/NM_001237 112 30
CDK9-Cyclin T1human NM_001261/NM_001240.2 95 7
CHK1 human AF016582 97 4
CHK2 human NM_007194 90 2
CK1γ2 human BC018693.2 92 5
CK1δ human NM_001893 100 5
CK2 human NM_001895 86 1
CLK2 human NM_003993.2 101 1
CSK human NM_004383 96 1
DAPK1 human NM_004938.2 96 13
DDR2 human NM_006182 85 13
DYRK1A human NM_130437.2 114 1
DYRK2 human NM_003583 96 2
DYRK3 human AY590695 106 1
EF2K human AAH32665 99 11
EIF2AK3 human NM_004836.5 97 1
EPH-A2 human NM_004431 93 12
EPH-A4 human NM_004438 124 10
EPH-B1 human NM_004441 112 6
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EPH-B2 human NM_004442 90 1
EPH-B3 human NM_004443 107 11
EPH-B4 human NP_004435.3 110 5
ERK1 human BC013992 91 1
ERK2 human NM_002745 103 6
ERK8 human AY065978 69 4
FGF-R1 human M34641 92 11
GCK human BC047865 89 12
GSK3b human L33801 94 13
HER4 human NM_005235 79 7
HIPK1 human NM_198268 106 6
HIPK2 human AF326592 104 3
HIPK3 human NM_005734 112 35
IGF-1R human NM_000875 65 7
IKKb human XM_032491 101 8
IKKe human NM_014002 123 36
IR human NM_000208.2 103 16
IRAK1 human NM_001569.3 89 12
IRAK4 human BC013316.1 83 11
IRR human NM_014215 92 6
JAK2 human NP_004963.1 90 4
JNK1 human L26318 98 21
JNK2 human L31951 100 15
JNK3 human NM_002753 92 2
Lck mouse X03533 118 29
LKB1 human NP_000446 100 7
MAPKAP-K2 human NM_032960 89 4
MAPKAP-K3 human NM_004635 67 6
MARK1 human AF154845 103 8
MARK2 human NM_004954 86 3
MARK3 human U64205 106 5
MARK4 human AK075272 95 4
MEKK1 human XM_042066 92 1
MELK human NM_014791 106 14
MINK1 human NM_015716 100 7
MKK1 human L05624 82 0
MKK2 human NM_030662 95 9
MKK6 human NM_002758 102 2
MLK1 human NM_005965 91 2
MLK3 human NM_033141 110 4
MNK1 human NM_002419 101 2
MNK2 human AB000409 96 25
MPSK1 human AF237775 105 5
MSK1 human AF074393 96 2
MST2 human CR407675 89 20
MST3 human U60206 117 9
MST4 human AAH65378 113 4
NEK2a human NM_016542 101 7
NEK6 human NM_002497 86 6
NUAK1 human NM_014397 103 20
OSR1 human NM_014840 99 3
p38a MAPK human NM_005109.2 108 9
p38b MAPK human L35264 107 3
p38d MAPK human Y14440 100 2
181
p38g MAPK human Y10487 99 25
PAK2 human Y10488 107 6
PAK4 human NM_002577 114 5
PAK5 human O96013 90 9
PAK6 human Q9P286 107 7
PDK1 human Q9NQU5 133 1
PHK human X80590 94 6
PIM1 human NM_002613 102 8
PIM2 human NM_002648 103 20
PIM3 human U77735 113 2
PKA human Q86V86 106 2
PKBa human NM_002730 101 12
PKBb human BC000479 93 1
PKCa human NM_001626 98 3
PKCz human NM_002742 106 10
PKCγ human NM_002737 93 4
PKD1 human NM_002739 105 5
PLK1 human NM_002744 112 20
PRAK human NM_005030 101 11
PRK2 human AF032437 94 13
RIPK2 human S75548 102 0
ROCK 2 human NM_003821 97 1
RSK1 rat U38481 78 6
RSK2 human NM_002953.3 105 10
S6K1 human NM_004586 88 1
SGK1 human NM_003161 94 14
SIK2 human NM_005627 109 3
SIK3 human NM_015191.1 102 16
SmMLCK human Sugen Kinase Database 15721 104 18
Src human NM_005417.3 105 1
SRPK1 human NM_003137 106 3
STK33 human BC031231.1 99 3
SYK human AAH01645.1 92 9
TAK1-TAB1 human NM_003188 and NM_006116 97 2
TAO1 human NM_020791 100 13
TBK1 human NM_013254 108 20
TESK1 human NM_006285.2 101 17
TIE2 human BC035514.1 89 4
TLK1 human NM_012290.4 110 20
TrkA human NM_001007792.1 84 15
TSSK1 human AY028964 107 5
TTBK1 human NM_032538.1 97 4
TTK human NM_003318 101 5
VEG-FR human NM_002019.3 80 6
WNK1 human NM_018979.3 102 2
YES1 human NM_005433 110 4
ZAP70 human NM_001079 102 5
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